Document:

Commercial Manufacturing and Supply Agreement

 Exhibit 10.19 

CERTAIN MATERIAL (INDICATED BY AND ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMISSION. 
  

			
	 DATED
	  	2009

ZOGENIX, INC. 

-and- 
 MGLAS AG

  
  

 
 Commercial Manufacturing and
Supply Agreement relating to 
 Glass Capsules 
  

 
  

 TABLE OF CONTENTS 

 

					
	 TABLE OF CONTENTS
	  	2
		
	 LIST OF SCHEDULES
	  	3
			
	1.	  	DEFINITIONS	  	4
			
	2.	  	SUPPLY OF GLASS CAPSULES TO ZOGENIX	  	9
			
	3.	  	CAPACITY, FORECASTS, ORDERS, LOGISTICS	  	11
			
	4.	  	PRICES AND PAYMENT CONDITIONS	  	12
			
	5.	  	INITIAL EQUIPMENT AND TOOLING	  	12
			
	6.	  	PATENTS, IMPROVEMENTS	  	15
			
	7.	  	STEERING COMMITTEE	  	18
			
	8.	  	WARRANTY	  	19
			
	9.	  	LIABILITY, BREACH OF CONTRACT; SANCTIONS	  	21
			
	10.	  	TERMINATION AND EXPIRY	  	23
			
	11.	  	CONFIDENTIALITY	  	24
			
	12.	  	GOVERNING LAW AND ARBITRATION	  	25
			
	13.	  	MISCELLANEOUS	  	26

  

 Page 2 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

 LIST OF SCHEDULES 

 

			
	 Ref. No.
	  	 Title

		
	1.	  	Technical Specification
		
	2.	  	Drawing for Glass Capsule
		
	3.	  	Capacity, Pricing and Payment Conditions
		
	4.	  	Asset Register
		
	5.	  	Maintenance and Repair
		
	6.	  	Confidentiality Agreement
		
	7.	  	New design equipment and tooling
		
	8.	  	Exit Documentation and Equipment
		
	9.	  	Field

  

 Page 3 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

 THIS AGREEMENT is made this First day of April 2009 

BETWEEN 
  

					
	(1)	  	(“ZOGENIX”)	 	ZOGENIX INC., whose registered office is at 12671 High Bluff, Suite 200, San Diego, CA 92130, USA; and
			
	(2)	  	(“MG”)	 	MGLAS AG whose principal office is at Otto-Liebmann-Str. 2, 97702 Münnerstadt, Germany, Schweinfurt HRB 677.

WHEREAS: 
  

	(A)	Zogenix is the owner of a needlefree injection device currently known as “DoseProTM”. The device requires a Glass Capsule in which injectate is stored
prior to injection. 

  

	(B)	MG is a manufacturer of Primary Packaging Materials, Primary Packaging Systems and Injection Systems for the Pharmaceutical Industry. 

 

	(C)	Zogenix intends to sell the Device currently known as DoseProTM on the market, and MG is prepared to cover the demand of Zogenix with respect to the Glass Capsules.

 IT IS AGREED as follows: 

1. DEFINITIONS 
 In this Agreement the
following terms shall have the following meanings; 
  

 Page 4 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	1.1.	“AFFILIATE” shall mean: 

  

	 	1.1.1.	An organization fifty percent or more of the voting stock of which is owned and / or controlled directly or indirectly by either party to this Agreement;

  

	 	1.1.2.	An organization which directly or indirectly owns and / or controls fifty percent or more of the voting stock or either party to this Agreement;

  

	 	1.1.3.	An organization which is directly or indirectly under common control with either party to this Agreement through common share holdings. 

 

	 	1.2.	“BATCH” shall mean the specific characteristics and quantity of manufactured Glass Capsules as stated in Schedule 1. 

 

	 	1.3.	“BUSINESS DAY” means a day other than a Saturday, Sunday or a day that is a statutory holiday in Germany or in the United States of America.

  

	 	1.4.	“CAPACITY” shall mean the quantity of Glass Capsules that MG is able to produce under normal conditions, using the Initial Equipment and Tooling as
stated in Schedule 4, which shall be revised as agreed by the parties as capacity changes. 

  

 Page 5 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	1.5.	“CONFIDENTIAL INFORMATION” shall mean any and all information, technology, know-how or commercial information, whatever its form or medium, including,
without limitation, the terms of this Agreement, budgets, forecasts, POs, pricing, financial and operating information and Technical Information, that is disclosed by a Party to the other Party, as per definition and to the extent of
Schedule 6. 

  

	 	1.6.	“DEVICE” shall mean Zogenix’s single use, disposable, prefilled, needlefree injection device currently known as DoseProTM, containing the
Glass Capsule, for the subcutaneous injection of pharmaceutical products. 

  

	 	1.7.	“EXIT SERVICES” shall mean services provided by MG to Zogenix, either directly or indirectly, to wholly and effectively transfer the Glass Capsule
manufacturing operation to a site other than MG. This includes support to remove Zogenix assets listed in Schedule 4, and transfer of documentation as defined in Schedule 8, in paper or electronic form, related to the Glass Capsule and batch
manufacturing history, but excludes the training of subsequent manufacturers in the Glass Capsule manufacturing process. 

  

	 	1.8.	“FIELD” shall mean the therapeutic classes of pharmaceutical or biotechnology products in which Zogenix or its licensees market products containing the
Device as listed in Schedule 9. 

  

	 	1.9.	“GLASS CAPSULE” shall mean the Glass Capsule component of the Device, as described in Schedule 1 and Schedule 2. 

 

	 	1.10.	“GLASS CAPSULE WORK CELL” shall mean the area set aside within the MG facility and the equipment, fixtures, and tooling for the manufacture and testing
of Glass Capsules. 

  

	 	1.11.	“IMPROVEMENTS” shall mean all improving modifications or adaptations to any of the Patents or Know-how, whether patentable or not, which might
reasonably be of commercial interest to either party in the design, manufacture, supply or use of the Device or Glass Capsule and which may be made, acquired by or disclosed to MG or Zogenix during the term of this Agreement.

  

 Page 6 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	1.12.	“INITIAL EQUIPMENT AND TOOLING” shall mean all equipment in the Glass Capsule Work Cell at MG’s facility as per Schedule 4. Any additional items
of equipment and tooling procured by Zogenix shall become part of the “Initial Equipment and Tooling”. 

  

	 	1.13.	“KNOW-HOW” shall mean all technical and other information not generally accessible to the public which relates to the design, manufacture, supply or
use of the Device or the Glass Capsule known to either party during the term of this Agreement. 

  

	 	1.14.	“LAWS” shall mean industry standards, laws or regulations applicable to the glass component manufacturing for pharmaceutical industry such as, but not
limited to, ISO 15378. 

  

	 	1.15.	“PATENTS” shall mean all patents and the patent applications owned or controlled by Zogenix or its Affiliates or MG or its Affiliates at any time
during the Term of this Agreement relating to the Device or the Glass Capsules. 

  

	 	1.16.	“PO” means any Purchase Order issued by Zogenix, agreed to by MG and executed by the parties in accordance with the terms of this Agreement.

  

	 	1.17.	“PRICING, PAYMENT CONDITIONS” shall have the meaning as stipulated in Schedule 3, listing the prices agreed by the parties to be charged by MG to
Zogenix. 

  

	 	1.18.	“RESERVED CAPACITY” shall be the difference in units between the quantity of Glass Capsules ordered by Zogenix during a period and the Capacity of any
currently agreed Shift Pattern for such period. 

  

 Page 7 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	1.19.	“SHIFT PATTERN” shall mean a specific combination of production labor, shifts, and work schedule which is intended to manufacture and yield a given
quantity of Glass Capsules over a specified period, and is associated with a Capacity. Shift Patterns are described in Schedule 3. 

  

	 	1.20.	“SPECIFICATIONS” shall mean written specifications of the Glass Capsule and of the processes to be used to produce and control the Glass Capsule,
agreed between the parties, and as further defined in Schedule 1. Specifications concerning the processes are only applicable in respect to the Initial Equipment and Tooling. 

 

	 	1.21.	“STANDBY PRICE” shall mean [***]. 

  

	 	1.22.	“STEERING COMMITTEE” shall be the joint Committee of which the details concerning representation and functions are set out in Section 7.

  

	 	1.23.	“TERM” means the total duration of the Agreement, including any extension after base term. 

 

	 	1.24.	References to: 

  

	 	1.24.1	the singular include the plural and vice versa; and 

  

	 	1.24.2	companies or persons include persons, firms, companies and all artificial organizations, wherever incorporated. 

 

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 Page 8 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	1.24.3.	Sections and Schedules refer to the Sections and Schedules of this Agreement. 

 

	 	1.25.	The Schedules form a part of the Agreement. 

2. SUPPLY OF GLASS CAPSULES TO ZOGENIX 
  

	 	2.1.	During the Term, MG shall use the Initial Equipment and Tooling to manufacture the Glass Capsules and sell them to Zogenix and Zogenix shall purchase the Glass Capsules
from MG on the terms of this Agreement. 

  

	 	2.2.	Exclusivity 

  

	 	2.2.1.	During the Term, MG shall be the exclusive supplier of the Glass Capsules for the Device of Zogenix, except in the event that MG is no longer able to supply Glass
Capsules as per Section 3. This applies to the direct supply of Zogenix, as well as indirect purchases by licensees of the Device, which commitment Zogenix shall warrant to MG through corresponding contractual protection.

  

	 	2.2.1.1.	As licensees enter into product development relationships with Zogenix for the purposes of developing their products with the Device, Schedule 9 will be amended to add
their Field(s). 

  

	 	2.2.1.2.	In the event that a product development relationship with a licensee is terminated, Schedule 9 will be amended to remove that Field(s). 

 

 Page 9 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	2.2.2.	During the Term, and as long as MG is the exclusive supplier of Glass Capsules to Zogenix, except in the event that MG is no longer able to supply Glass Capsules as per
Section 3, MG shall not, solely or with any other party, develop, manufacture, or distribute, any product which is a component of, or is, a needle free injection device for use in the Field, unless said product is or becomes without MG’s
fault, a standard finished product or intermediate product of MG. In any case, MG shall not impart any Confidential Information to the other party, and MG shall not, as far as legally possible, permit the other party to visit or observe the Glass
Capsule Work Cell. MG shall not permit any of its employees or temporary staff who may have substantially participated in the development of the Glass Capsule manufacturing process, or in the manufacturing of Glass Capsules, to participate in the
development or manufacture of a needle-free injection device, or its components, for any other company, for use in the field. 

  

	 	2.3.	In the event that the total quantity of Glass Capsules ordered by Zogenix for any consecutive [***] month period results in a Reserved Capacity, which is below the
actual agreed Shift Pattern, [***]. In such event, [***]. In the event that any forecasted Reserved Capacity exceeds the annual maximum limit for the then-current Shift Pattern, the Steering Committee shall implement appropriate actions to resolve
the situation; in such case, MG shall not be obligated to incur direct costs beyond the annual maximum limit for Reserved Capacity without reasonable compensation as agreed by the parties. The Reserved Capacity and Standby Price shall be listed as a
line item in any binding Purchase Order which will result in Reserved Capacity. For the avoidance of doubt, this section does not apply in the event that MG ships less than the ordered quantity by the due date if the ordered quantity is equal to or
greater than Capacity. 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 Page 10 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

 3. CAPACITY, FORECASTS, ORDERS, LOGISTICS 

 

	 	3.1.	The parties will agree on the Capacity/Shift Pattern as described in Schedule 3. The Capacity shall from time to time be revised by agreement, following recommendations
of the Steering Committee. 

  

	 	3.2.	If Zogenix’s forecasts for Glass Capsules exceeds [***] of agreed Capacity as stipulated in Schedule 3 (or if either party foresees that that could be the case),
then the parties shall in good faith discuss means of increasing MG’s output capacity, or other appropriate means of dealing with the situation. 

  

	 	3.3.	Capacity increase of the Initial Equipment and Tooling without fundamental changes to the manufacturing and process technology: 

 

	 	3.3.1.	This capacity can be increased by the elimination of bottlenecks in individual manufacturing phases. 

 

	 	3.3.2.	In this case, Zogenix shall, at its option, invest in the respective equipment, which will then be recorded in the asset register (Schedule 4).

  

	 	3.4.	For a capacity increase of the Initial Equipment and Tooling, as stipulated in Section 3.2, Schedule 3 “Capacity” shall be amended accordingly.

  

	 	3.5.	Zogenix will provide updated rolling [***] forecasts at the end of [***]. 

  

	 	3.5.1.	Binding PO’s will be placed at [***]. 

 

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 Page 11 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	3.5.1.1.	In the event that order quantities require a change in shift pattern as described in Schedule 3 the Steering Committee will determine the appropriate course of action.

  

	 	3.5.2.	All PO’s will be for full lot quantities of Glass Capsules. 

  

	 	3.5.3.	MG shall ship Glass Capsules ordered by Zogenix in accordance with the quantities, delivery dates, and delivery and shipping instructions specified in the PO. MG will
notify Zogenix, in writing, of potential delivery delays as soon as is reasonably possible. MG will, prior to shipment, notify Zogenix about the shipping date and estimated delivery date of the Glass Capsules. 

4. PRICES AND PAYMENT CONDITIONS 
  

	 	4.1.	The price which MG will charge Zogenix for Glass Capsules and the respective payment terms shall be set out in Schedule 3 in € and shall be adjusted pursuant to
Section 4.2 below. 

  

	 	4.2.	Prices shall be reviewed annually as follows: 

  

	 	4.2.1.	[***]. 

 5. INITIAL EQUIPMENT AND TOOLING

  

	 	5.1.	Zogenix owns, at MG’s facility in Münnerstadt, a quantity of equipment and tooling, listed in Schedule 4, which the parties shall maintain and update from
year to year. The Initial Equipment and Tooling is not the property of MG and MG may not use it for any purpose other than to perform their obligations under this Agreement, but it is the basis for MG’s obligations under this Agreement,
according to Section 2.1. 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 Page 12 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	5.2.	Additional equipment and tooling provided by Zogenix as added to the register by mutual agreement hereafter shall also be included as “Initial Equipment and
Tooling”. 

  

	 	5.3.	From time to time Zogenix has placed, and may place in the future, at MG’s facility in Münnerstadt a quantity of firmly installed fixtures and fittings,
listed/to be listed in Schedule 4, which the parties shall maintain and update from year to year. 

  

	 	5.4.	The Steering Committee shall determine how to proceed when out-dated equipment is no longer utilized. Section 10 states how to proceed if the Agreement is
terminated. 

  

	 	5.5.	Upon request by Zogenix, MG shall not unreasonably withhold permission, within a reasonable time after receiving the request, for Zogenix employees, potential
customers, customers, investors, lenders, authorities or other Zogenix authorized visitors, in mutual agreement with MG, to enter the MG premises and the Glass Capsule Work Cell. However, the above does not apply to any company manufacturing or
processing glass tubes as well as their employees or affiliated companies. 

  

	 	5.6.	MG has signed a Subordination and Waiver Agreement with Zogenix and GE Capital Corporation (and agrees to sign one for any other secure lender to Zogenix, but does not
accept any responsibility insofar) in a form reasonably agreeable to MG with respect to specified Zogenix assets, used in the performance of services under this Agreement. 

 

	 	5.7.	Zogenix will insure the Initial Equipment and Tooling against all such risks, including general liability, as Zogenix reasonably considers to be normal to insure
against for equipment and tooling of that type, at most in line with MG’s own insurance coverage. 

  

 Page 13 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

 MG shall nevertheless use reasonable care to avoid causing damage to the Initial Equipment
and Tooling. MG is providing insurance in the amount of 7.3 million USD to cover the following risks to Initial Equipment and Tooling which are under their control: 

 

	 	•	 	 Fire, lightning, explosion, aircraft 

  

	 	•	 	 Strike, civil commotion, riot 

  

	 	•	 	 Storm, hail 

  

	 	•	 	 Vehicle impact, sprinkler leakage, smoke/soot 

  

	 	•	 	 Flood, earthquake, landslide, avalanche, volcanic action, sinking of earth, snow pressure 

 

	 	•	 	 Burglary, theft 

  

	 	•	 	 Innominated perils 

  

	 	5.8.	MG will be responsible for, and bear the cost of the timely maintenance, as described in Schedule 5, and the physical presence of the Initial Equipment and Tooling so
as to ensure that it remains capable of performing its role in the supply of Glass Capsules to Zogenix. 

  

	 	5.9.	In order to maintain effectively-functioning equipment and production uptime, Zogenix authorizes MG to service Zogenix equipment, either directly or with authorized
contractors, at Zogenix’s cost, as follows: 

  

	 	5.9.1.	Zogenix authorizes MG to effect repairs on Zogenix equipment, either by MG employees or contractors, and MG shall only permit repairs by those employees or contractors
who have been agreed by Zogenix as qualified to perform such repairs. MG shall establish and maintain business relationships with contractors who are necessary to perform repairs which cannot be performed by MG employees. MG shall notify Zogenix in
advance of performing major repairs; otherwise, within 48 hours of effecting the repair. The cost of repairs shall be paid or reimbursed by Zogenix. 

 

 Page 14 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	5.9.2.	Zogenix authorizes MG to replace defective, damaged, worn-out, or nonfunctional components of Zogenix equipment as specified in a spare parts list and replacement
instructions; such list to be agreed upon by the Steering Committee. MG shall procure such parts directly or through Zogenix, and maintain an inventory of such parts as specified on the spare parts list; the cost of spare parts shall be paid or
reimbursed by Zogenix. 

  

	 	5.9.3.	MG shall maintain records, as agreed by the Steering Committee, of all equipment maintenance, repairs, and spares replacement. 

 

	 	5.10.	MG will be responsible for, and bear the cost of facility upkeep and maintenance. 

6. PATENTS, IMPROVEMENTS 
  

	 	6.1.	All Improvements to the design of the Glass Capsule, as far as protected by IP rights, shall be fully owned by Zogenix regardless of the originator of the improvement.

  

	 	6.2.	All Improvements to the manufacturing processes and equipment which are non-specific to the Glass Capsule shall be fully owned by MG regardless of the originator of the
improvement. 

  

	 	6.3.	All Improvements to the manufacturing processes and equipment which are specific to the design of the Glass Capsule shall be owned by Zogenix regardless of the
originator of the Improvement. Such improvements are defined as those which apply to the strengthening of Glass Capsules, formation of the orifice and dimensions, and testing as per Schedules 1 and 2. Zogenix herewith grants a royalty-free license
to MG to use the improvement during the Term. 

  

 Page 15 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	6.4.	Any Improvements to the manufacturing processes which cannot be assigned as being either specific or non-specific to the Glass Capsule shall be jointly owned, with each
party granting a royalty-free license to the other to use the Improvement during and after the Term of the agreement. 

  

	 	6.5.	The party owning an Improvement as per the Articles above, will be entitled to file an Individual Property Right (patents or the like), as far as such Improvement
qualifies for invention, at its own cost. 

  

	 	6.6.	The party not performing the patent filing undertakes, without cost to the filing party, and in so far as it is able, to obtain all necessary assignment documents for
the filing party to render all signatures which shall be necessary for such patent filing and to provide reasonable assistance to the filing party in all other ways which are necessary for such applications. 

 

	 	6.7.	If one of the parties grants the other party the right to patent an Improvement developed by said party, the party who has made the development shall be compensated
appropriately by the other party. 

  

	 	6.8.	If MG acquires any knowledge of any possible misappropriation or other unauthorized use of Know How, or infringement of a claim of a Patent or Zogenix trade mark, it
shall without undue delay provide Zogenix with all information it has relating to such infringement and reasonably assist Zogenix in any enforcement action which Zogenix takes, any expenses and other substantial costs to be borne by Zogenix.

  

 Page 16 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	6.9.	Each party shall immediately notify the other if any claim is made against it by any third party for possible or potential infringement of a patent or other rights of
such third party in connection with the development, manufacture, or sale of the Glass Capsule or the Device. The notified party agrees to render such reasonable assistance (excluding financial assistance) as the notifying party may reasonably
request in defending such claim. 

  

	 	6.10.	The notifying party shall, if so requested by the other, keep the other informed of all developments in any such action. If Zogenix reasonably notifies MG that it
considers that such an action against MG might affect Zogenix’s wider business interests or those of Zogenix’s licensees, MG shall wherever possible give Zogenix reasonable opportunity to comment in advance upon action to be taken and take
Zogenix’s representations in to account. If Zogenix elect to take full control of the action they will, in writing, undertake to indemnify MG against all consequences of such action 

 

	 	6.11.	Zogenix shall be responsible for any binding and final judgments arising out of an infringement action brought by a third party, unless the infringement pertains to an
Improvement solely owned by MG. If the infringement pertains to an Improvement solely owned by MG, then MG shall be responsible for any such binding and final judgments. Further, as between MG and Zogenix, whichever party is responsible for the
judgment shall also be responsible for its reasonable attorney’s fees and related reasonable expenses and, if the other party was the notifying party under Section 6.9 or otherwise incurred such fees or expenses in defense of the action,
those of the other party. 

  

 Page 17 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

 7. STEERING COMMITTEE 

 

	 	7.1.	The parties shall establish a Steering Committee composed of six members, with an equal number of representatives from each of MG and Zogenix. Prior to starting the
commercial manufacture of the Device, the parties will review membership of the committee to ensure that it is appropriate to the transition to commercial manufacture. Both parties will ensure that their representatives attend regular meetings of
the Committee and report matters relevant to the performance of this Agreement. The meetings will be chaired by a representative of the parties; until the end of the first complete calendar year, the chairperson will be nominated by Zogenix; the
chairperson for the following calendar year will be nominated by MG and the chair will continue to alternate in this way on a calendar-annual basis. Minutes of the Committee’s meetings, to be signed by both parties, will be circulated to both
parties. 

  

	 	7.2.	The Steering Committee will perform the following functions: 

  

	 	7.2.1.	consider revisions to the Specification and the impact of those revisions upon yields, capacity, costs and other terms of this Agreement; 

 

	 	7.2.2.	review service levels and the performance of both parties; 

  

	 	7.2.3.	arrange, within the first 12 months of this Agreement, in sensible compliance with Section 2. a detailed risk analysis of the operation required by this Agreement,
agreeing actions to be taken as a result of that analysis and monitoring the implementation of those actions and reviewing the terms of this Agreement; 

  

	 	7.2.4.	Capacity and contingency planning, investing in increasing capacity and revisions to the Capacity; 

 

 Page 18 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	7.2.5.	Reviewing the terms of this Agreement, and 

  

	 	7.2.6.	such other major functions as the parties jointly agree to assign to it. 

  

	 	7.3.	The Steering Committee may issue recommendations (especially in technical and pharmaceutical matters) to the parties but cannot bind either party to a legal commitment.
However, each party will reasonably co-operate with the other in implementing the findings of the committee, to the extent that such implementation is necessary to give effect to this Agreement and does not unfairly and materially prejudice the
interests of that party. The relevant decisions are to be taken by the party concerned and shall only be deemed to bind that party if confirmed in a written note signed by that party. 

 

	 	7.4.	Each Party shall forthwith upon execution of this Agreement appoint one of its employees to be a relationship manager responsible for liaison between the parties. The
relationship managers shall meet whenever necessary and appropriate to review the current status of the business relationship and manage any issues that have arisen, including costs. 

8. WARRANTY 
  

	 	8.1.	MG Warranty 

  

	 	8.1.1.	MG warrants that all Glass Capsules delivered hereunder will conform to the Technical Specifications as per Schedule 1 and other requirements as set forth in the
Quality Agreement, thus, this MG warranty does not cover all such defects and deviations which result from these Specifications and any requirements as per the Quality Agreement. 

 

 Page 19 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	8.2.	Non-conforming Glass Capsules 

  

	 	8.2.1.	Within a reasonable time after delivery of the Glass Capsules to the facility designated by Zogenix, but not more than [***] business days, Zogenix or its designee
shall inspect the Glass Capsules at its own cost, otherwise the Glass Capsules will be considered accepted. If Zogenix or its designee finds that the Glass Capsules as per Schedule 1 do not conform to the warranty as set forth in Section 8.1,
Zogenix shall, without undue delay, give MG written notice of any claim setting forth the details of such non-conformity, or otherwise shall be deemed to have accepted the shipment - except for defects/non-conformances which could not have been
reasonably discovered by means available to Zogenix at the time of acceptance (so called latent defects). MG shall re-sort or replace, at no cost to Zogenix, any Batches or respective parts thereof not in conformance with the Technical Specification
or the Quality Agreement within [***] after MG receives the above-mentioned written notice and samples from Zogenix and accepted the complaint. This time limit shall, in accordance with Section 8.3 below, be suitably extended in accordance with
the availability of free production capacities. In no case will the warranty exceed the period of [***] after delivery. 

  

	 	8.3.	If MG will have to supply Glass Capsules to replace those which might not conform, within a reasonable or agreed upon time, taking into account the Capacity, MG is not
obliged to produce beyond the agreed Capacity of the equipment; however, MG is obliged to utilize extra resources or shifts, when necessary and when not constrained by local governmental regulations, in order to resolve any inventory shortage, at
its expense. 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 Page 20 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	8.4.	In order to provide for discovery of latent defects in the last batch(es) delivered during the Term of this agreement, this section shall survive termination of the
agreement for [***]. 

 9. LIABILITY, BREACH OF CONTRACT; SANCTIONS 

 

	 	9.1.	MG’s entire liability to Zogenix for the following failures to perform this Agreement and the transactions based on it shall be as described below and MG shall not
have any other liability to Zogenix for such failures: 

  

	 	9.1.1.	if MG does not deliver Glass Capsules in the agreed quantity or within the agreed delivery time – MG shall be liable for all direct costs and expenses but shall
not be liable for any consequential or economic losses suffered by Zogenix; 

  

	 	9.1.2.	if product liability or other claims arise due to the Glass Capsules delivered by MG– for all cost and expenses as per the effective binding statutory legal
provisions; 

  

	 	9.1.3.	if MG commits otherwise a breach of contract – for all resulting direct and foreseeable costs and damages. 

 

	 	9.1.4.	There is no liability of MG vis-à-vis Zogenix at all as far as the failure due to the Initial Equipment and Tooling provided MG has duly maintained such
equipment (Article 5.8). Except any strict legal liability as per Section 9.1.2, MG’s total liability shall be limited to [***]. 

 

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 Page 21 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	9.2.	Limitation of Liability 

  

	 	9.2.1.	In no case shall MG be liable to Zogenix for any loss of profit or other similar losses, in particular loss of production or business, as a result of MG’s failure
to perform this Agreement or any transactions based on it, in particular not for failures due to non-foreseeable circumstances beyond its reasonable control, such as operational disturbances and breakdowns; Force Majeure, Article 13.7.

  

	 	9.2.2.	In any case, the liability of MG pursuant to Section 9.1 shall be limited [***]. 

 

	 	9.3.	Zogenix’s entire liability to MG for failing to perform this Agreement shall be as described below and Zogenix shall not have any other liability to MG for such
failures: 

  

	 	9.3.1.	if Zogenix commits a breach of contract – for all resulting direct and foreseeable cost and damages. 

 

	 	9.3.2.	if damages are incurred solely by a failure on the part of personnel of Zogenix working at MG premises to act with due regard to safety and site regulations for all
resulting direct and foreseeable cost and damages; should MG personnel be involved, all resulting direct and foreseeable costs shall be proportionally divided between Zogenix and MG based on fault. 

 

	 	9.3.3.	In no case shall Zogenix be liable to MG for any loss of profit or other similar losses, in particular loss of production or business, as a result of Zogenix’s
failure to perform this Agreement or any transaction based on it, in particular not for failures due to non-foreseeable circumstances beyond their reasonable control (such as operational disturbances and breakdowns). 

 

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 Page 22 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	9.4.	Each of Zogenix and MG shall use all reasonable efforts to mitigate damages possibly suffered by them. 

 

	 	9.5.	This section shall survive the termination of this agreement for [***]. 

10. TERMINATION AND EXPIRY 
  

	 	10.1.	This Agreement shall have a term of three (3) years firm from the date first set forth above. Zogenix and MG may each terminate this agreement by serving not less
than [***] months advance written notice to the other party. 

  

	 	10.2.	Either party may terminate this Agreement by written notice taking immediate effect if: 

 

	 	10.2.1.	the other commits a material breach of its obligations which is either incapable of remedy or is not remedied within [***] days of written notice requiring remedy; or

  

	 	10.2.2.	the other becomes the subject of a formal procedure relating to the affairs of insolvent companies or otherwise becomes insolvent or incapable of paying its debts as
they fall due; 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 Page 23 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	10.3.	In the event of termination and, if such termination is not the result of a default of Zogenix, including but not limited to events as per Section 10.2, MGlas will
provide the Exit Services that are necessary to support production of Glass Capsules through and up until which time as commercial production capability has been established in an alternative location. In this respect Zogenix will pay MGlas for the
services rendered, including for production and technical transfer support, charged at reasonable rates [***]. 

  

	 	10.4.	In addition to the foregoing, but except where termination is a result of a default of MGlas, Zogenix will also pay MGlas for its direct costs incurred in respect of
removal of the Zogenix equipment and the return of the respective area of the MGlas premises where the Zogenix equipment was housed to a reasonable tidy state (making good any repairs that are incurred by the premises solely and directly as a result
of the Zogenix equipment being housed there) up to a maximum financial contribution of [***], all as evidenced by appropriate documentation provided by MGlas. 

11. CONFIDENTIALITY 
  

	 	11.1.	Confidential Information. Except as expressly provided, the Parties agree that, for the Term and [***] years thereafter, the receiving Party shall keep
completely confidential and shall not publish or otherwise disclose and shall not use for any purpose except for the purposes contemplated by this Agreement any Confidential Information furnished to it by the disclosing Party hereto pursuant to this
Agreement. 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 Page 24 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	11.2.	Details of the Parties’ rights and obligations concerning the Confidential Information including its definition are laid down in the “Confidentiality
Agreement” as per Schedule 6. 

 12. GOVERNING LAW AND ARBITRATION 

 

	 	12.1.	This Agreement and the transactions based on it shall in all respects be governed by German law. 

 

	 	12.2.	Dispute Resolution. In the event of any dispute, controversy or claim arising out of, relating to or in connection with any provision of this Agreement, the
Parties shall first try to settle their differences amicably between themselves, and, if not resolved, by referring the disputed matter to the respective chief executive officers of each Party. Either Party may initiate such informal dispute
resolution by sending written notice of the dispute to the other Party, and, within thirty (30) days after such notice, such representatives of the Parties shall meet for attempted resolution by good faith negotiations.

 If such representatives are unable to resolve a dispute within thirty (30) days of their first meeting of
such negotiations, either Party may seek to have such dispute resolved by binding arbitration of three arbitrators under the then-existing Comprehensive Arbitration Rules and Procedures of ICC, Paris. The Parties hereby consent to conduct such
binding arbitration procedures in Paris, France, in English language. 
  

 Page 25 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

 13. MISCELLANEOUS 
  

	 	13.1	Assignment or Transfer. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of
the other Party, except either Party may make such an assignment without the other Party’s consent to a successor of substantially all of the business of such Party, whether in merger, a sale of stock, sale of assets or other transaction. Any
such permitted successor or assignee of rights and/or obligations hereunder shall, in writing to the other Party, expressly assume performance of such rights and/or obligations within 60 days of the closing of the transaction. Any permitted
assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this section shall be null and void. 

 

	 	13.2	Independent Contractors. The parties act as independent contractors. This Agreement shall not constitute a partnership and neither party shall have any
authority (as agent or otherwise) to bind the other to any commitment whatsoever. 

  

	 	13.3	Salvatory Clause. If any provision in this Agreement is found by a court of competent jurisdiction (from which there is no appeal or, if there is, no
appeal is lodged or any appeal is withdrawn) or arbitrator to be illegal or invalid that clause shall be deemed removed and the remainder shall be unaffected. The parties shall endeavor to agree an alternative clause having like effect, as a
substitute for the provision that has been removed. 

  

 Page 26 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	13.4	Notices. All notices to be served shall be served either personally or by facsimile and by registered airmail (or some other service producing a receipt
confirming arrival). The notification shall be addressed to: 

 Zogenix, Inc. 

Attention: Chief Financial Officer 

12671 High Bluff. Suite 200 

San Diego, CA 92130 

USA 
 With a
copy to: 
 John J. Turanin, VP Operations 

Zogenix, Inc. 

5858 Horton Street, Suite 455 

Emeryville, CA 94608 USA 

All notices from Zogenix to MG shall be made by facsimile and by registered airmail (or some other service producing a receipt
confirming arrival) and be addressed to: 
 Mr. Hubertus Bürger, CFO 

MGlas AG 

Otto-Liebmann-Str. 2 

97702 Münnerstadt 

GERMANY 
  

 Page 27 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

 With a copy to: 

Mr. Wolfgang Heidl, CEO 

MGlas AG 

Otto-Liebmann-Str. 2 

97702 Münnerstadt 

GERMANY 
 or in
each case to such other address as shall be notified for the purpose. Notices shall be deemed served immediately if served by facsimile or in accordance with the receipt for the registered airmail, if not. 

 

	 	13.5	Entire Agreement; Amendment. This Agreement and the Quality Agreement set forth the complete, final and exclusive agreement and all the covenants, promises,
agreements, warranties, representations, conditions and understandings between the Parties hereto supersedes and terminates all prior agreements and understandings between the Parties, in particular the ”Prepayment Letter Agreement” dated
December 5, 2006, the “Pre-Commercial Letter Agreement” dated March 15, 2007 and the “Commercial Letter” dated February 12, 2008. There are no covenants, promises, agreements, warranties, representations,
conditions or understandings, either oral or written, between the Parties other than are in this Agreement. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and
signed by an authorized officer of each Party. 

  

	 	13.6	Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or
appropriate to carry out the purposes and intent of this Agreement. 

  

 Page 28 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	13.7	Force Majeure. Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by
Force Majeure and the non-performing Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting Force Majeure continues and the non-performing Party takes reasonable
efforts to remove the condition. 

 For purposes of this Agreement, “Force Majeure” shall mean
conditions beyond the control of the Parties or either Party, including without limitation an act of God, revolution, acts of public enemies, blockade or embargo, terrorist act, war, civil commotion, epidemic, failure or default of public utilities
or common carriers, destruction of production facilities or materials by fire, earthquake, flood, explosion, storm or like catastrophe, casualty or accident. Zogenix will have the right to terminate this agreement in the event that MG is prevented
from performance due to a Force Majeure Event for more than ninety (90) business days. 
  

	 	13.8	No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a
waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to a written and signed waiver as to a particular matter for a particular period of time. 

 

	 	13.9	Counterparts. This Agreement may be executed in two (2) or more counterparts and by facsimilie signature, each of which, once so executed and delivered,
shall be deemed an original, but all of which shall constitute the same Agreement. 

  

 Page 29 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

	 	13.10	Maintenance of Records. Each Party shall keep and maintain all records required by law or regulation with respect to the Glass Capsules and shall make copies of
such records available to the other Party upon request, including without limitation, the documents and records set forth in the Technical Agreement. 

  

	 	13.11	No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against either Party. 

 

	 	13.12	Headings. The headings for each Article in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the
meaning of the language contained in the particular article or section. 

  

									
	In Witness of the above agreement	 		 		 	
				
	     /s/ Roger L. Hawley
	 		 	Dated:	 	       May 18, 2009

	For Zogenix, Inc.	 		 		 	
					
	Signed By:	 	      
	 		 		 	
				
	     /s/ [illegible]
	 		 	Dated:	 	       08.05.2009

	For MGlas AG	 		 		 	
					
	Signed By:	 	     /s/ [illegible]
	 		 		 	

 Each of the signatories warrants that they have authority to bind the party for whom they sign. 

 

 Page 30 / 30 

 

			
	MSA-Zogenix_MG_final_090508	  	Vers.: Final

 Schedule 1 

Technical Specification 
 to 

 Commercial Manufacturing and Supply Agreement 

between 
 MGlas AG 

and 
 Zogenix Corporation

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 1 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

 Approvals 

 

					
			
	Originator:	  	See attached approval from Mike Hudson	  	Date: 07.1.10
	  	 	  
		  	Mike Hudson, Manufacturing Operations, Document Owner	  	
			
	Approved by:	  	/s/ Eric Scharin	  	Date: 08 JUL 08
	  	 	  
		  	Eric Scharin, Technical Operations	  	
			
	Approved by:	  	/s/ Brooks Boyd	  	Date: 07 JUL 08
	  	 	  
		  	Brooks Boyd, Product Development	  	
			
	Approved by:	  	See attached approval dated 19 AUG 08	  	Date: 21 AUG 08
	  	 	  
		  	 Dr. Bernhard Hohlwegler, Director, QM, MGlas AG (MG)

Otto-Liebmann-Straße 2
 DE-97702
Münnerstadt - Germany
	  	
			
	Approved by:	  	/s/ Mary Fiala	  	Date: 21 AUG 08
	  	 	  
		  	Mary Fiala, Quality	  	

  

	1.	PURPOSE: 

This document specifies the raw material and manufacturing processes required for the production of the Glass
Capsule used in the manufacture of the Device currently known as “DoseProTM. 
  

	2.	SCOPE: 

 This document
applies to the raw material, manufacturing and inspection requirements for the manufacture of glass capsules, including cut blanks and formed capsules, to ensure compliance with quality criteria and to prevent deterioration in quality during
handling and shipping. 
  

	3.	Definitions: 

  

	3.1	Certificate of Analysis (COA): A signed document accompanying production batches stating one or more property values and their uncertainties, and confirming that
the necessary procedures have been carried out to ensure their validity and traceability. 

  

	3.2	Certificate of Compliance or Conformance (COC): A signed document that certifies production batches have been tested and released according to a specification.
At minimum, a certificate of conformance should include relevant part, lot and batch numbers, product codes, quantities, materials and other relevant information for traceability. 

 

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 
  

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

					
	
 

	 	 Technical Specification

 
 Page 2 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	3.3	Device shall mean Zogenix’ single use, disposable, prefilled, needle-free injection device currently known as DoseProTM, as described in the agreed
Specifications. 

  

	3.4	Glass Capsule or Product shall mean the Glass Capsule component of the Device currently known as DoseProTM, as described in the agreed Specifications.

  

	4.	References: 

  

	4.1	[***] 

  

	4.2	[***] 

  

	4.3	[***] 

  

	4.4	[***] 

  

	4.5	[***] 

  

	4.6	[***] 

  

	4.7	[***] 

  

	4.8	[***] 

  

	4.9	[***] 

  

	5.	Responsibilities: 

  

	5.1	MG is responsible for manufacturing the Product according to this Technical Specification, related drawings and for notifying and obtaining approval from Zogenix for
significant changes according to the MG change control system MG-V VII-20. 

  

	5.2	MG is responsible for clearly defining all process steps (including IPC and final inspection) in MG’s Standard Operating Procedures (SOPs).

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 3 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	5.3	The Raw Material Supplier (Schott) is responsible for providing materials and services according to the cTLB. 

 

	5.4	Certification: For each batch an appropriate Certificate of Conformance has to be provided. 

 

	6.	Manufacturing Process Summary 

  

	6.1	Glass Capsules are manufactured in the following process stages: 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	6.2	NO definition of batch size (targeted approx. [***] capsules – adapted to the quantity per pallet) 

 

	6.3	Batch number: MG YY MM DD 

  

	7.	MATERIALS: 

  

	7.1	Glass Tubing 

  

	 	7.1.1	[***] 

  

	 	7.1.2	[***] 

  

	 	7.1.3	[***] 

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 4 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	7.1.4	[***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	7.2	Packaging 

 [***] 

 

	7.3	Labeling 

 As specified in cTLB.

  

	8.	In-Process Controls, Final Inspection, Testing Requirements 

  

	8.1	Required dimensional test attributes must meet specified tolerances (IPC + final inspection) 

 

			
	 Test Attribute
	  	 Specification

	 [***]
	  	[***]
	
	 Major Parameters

		
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 5 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	8.2	Required visual test attributes (IPC + final inspection) 

  

			
	 Inspection Attribute
	  	 Specification

		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  

	8.3	In-Process Control 

 In-process
control shall be carried out in accordance with the relevant 
 Standard Operating Procedures and this Technical
Specification 
 (including table: 8.1.1.) 

Table: 8.1.1. In-Process Control for Glass Capsule Manufacture 

 

									
	Process	  	IPC Parameter	  	Frequency	  	Acceptance criteria	  	 Measurement:

method and device

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 6 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

									
	Process	  	IPC Parameter	  	Frequency	  	Acceptance criteria	  	 Measurement:

method and device

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 7 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

									
	Process	  	IPC Parameter	  	Frequency	  	Acceptance criteria	  	 Measurement:

method and device

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	8.4	Final Inspection 

  

	 	8.4.1	Trained personnel perform a final inspection (is a combination of a visual and dimensional inspection), before the consignment is delivered to Patheon UK.

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 8 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	 	8.4.2	Sampling size, inspection requirements and acceptance limits are defined in Appendix 2. 

 

	 	8.4.3	The final inspection must be carried out as specified in SOP MG-A VII 33 and will be accepted or rejected based upon the agreed acceptable quality limits ref
Appendix 2. 

  

	8.5	Retained Capsules stored at MG 

  

	 	8.5.1	[***] 

  

	8.6	Calibration 

 MG monitors all
calibration activities to be carried out periodically. The scope of calibration activities is defined in a controlled MG document. 
  

	9.	deviations 

  

	9.1	Significant deviation from critical process parameters (examples: oven zone out of limit, conductivity, etc.) as listed in this document must be appropriately
documented, reviewed and approved by Zogenix. 

  

	9.2	In case of out-of-specification results or deviations which may impact product quality, the affected capsules will be quarantined and MG will contact Zogenix QA to
discuss further action. 

  

	9.3	Every critical and major deviation must be documented in the Batch Manufacturing Record (BMR). 

 

	10	Product Release Documentation 

  

	10.1	Certificate of Conformance (Glass Tube Supplier) 

  

	 	10.1.1	For each batch of starting material used by MG in the production of glass [***] blanks, a Certificate of Conformance, which is provided by [***] and incorporates the
arsenic certification, is documented by MG and a copy can be provided to Zogenix on request. A remark should be included in the MG COA. 

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 9 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	10.2	Certificate of Analysis (COA) 

  

	 	10.2.1	A Certificate of Analysis is required for each batch confirming compliance with product specification, (i.e. drawing and agreed inspection requirements) and ISO
15378. This document will include: 

  

	 	•	 	 Quantity released (lot size) 

  

	 	•	 	 Dimensions 

  

	 	•	 	 Glass type 

  

	 	•	 	 Batch number 

  

	 	•	 	 Cross reference to [***] 

  

	 	•	 	 certificate 

  

	 	•	 	 Start of production (date) 

  

	 	•	 	 Compliance of test attributes and final inspection AQL listed in Appendix 2 and the final inspection form 

 

	 	•	 	 Customer purchase order number + date 

  

	 	•	 	 Item description 

  

	 	•	 	 Part number of product (3500-1273-01) including revision status 

 

	 	•	 	 EP test results (as per scheduled test frequency) 

  

	 	•	 	 Significant process deviations 

  

	 	•	 	 Remark for 100% proof test 

  

	 	•	 	 Confirmation of results for all 100% inspected IPC checks 

 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 10 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

 Table 10.2 Final Inspection Test Attributes 

 

			
	 Test Attribute
	  	 Specification

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  

	10.3	Batch Record 

  

	 	10.3.1	A Batch Manufacturing Record (BMR) is required for every batch. After the completion of the batch, the original BMR will be archived at MG’S location (10
years). Significant parameters/ deviations/ measurements and values will be displayed in the COA. 

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 11 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	 	10.3.2	The BMR must include or reference the location of all raw data. If possible electronic records may be copied on to a non-rewritable disk and attached to the BMR.
Remark: Data of flame inspection cannot be copied on to CD. 

  

	 	10.3.3	Zogenix Quality or designee approval is required prior to release of batch for shipment. 

 

	10.4	Delivery 

  

	 	10.4.1	Includes delivery note (one for each batch) with the following information: 

 

	 	•	 	 Customer order number (Zogenix and recipient, if necessary) 

 

	 	•	 	 Transport company 

  

	 	•	 	 MG delivery note number 

  

	 	•	 	 Date and quantity dispatched 

  

	 	•	 	 Item description 

  

	 	•	 	 Part number (3500-1273-01) and revision level 

  

	11.	Packaging and Labeling 

  

	11.1	Packaging Environment 

 The
inspected glass capsules shall be packaged in an unclassified environment 
  

	11.2	Retained Samples 

  

	 	11.2.1	[***] 

  

	 	11.2.2	[***] 

  

	 	11.2.3	[***] 

  

	 	11.2.4	[***] 

  

	 	11.2.5	[***] 

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 12 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	11.3	Packaging and Labeling Materials for Standard Production 

  

	 	11.3.1	[***] 

 [***] 

[***] 
 [***]

  

	 	11.3.2	[***] 

 [***] 

[***] 
 [***]

  

	 	11.3.3	[***] 

 [***] 

[***] 
 [***]

 [***] 
  

	 	11.3.4	[***] 

 [***] 

 

	11.4	Packaging Instructions for Standard Production 

  

	 	11.4.1	[***] 

  

	 	11.4.2	[***] 

  

	 	11.4.3	[***] 

  

	 	11.4.4	[***] 

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 13 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	 	11.4.5	[***] 

 [***] 

[***] 
 [***]

 [***] 

[***] 
 [***]

  

	 	11.4.6	[***] 

  

	 	11.4.7	[***] 

  

	11.5	Labeling of Retained Samples 

[***] 

 

 

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 14 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	11.6	Labeling for Regular Delivery of Capsules for Processing 

  

	 	11.6.1	PP-Well box (with [***] full trays) to be labeled with: 

 

 

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 15 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	 	11.6.2	Shipping pallet to be labeled as follows and marked with ‘Fragile – This Way Up’. 

 

 

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 16 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	12	APPendix 1: MG Owned Documents 

  

	12.1	The basis upon which an SOP is written is the MG master SOP MG-V IV-1 (“Preparation and handling of MG documentation”). 

 

	12.2	Change Control is performed according to the MG CCM = SOP MG-V VII-20 

MG owned documents subject to joint change control with Zogenix 

 

			
	 Document Number
	  	 Document Title

		
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 17 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	13.	Appendix 2: Sampling plan 

Single sampling plan for normal inspection (ISO 2859 1:1999(E)) 

 

											
	 Inspection Attribute
	  	 Inspection
level
	  	AQL	 	 Lot Size
	  	Sample
Size	 	 If the number of non-conforming

items is:

	 1. [***]
 2.
[***]
  
	  	 [***]

[***]
	  	[***]  

[***]
	 	 [***]
  
	  	[***]  
	 	 [***]
  

	  	  	 	[***]	  	[***]  
	 	 [***]
  

						
	[***]	  	 [***]

[***]
	  	  
 [***]

 
 [***]
	 	[***]	  	[***]	 	[***]
	  	  	 	 [***]
  
	  	  
 [***]

 
	 	  
 [***]

 

						
	[***]	  	 [***]

[***]
	  	  
 [***]

 
 [***]
	 	[***]	  	[***]	 	[***]
	  	  	 	[***]	  	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 18 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

 Single sampling plan for normal inspection (ISO 2859 1:1999(E)) 

 

											
	 Inspection Attribute
	  	 Inspection
level
	  	AQL	 	 Lot Size
	  	Sample
Size	 	 If the number of non-conforming

items is:

	[***]	  	 [***]

[***]
	  		 	[***]	  	[***]	 	[***]
	  	  	[***]  

[***]
	 	[***]	  	[***]	 	[***]

 Double sampling plan for normal
inspection (ISO 2859 1:1999(E)) 
  

															
	  	 	Step 1	 	Step 2
	 Inspection Attribute
	  	Inspection
level	 	AQL	 	Lot Size	 	Sample
Size	 	If the number of non-
confirming items is:
	 	Sample
Size	 	If the number of non-
conforming items is:

	 [***]
	  	[***]	 	  
 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 19 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	14.	Appendix 3: Packing diagram 

[***] 
  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

					
	
 

	 	 Technical Specification

 
 Page 20 of 20

			
	 Part Number: 6200-1273-01 
	 	Revision: B	 	Effective Date: AUG 21 2008
	
	Document Name: Technical Specification for Glass Capsule, [***], Part Number 3500-1273-01

 

	15.	Document History 

CHANGE
HISTORY 
  

									
	 Rev.
	  	DCO #	 	 Description
	  	Originator	 	Effective
Date
	[***]	  	[***]	 	[***]	  	[***]	 	[***]
	[***]	  	[***]	 	[***]	  	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 ZOGENIX PROPRIETARY AND
CONFIDENTIAL 

 Schedule 2 

Drawing Glass Capsule 
 Drawing Number
3570-1273-01, Rev. A 
 to 

Commercial Manufacturing and Supply Agreement 

between 
 MGlas AG 

and 
 Zogenix Corporation

  

 1/2 

 [***] 
  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 2/2 

 Schedule 3 

Capacity, Pricing and Payment Conditions 

to 
 Commercial Manufacturing and
Supply Agreement 
 between 

MGlas AG 
 and 

Zogenix Corporation 
  

 1/2 

									
	 Shift

Pattern
	 	 Annual Capacity

(Capsules)
	 	 Average Capsules

per Month*
	 	 Direct Staff
	 	 09 Price

per Capsule (€)

	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
					
	 [***]
	 		 		 		 	
					
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
					
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
					
	 [***]
	 		 		 		 	
					
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
					
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
					
	 [***]
	 		 		 		 	

 Shift Pattern A 

[***] 
 [***] 

[***] 
 [***] 

Shift Pattern B 
 [***] 

[***] 
 [***] 

[***] 
 Shift Pattern C 

[***] 
 [***] 

[***] 
 [***] 

The prices above are effective 1 January 2009 and are valid until 31 December 2009 as per Section 4.2.1. 

Payment terms [***] 
  

	*	Initial Equipment and Tooling 

	**	Per section 2.3 

	***	Maximum to be determined at time of agreement on shift pattern unit price 

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 2/2 

 Inventory List Zogenix Status 04.08.2008 

Schedule 4 
 Asset Registers 

 - “The Initial Equipment and Tooling” 

to 
 Commercial Manufacturing and
Supply Agreement 
 between 

MGlas AG 
 and 

Zogenix Corporation 
  

 1/11 

 Inventory List Zogenix Status 04.08.2008 

 

 Glass Capsule Department – Zogenix Property 

1. Workstation: Flaming and Inspection 
  

													
	 Pos.
	  	 Description
	  	Qty.	 	Type	 	Location	 	Owner	 	Serial
No.
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 2/11 

 Inventory List Zogenix Status 04.08.2008 

 

 2. Workstation: Ion-Exchange / Washing / Packaging 

 

													
	 Pos.
	  	 Description
	  	Qty.	 	Type	 	Location	 	Owner	 	Serial
No.
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 3/11 

 Inventory List Zogenix Status 04.08.2008 

 

 3. Workstation: IPC – Office 

 

													
	 Pos.
	  	 Description
	  	Qty.	 	Type	 	Location	 	Owner	 	Serial
No.
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 4/11 

 Inventory List Zogenix Status 04.08.2008 

 

 4. Workstation: Storage 

 

													
	 Pos.
	  	 Description
	  	Qty.	 	Type	 	Location	 	Owner	 	Serial
No.
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 5/11 

 Inventory List Zogenix Status 04.08.2008 

 

 5. Workstation: Laser-system 

 

													
	 Pos.
	  	 Description
	  	Qty.	 	Type	 	Location	 	Owner	 	Serial
No.
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 6/11 

 Inventory List Zogenix Status 04.08.2008 

 

 6. Workstation: Proof-Tester 

 

													
	 Pos.
	  	 Description
	  	Qty.	 	Type	 	Location	 	Owner	 	Serial
No.
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 7/11 

 Inventory List Zogenix Status 04.08.2008 

 

 7. Workstation: Cutting 

 

													
	 Pos.
	  	 Description
	  	Qty.	 	Type	 	Location	 	Owner	 	Serial
No.
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 8/11 

 Inventory List Zogenix Status 04.08.2008 

 

 8. Workstation: Miscellaneous 

 

													
	 Pos.
	  	 Description
	  	Qty.	 	Type	 	Location	 	Owner	 	Serial
No.
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 9/11 

 Inventory List Zogenix Status 04.08.2008 

 

 9. Workstation: Blank Washing 

 

													
	 Pos.
	  	 Description
	  	Qty.	 	Type	 	Location	 	Owner	 	Serial
No.
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 10/11 

 Inventory List Zogenix Status 04.08.2008 

 

 10. Workstation: CF1 and Oven 

 

													
	 Pos.
	  	 Description
	  	Qty.	 	Type	 	Location	 	Owner	 	Serial
No.
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
							
	 [***]
	  	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 [***] 

 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 11/11 

 Schedule 5 

Maintenance 
 to 

Commercial Manufacturing and Supply Agreement 

between 
 MGlas AG 

and 
 Zogenix Corporation

  

 1/2 

																									
	 	  	Daily	  	Weekly	  	2
Weekly	  	Monthly	  	3
Monthly	  	4
Monthly	  	6
Monthly	  	12
Monthly	  	2 Yearly	  	3
Yearly	  	5
Yearly	  	 
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  		  		  	[***]	  		  		  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 [***] 

[***]. 
  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 2/2 

 Schedule 6 

Confidentiality Agreement 
 to 

 Commercial Manufacturing and Supply Agreement 

between 
 MGlas AG 

and 
 Zogenix Corporation

  

 1/5 

 ZOGENX 

CONFIDENTIALITY AGREEMENT 

THIS CONFIDENTIALITY AGREEMENT (the Agreement”) is made and entered into as of September 18,
2006 (the “Effective Date”) by and between Zogenix (“ZOGENIX”) a California Corporation having its principal place of business at 3929 Point Eden Way, Hayward, CA 94545 and MGLAS (“Second Party”)
having its principal place of business at Otto-Liebmann-Str. 2, Munnerstadt, Germany. ZOGENIX and Second Party shall collectively be referred to as “Parties”. 

In order to pursue mutual business purposed, the Parties recognize that there is a need to exchange certain confidential information of the Parties to be
used only for such mutual business purposes and to protect such confidential information from unauthorized use of disclosure. No other relationship, express or implied, are created or binding between the Parties due to the disclosure of such
information. 
  

	1.	Conditional Information and Materials: 

  

	(a)	“Confidential Information” means any oral, written, graphic, machine-readable or other information that the Parties designate as being confidential or
proprietary or which, under the circumstances surrounding disclosure, ought to reasonable be treated as confidential. Confidential Information includes, but is not limited to, information relating to released or unreleased products or services of
the Parties, the marketing or promotion of any of the Parties’ products or services, the Parties’ business policies or practices, marketing plans, product, or service plans, business strategies, financial information, forecasts, personnel
information, customer lists, trade secrets, inventions, formulas, processes, databases, ideas, software (including source and object code), hardware configuration, computer programs, algorithms, intellectual property strategies and plans, filed but
unpublished patent applications, copyright and trademark plans, potential business partnerships and strategies, and information received from others that the Parties are obligated to treat as confidential subsidiary and/or agents is covered by this
agreement. 

  

	(b)	A Party’s Confidential Information shall not include information that: 

 

	 	i.	is or becomes a part of the public domain through no ace or omission of the receiving Party; 

 

	 	ii	was in the receiving Party’s lawful possession prior to the disclosure and had not been obtained by the other Party either directly or indirectly from the
disclosing Party, as demonstrated by files in existence at the time of disclosure; 

  

	 	iii.	is furnished by the disclosing Party to a third party without restrictions similar to those contained in this Agreement; 

 

	 	iv	is lawfully disclosed to the receiving Party by a third party without restriction on disclosure; or 

 

	 	v.	is independently developed by the receiving Party without reference to Confidential Information received under this Agreement. 

 

 2/5 

	(c)	“Confidential Materials” shall mean all tangible materials containing Confidential Information, including without limitation written or printed documents and
computer disks or tapes, whether machine or user readable. 

  

	2.	Use 

 Each Party agrees not to use the
Confidential Information received from the other Party for its own use or for any purposed other than to carry out discussions concerning a business relationship between the Parties and such business relation itself. Neither Party shall disclose or
permit disclosure of any confidential Information of the other Party to third parties or to employees of the Party receiving Confidential Information, other than directors, officers, employees, consultants and agents who are required to have the
information in order to carry out the purpose of this Agreement. No other rights, and particularly licenses to trademarks, inventions, copyrights, patents, mask work protection rights, or any other intellectual property rights, are implied or
granted under this Agreement or by the conveying of Confidential Information between the Parties. 
  

	3.	Copying 

 Confidential Information
supplied shall not be reproduced in any form except as required to accomplish the intent of this Agreement. 
  

	4.	Ownership: 

 All Confidential Information,
unless otherwise specified in writing, shall remain the property of the disclosing Party, shall be used by the receiving Party only for the purpose intended, and such Confidential Information and Confidential materials, including all copies thereof,
shall be returned or destroyed within ten (10) days after (i) the receiving Party’s need for it has expired, (ii) upon the request of the disclosing Party, or (iii) upon the termination of this Agreement. At the request of
the disclosing Party, the receiving Party shall furnish a certificate signed by an officer or authorized representative of the receiving Party certifying that Confidential Information not returned to the disclosing Party has been destroyed.

  

	5.	Restrictions: 

  

	(a)	The Parties agree not to disclose any confidential Information to third parties. However, a receiving Party may disclose Confidential Information in accordance with a
judicial or other government order provided that the receiving Party shall give the disclosing Party immediate notice of the order prior to such disclosure, shall allow the disclosing Party a reasonable time to oppose such process and shall comply
with any applicable protective order. 

  

	(b)	Each Party shall take reasonable security precautions, at least as great as the precautions each Party takes to protect its own confidential information, to keep the
Confidential Information confidential. Each Party agrees to notify the other in writing of any actual or suspected misuses, misappropriation or unauthorized disclosure of Confidential Information of the disclosing Party which may come to the
receiving Party’s attention. 

  

	(c)	Neither Party may duplicate, translate, transfer, or cause, permit or attempt the reverse engineering, disassembly or decompilation of any software disclosed under the
Agreement. 

  

 3/5 

	(d)	The commitments of each Party under this Agreement shall survive any termination of any relationship between the Parties and shall continue for a period terminating on
the later of (i) [***] years following the date of this Agreement or (ii) [***] years from the end of this calendar year in which any relationship of the parties has been terminated. Additionally, upon termination of this Agreement, both
parties acknowledge that Confidential Information disclosed to each other under this Agreement does not automatically become part of the public domain. Both parties agree to take reasonable precautions to prevent disclosure of Confidential
Information after the termination of this Agreement. 

  

	6.	Rights and Remedies: 

 The Parties
acknowledge that monetary damages may not be a sufficient remedy for unauthorized disclosure of Confidential Information and that a Party shall be entitled, without waiving any other rights or remedies, to such injunctive or equitable relief as may
deemed proper by a court of competent jurisdiction. 
  

	7.	Miscellaneous: 

  

	(a)	This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof and merges all prior discussions between them as
Confidential Information. It shall not be modified except by written agreement dated subsequent to the date of this Agreement and signed by authorized representatives of both Parties. None of the provisions of this Agreement shall be deemed to have
been waived by any act or acquiescence on the part of either Party, its agents, or employees, but only by an instrument in writing signed by an officer or authorized representative of either Party. 

 

	(b)	This Agreement and all matter arising out of or relating to this Agreement shall be governed by the laws of Germany, excluding choice of law provisions.

  

	(c)	Any legal action or proceeding relating to this Agreement shall be instituted in the binding arbitration, with three arbitrators under the then-existing comprehensive
Rules and Procedures of ICC, Paris, in the English language. The Parties agree to submit to jurisdiction of, and agree that venue is proper in, these courts in any such legal action or proceeding. The prevailing Party shall be entitled to reasonable
attorney fees and expenses. 

  

	(d)	In the event any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions of this Agreement shall remain in full force.

  

	(e)	All obligations created by this Agreement shall be survive change or termination of any other business relationships between the Parties. 

 

	(f)	The Parties are independent contractors. Nothing contained in this agreement shall be construed (i) to give either party the power to direct or control the
day-to-day activities of the other or (ii) to constitute the Parties as partners, joint ventures, co-owners or otherwise as participants in a joint or common undertaking. 

 

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 4/5 

 IN WITNESS WHEREOF, the Parties hereto have executed this
Agreement as of the date shown above. 
  

					
	SECOND PARTY	 		 	ZOGENIX
			
	 /s/ [illegible]
	 		 	 /s/ John J. Turanin

	Authorized Signature	 		 	Authorized Signature
			
	 /s/ [illegible]
	 		 	 John J. Turanin

	Printed Name	 		 	 Printed Name

			
	 CFO
	 		 	 VP Operations

	Title	 		 	Title
			
	 26/OCT/06
	 		 	 /s/ John J. Turanin

	Date	 		 	Date 26/OCT/06

  

 5/5 

 Schedule 7 

The New Design Equipment and Tooling 

to 
 Commercial Manufacturing and
Supply Agreement 
 between 

MGlas AG 
 and 

Zogenix Corporation 
  

 1/2 

 [***] 
  

  

	[***]	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 2/2 

 Schedule 8 

Exit Documentation and Equipment 
 to

 Commercial Manufacturing and Supply Agreement 

between 
 MGlas AG 

and 
 Zogenix Corporation

  

 1/2 

	1)	Standard Operating Procedures 

  

	 	a)	All SOPs associated only with DosePro manufacturing, testing and work cell 

 

	 	b)	Change history documentation 

  

	2)	Validation/Qualification Documents 

  

	 	a)	All product specific documents 

  

	3)	Materials 

  

	 	a)	Receipt records (Delivery Notes) for 

  

	 	i)	Glass Tubes 

  

	 	ii)	Laser Gases (nitrogen, fluorine in neon, krypton, neon, helium) 

  

	 	iii)	Solutions for Branson, Lancer and Ionx (Deconex OP146/OP171, acetic acid, potassium nitrate/salt) 

 

	 	b)	Material testing records for 

  

	 	i)	Glass Tubes (incoming inspection) 

  

	 	c)	The records of the listed materials described above will be provided for 

  

	 	i)	any remaining stock which are to be transferred to Zogenix and 

  

	 	ii)	those which were consumed during production for two years prior to the date of termination. 

 

	4)	Product 

  

	 	a)	Product specific Batch Records 

  

	 	b)	Release testing records 

  

	 	c)	Other essential documents as mutually agreed by the Steering Committee 

  

	 	d)	These records will be provided for the period specified in the Quality Agreement. Thereby, the obligation as per clause 10.3 of the Quality Agreement will be considered
as fulfilled if and insofar as MG transfers the original documents to Zogenix, e.g. as per clauses 1.7 and 10.3 of the Manufacturing and Supply Agreement. 

 

	5)	Equipment 

  

	 	a)	All equipment listed on asset list 

  

	 	b)	Spares and Zogenix owned consumables 

  

	 	c)	Maintenance record 

  

	 	d)	Calibration records 

  

	 	e)	Relevant log books 

  

	 	f)	Design specs or user requirements 

  

 2/2 

 Schedule 9 

Field 
 to 

Commercial Manufacturing and Supply Agreement 

between 
 MGlas AG 

and 
 Zogenix Corporation

  

 1/2 

 The following therapeutic classes are included in Definition 1.8 “FIELD”: 

Neurology 

Pain 
  

 2/2Co-Promotion Agreement

 Exhibit 10.20 

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 EXECUTION VERSION 

CO-PROMOTION AGREEMENT 

by and between 

ZOGENIX, INC. 

and 
 ASTELLAS
PHARMA US, INC. 
 Dated as of July 31, 2009 

 TABLE OF CONTENTS 

 

			
	 	  	PAGE
	 ARTICLE I DEFINITIONS
	  	1
		
	 ARTICLE II GRANT
	  	15
		
	 Section 2.1     Grant of Promotion Rights
	  	15
		
	 Section 2.2     Performance Through Affiliates and Subcontracting
	  	16
		
	 Section 2.3     Limitation on Sumatriptan Promotion
	  	16
		
	 Section 2.4     [***]
	  	16
		
	 Section 2.5     Retention of Rights
	  	16
		
	 Section 2.6     New Formulations or Dosage Forms
	  	17
		
	 ARTICLE III COORDINATION OF ACTIVITIES
	  	17
		
	 Section 3.1     Establishment of Committees
	  	17
		
	 Section 3.2     Joint Steering Committee
	  	17
		
	 Section 3.3     Joint Product Team
	  	18
		
	 Section 3.4     Joint Medical Team
	  	18
		
	 Section 3.5     Joint Promotional Review Committee
	  	19
		
	 Section 3.6     Other Terms Applicable to Committees
	  	19
		
	 Section 3.7     Disputes
	  	21
		
	 Section 3.8     Alliance Manager
	  	21
		
	 ARTICLE IV PRODUCT PROMOTION
	  	22
		
	 Section 4.1     Product Detailing by Astellas
	  	22
		
	 Section 4.2     Product Detailing by Zogenix
	  	23
		
	 Section 4.3     Mutual Promotion
	  	24
		
	 Section 4.4     Representations to Customers
	  	25
		
	 Section 4.5     Staffing and Training
	  	25

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

			
	 Section 4.6     Promotional Materials; Educational Materials
	  	26
		
	 Section 4.7     Commercial Plan (Including Base Brand A&P Budget)
	  	27
		
	 Section 4.8     Promotion Reports
	  	29
		
	 Section 4.9     Medical Inquiries
	  	29
		
	 Section 4.10   Trademarks
	  	30
		
	 Section 4.11   Product Website
	  	31
		
	 ARTICLE V CLINICAL, COMPLIANCE, AND REGULATORY AFFAIRS
	  	31
		
	 Section 5.1     Regulatory Approvals
	  	31
		
	 Section 5.2     Compliance with Regulatory Requirements
	  	32
		
	 Section 5.3     Compliance
	  	32
		
	 Section 5.4     Communications with Regulatory Authorities
	  	33
		
	 Section 5.5     Product Complaints
	  	34
		
	 Section 5.6     Adverse Drug Experience Reports
	  	34
		
	 Section 5.7     Recalls or Other Corrective Action
	  	35
		
	 Section 5.8     Assistance
	  	35
		
	 ARTICLE VI MANUFACTURING AND SUPPLY; SALES; PRICING
	  	35
		
	 Section 6.1     Obligations of Zogenix
	  	35
		
	 Section 6.2     Volume Forecasts; Sample Forecasts
	  	36
		
	 Section 6.3     [***]
	  	37
		
	 Section 6.4     Sales; Pricing
	  	37
		
	 Section 6.5     Samples
	  	38
		
	 Section 6.6     Manufacturing Matters; Inability to Supply
	  	39
		
	 ARTICLE VII COMPENSATION; RECORDKEEPING; AUDITS
	  	39
		
	 Section 7.1     Astellas Up-Front and Milestone Payments
	  	39
		
	 Section 7.2     A&P Expenses
	  	40

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

			
	 Section 7.3     Certain Medical Affairs Expenses
	  	40
		
	 Section 7.4     Expenses Associated with Certain Phase IV Studies
	  	41
		
	 Section 7.5     Other Expenses
	  	41
		
	 Section 7.6     Quarterly Payment of Expenses
	  	41
		
	 Section 7.7     Service Fees and Adjustment Payments
	  	42
		
	 Section 7.8     Tail Payments
	  	43
		
	 Section 7.9     Maintenance of Records; Audits
	  	43
		
	 Section 7.10   Payments
	  	45
		
	 Section 7.11   Zogenix Segment/Astellas Segment
	  	46
		
	 ARTICLE VIII TERM AND TERMINATION
	  	46
		
	 Section 8.1     Term
	  	46
		
	 Section 8.2     Early Termination
	  	46
		
	 Section 8.3     Force Majeure
	  	49
		
	 Section 8.4     Effect of Termination
	  	49
		
	 ARTICLE IX REPRESENTATIONS AND WARRANTIES
	  	51
		
	 Section 9.1     Representations and Warranties of Zogenix
	  	51
		
	 Section 9.2     Representations and Warranties of Astellas
	  	53
		
	 Section 9.3     Product Warranty
	  	55
		
	 Section 9.4     Zogenix Disclaimer
	  	56
		
	 Section 9.5     Astellas Disclaimer
	  	56
		
	 ARTICLE X INTELLECTUAL PROPERTY MATTERS
	  	56
		
	 Section 10.1   Intellectual Property Prosecution and Maintenance
	  	56
		
	 Section 10.2   Ownership
	  	56
		
	 Section 10.3   Infringement
	  	56
		
	 ARTICLE XI INDEMNIFICATION; LIMITS ON LIABILITY
	  	57

			
	 Section 11.1     Indemnification
	  	57
		
	 Section 11.2     Consequential Damages
	  	59
		
	 ARTICLE XII CONFIDENTIALITY AND PUBLICITY
	  	59
		
	 Section 12.1     Proprietary Information
	  	59
		
	 Section 12.2     Disclosures Required by Law
	  	59
		
	 Section 12.3     Publicity
	  	59
		
	 Section 12.4     Survival
	  	60
		
	 ARTICLE XIII NOTICES
	  	60
		
	 Section 13.1     Notices
	  	60
		
	 ARTICLE XIV INSURANCE
	  	61
		
	 Section 14.1     Insurance
	  	61
		
	 ARTICLE XV MISCELLANEOUS
	  	62
		
	 Section 15.1     Arbitration
	  	62
		
	 Section 15.2     Headings
	  	63
		
	 Section 15.3     Severability
	  	63
		
	 Section 15.4     Entire Agreement
	  	63
		
	 Section 15.5     Amendments
	  	63
		
	 Section 15.6     Counterparts
	  	64
		
	 Section 15.7     Waiver
	  	64
		
	 Section 15.8     Force Majeure
	  	64
		
	 Section 15.9     Successors and Assigns
	  	65
		
	 Section 15.10   Assignment
	  	65
		
	 Section 15.11   Construction
	  	65
		
	 Section 15.12   Governing Law
	  	66
		
	 Section 15.13   Equitable Relief
	  	66

			
	 Section 15.14     Relationship Between Parties
	  	66
		
	 Schedules:
	  	
		
	 Schedule         – Primary Specialty Classifications of Professionals in the
Astellas Segment
	  	
	 Schedule         – Post-Effective Date Expenses
	  	
	 Schedule         – Primary Specialty Classifications of Neurologist Professionals in
the Zogenix Segment
	  	

 CO-PROMOTION AGREEMENT 

This Co-Promotion Agreement (this “Agreement”) is made as of July 31, 2009 (the “Effective Date”),
by and between Zogenix, Inc., a Delaware corporation (“Zogenix”), and Astellas Pharma US, Inc., a Delaware corporation (“Astellas”). Each of Zogenix and Astellas is referred to herein individually as a
“Party” and collectively as the “Parties.” 
 WHEREAS, Zogenix desires to collaborate with
Astellas in the promotion and marketing of the Product in the Territory (each as defined below), and Astellas desires to collaborate with Zogenix with respect to such promotion and marketing, all in accordance with the terms and conditions contained
herein; 
 NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants herein contained, the Parties hereto
intending to be legally bound hereby agree as follows: 
 ARTICLE I 

DEFINITIONS 

As used in this Agreement, the following terms shall have the following meanings: 

Section 1.1 “3PL” has the meaning set forth in Section 6.3(b)(ii). 

Section 1.2 “A&P Expenses” means Post-Effective Date costs and expenses paid by a Party (or any
of its Affiliates) to a Third Party in connection with the marketing, advertising and Promotion of the Product, including costs and expenses with respect to: [***] in a Base Brand A&P Budget in accordance with Article III. Notwithstanding the
foregoing, “A&P Expenses” shall not include Excluded Expenses. 
 Section 1.3
“Act” means the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301, et. seq., as it may be amended from time to time, and the rules, regulations, and requirements promulgated or issued thereunder. 

Section 1.4 “Adverse Drug Experience” means any “adverse drug experience” as defined or
contemplated by 21 C.F.R. 312.32 or 314.80, as may be amended from time to time, associated with the use of the Product. 

Section 1.5 “Adverse Drug Experience Report” means any oral, written or electronic report of any
Adverse Drug Experience transmitted to any Person. 
 Section 1.6 “Affiliate” means, with
respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control with, such first Person. For the purposes of this definition, “control” (including, with correlative meanings,
the terms “controlling,” “controlled by” and “under common control with”), as applied to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and
policies of that Person, whether through the ownership of voting securities, by contract or otherwise. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 1 

 Section 1.7 “Agreement” has the meaning set forth in
the preamble to this Agreement. 
 Section 1.8 “Agreement Month” means each calendar month
during the Term (including any partial calendar month in the case of the first and last calendar months of the Term). 

Section 1.9 “Agreement Quarter” means the Initial Agreement Quarter, and each successive calendar
quarter during the Term after the Initial Agreement Quarter (including any partial calendar quarter in the case of the last calendar quarter during the Term). 

Section 1.10 “Agreement Year” means each calendar year during the Term (including any partial
calendar year in the case of the first and last calendar years of the Term). 
 Section 1.11
“Alliance Manager” has the meaning set forth in Section 3.8. 
 Section 1.12
“Allocated A&P Expenses” means those A&P Expenses designated as such in the Base Brand A&P Budget and allocated between the Parties as set forth in the Base Brand A&P Budget based on [***], including, to the extent
designated as Allocated A&P Expenses, (a) A&P Expenses for [***] and (b) A&P Expenses for [***]. 

Section 1.13 “Astellas” has the meaning set forth in the Preamble to this Agreement. 

Section 1.14 “Astellas Compliance Materials” has the meaning set forth in Section 5.3(a).

 Section 1.15 “Astellas [***]” has the meaning set forth in Section 4.1(a).

 Section 1.16 “Astellas Net Sales” means, with respect to a particular calendar month,
the product of (a) the Astellas Segment Dispensed Units for such calendar month, multiplied by (b) the Net Selling Price for that calendar month. 

Section 1.17 “Astellas Promotional Effort” has the meaning set forth in Section 4.1(a).

 Section 1.18 “Astellas Sales Force” means the field force of Sales Representatives
employed or contracted by Astellas. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 2 

 Section 1.19 “Astellas Segment” means Professionals in
the Territory with the primary classifications set forth on Schedule 1.19. 
 Section 1.20 “Astellas
Segment Dispensed Units” means, with respect to a particular calendar month, the number of [***] as measured by the third party national audit by Wolters Kluwer (or such other Third Party data source as the Parties may agree from time to
time), excluding [***] (as agreed upon in the Base Brand A&P Budget). By way of clarification, as of the Effective Date, such number of [***] is described as [***] data in the third party national audit by Wolters Kluwer (and, for clarity, such
number, as of the Effective Date, excludes [***] such audit). 
 Section 1.21 “Astellas
Trademarks” means those Trademarks owned or Controlled by Astellas or its Affiliates and identified in a Trademark Consent. 

Section 1.22 “Back Order Events” has the meaning set forth in Section 6.3(c). 

Section 1.23 “Base Brand A&P Budget” means the detailed budget developed in connection with each
Commercial Plan setting forth the level of spending with respect to A&P Expenses for which each Party shall be responsible pursuant to this Agreement. The Initial Base Brand A&P Budget has been exchanged in connection with the execution of
this Agreement and is made binding hereunder. 
 Section 1.24 “Business Day” shall mean a
day other than a Saturday or Sunday on which banking institutions in California and Illinois are open for business. 

Section 1.25 “Call Plan” means, with respect to the applicable period, the planning document, in a
mutually agreed upon format, proposed by the JPT and approved by the JSC, identifying Jointly Called On Physicians and setting forth call frequency objectives for such Professionals, and identifying Professionals in the Astellas Segment that
Astellas does not intend to call upon during the applicable period and with respect to which the Zogenix Sales Force shall have the right to make calls. 

Section 1.26 “cGMP” shall mean “current Good Manufacturing Practices” as such term is
defined from time to time by the FDA or other relevant Governmental Authority having jurisdiction over the manufacture or sale of the Product pursuant to its regulations, guidelines or otherwise. 

Section 1.27 “Claim” has the meaning set forth in Section 11.1(a). 

Section 1.28 “Co-Funded A&P Expenses” has the meaning set forth in Section 7.2. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 3 

 Section 1.29 “Co-Funded Medical Affairs Expenses” has
the meaning set forth in Section 7.3. 
 Section 1.30 “Co-Funded Phase IV Expenses”
has the meaning set forth in Section 7.4. 
 Section 1.31 “Co-P2 Detail” means a
Detail in which the promotional message involving the Product receives [***] during the contact and [***] during the contact, and with respect to which [***] of Incentive Compensation of the applicable Sales Representative as applied to the Product
is [***]. 
 Section 1.32 “Commercial Plan” means the planning document, in a mutually
agreed upon format, setting forth brand objectives, strategic initiatives, and tactical activities related to the Promotion of the Product in the Territory. The Initial Commercial Plan has been exchanged in connection with the execution of this
Agreement and is made binding hereunder. 
 Section 1.33 “Commercial Officers” means the
designated commercial heads of Zogenix and Astellas (or their respective Affiliates), who may be the Chief Executive Officer, Chief Operating Officer, Chief Commercial Officer, Executive Vice President/Senior Vice President of Sales and Marketing,
Vice President of Marketing, Vice President of Sales, or Executive Vice President/Senior Vice President of Commercial (or, if there is no such officer, such other executive or senior officer of the Party or an Affiliate designated by the Chief
Executive Officer of the Party); provided that [***] may be a member of a Committee except [***] 

Section 1.34 “Competing Activities” has the meaning set forth in Section 2.3. 

Section 1.35 “Compliance Materials” has the meaning set forth in Section 5.3(b). 

Section 1.36 “Compliance Records” has the meaning set forth in Section 7.9(a)(i). 

Section 1.37 “Components” means any Product in-process materials, including actuator assemblies.

 Section 1.38 “Confidentiality Agreement” means that certain Confidentiality Agreement
between Zogenix and Astellas US LLC dated August 18, 2008. 
 Section 1.39 “Control”
or “Controlled” means, with respect to patents, know-how, data, information, or other intellectual property rights of any kind, the possession by a Person of the ability to grant a license or sublicense in and to such rights without
violating the terms of any agreement or arrangement between such Person and any other Person. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 4 

 Section 1.40 “DDMAC” means the FDA’s Division of
Drug Marketing, Advertising and Communications, or any successor Governmental Authority performing comparable functions in the Territory. 

Section 1.41 “Deductions” means, with respect to a particular calendar month, the following
deductions paid, incurred or accrued, applied in a consistent manner and (as applicable) calculated in accordance with GAAP (consistently applied): [***] 

Section 1.42 “Demand Unit” means, with respect to a particular period, the number of [***] as
measured by the third party national audit by Wolters Kluwer (or such other Third Party data source as the Parties may agree from time to time), excluding [***] (as agreed upon in the Base Brand A&P Budget). By way of clarification, as of the
Effective Date, such number of [***] is described as [***] data in the third party national audit by Wolters Kluwer (and, for clarity, such number, as of the Effective Date, excludes [***] such audit). 

Section 1.43 “Detail” means an in-person, face-to-face sales presentation of the Product made by a
Sales Representative to a Professional, including a P1 Detail, a P2 Detail, or a Co-P2 Detail. 

Section 1.44 “Development Officers” means the designated lead development heads of Zogenix and
Astellas (or their respective Affiliates), who may be the Chief Development Officer or Executive Vice President/Senior Vice President of Development or Research and Development (or, if there is no such officer, such other executive officer or senior
officer of the Party or an Affiliate designated by the Chief Executive Officer of the Party). 

Section 1.45 “Effective Date” has the meaning set forth in the preamble to this Agreement.

 Section 1.46 “Enforcement Action” has the meaning set forth in Section 10.3(b).

 Section 1.47 “Excluded Expenses” means costs and expenses paid by a Party (or any of its
Affiliates) in connection with: [***] 
 Section 1.48 “Expense Records” has the meaning set
forth in Section 7.9(a)(iv). 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 5 

 Section 1.49 “FDA” means the United States Food and
Drug Administration or any successor agency performing comparable functions in the Territory. 

Section 1.50 “Final Astellas Promotional Period” has the meaning set forth in Section 7.8.

 Section 1.51 “Force Majeure Event” has the meaning set forth in Section 15.8(a).

 Section 1.52 “GAAP” means generally accepted accounting principles as applied in the
United States. 
 Section 1.53 “Generic Drug Act” has the meaning set forth in
Section 9.1(h). 
 Section 1.54 “Governmental Authority” means any court, agency,
authority, department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or any supranational
organization of which any such country is a member, which has competent and binding authority to decide, mandate, regulate, enforce, or otherwise control the activities of the Parties contemplated by this Agreement. 

Section 1.55 “Health Care Provider” means any “health care provider,” as that term is used
in the PhRMA Code. 
 Section 1.56 “Hospital Segment” means the non-federal hospital
setting outside of Emergency Medicine. 
 Section 1.57 “Incentive Compensation” means, with
respect to a Sales Representative and the Product, the variable, periodic target compensation [***] to which the Sales Representative becomes eligible based on the performance by such Sales Representative. 

Section 1.58 “Indemnified Party” has the meaning set forth in Section 11.1(a). 

Section 1.59 “Indemnified Person” has the meaning set forth in Section 11.1(a). 

Section 1.60 “Indemnifying Party” has the meaning set forth in Section 11.1(a). 

Section 1.61 “Initial Agreement Quarter” means the period commencing on the Effective Date and
ending on September 30, 2009. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 6 

 Section 1.62 “Initial Base Brand A&P Budget” means
the first Base Brand A&P Budget under this Agreement, which Base Brand A&P Budget shall cover the period commencing on the Effective Date and ending on [***] shall set forth a preliminary budget, including [***], for the period commencing on
[***] (such preliminary budget for [***], the “Preliminary 2010 Budget”). 
 Section 1.63
“Initial Commercial Plan” means the first Commercial Plan under this Agreement, which Commercial Plan shall cover the activities to be conducted and the expenses for which each Party shall be responsible during the Launch Period.
The Initial Commercial Plan shall include the Initial Base Brand A&P Budget. 
 Section 1.64
“Initial Period” has the meaning set forth in Section 4.7(a). 
 Section 1.65
“Initial Sales Force Training Program” has the meaning set forth in 4.5(d). 
 Section 1.66
“Initial Sample Forecast” has the meaning set forth in Section 6.2(c). 
 Section 1.67
“Initial Term” has the meaning set forth in Section 8.1(a). 
 Section 1.68
“Initial Volume Forecast” has the meaning set forth in Section 6.2(b). 
 Section 1.69
“JAMS” has the meaning set forth in Section 15.1. 
 Section 1.70 “Jointly
Called On Physicians” means Professionals to whom both Zogenix and Astellas may direct Details in accordance with the Call Plan, which Professionals shall consist of (a) in the case of Zogenix, [***], and (b) in the case of
Astellas, [***]. 
 Section 1.71 “JMT” has the meaning set forth in Section 3.1.

 Section 1.72 “JPRC” has the meaning set forth in Section 3.1. 

Section 1.73 “JPT” has the meaning set forth in Section 3.1. 

Section 1.74 “JSC” has the meaning set forth in Section 3.1. 

Section 1.75 “Launch” means the first commercial sale of the Product in the Territory to a Third
Party once all Regulatory Approvals have been obtained. 
 Section 1.76 “Launch Period” has
the meaning set forth in Section 4.1(b). 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 7 

 Section 1.77 “Legal Requirements” means (a) the
American Medical Association Guidelines on Gifts to Physicians from Industry, (b) the PhRMA Code, (c) the Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers, dated April, 2003, (d) the Act, the
Generic Drug Act, the PDMA, the FDA’s applicable regulations and guidelines concerning the advertising of prescription drug products, and DDMAC’s applicable promotional guidelines, and (e) all federal, state and local laws, and the
rules, regulations, guidances, guidelines and requirements of all Governmental Authorities in effect from time to time applicable to the manufacture, Promotion, distribution, warehousing, handling, and sale of the Product (including Samples) in the
Territory, including those governing price reporting, reimbursement, monetary disclosure, anti-kickback matters, false claims, and equal employment and non-discrimination. 

Section 1.78 “Letter Agreement” has the meaning set forth in Section 15.4. 

Section 1.79 “Loss” has the meaning set forth in Section 11.1(a). 

Section 1.80 “[***] Threshold” has the meaning set forth in Section 8.2(c)(ii). 

Section 1.81 “[***] Threshold” has the meaning set forth in Section 8.2(c)(ii). 

Section 1.82 “[***]” means, with respect to a particular period, the Astellas [***] or the Zogenix
[***], as applicable. 
 Section 1.83 “NDA” means the “new drug application” (as
such term is used under the Act) with respect to the Product with reference number 22-239 that was submitted by Zogenix to the FDA on December 28, 2007 and approved by the FDA on July 15, 2009, and all subsequent submissions, supplements,
and amendments thereto. 
 Section 1.84 “Net Sales” means, with respect to a particular
[***], the gross invoiced sales of Product to a Third Party in the Territory for that [***], less the Deductions for that [***]. 

Section 1.85 “Net Selling Price” means, with respect to a particular [***], the quotient of
(a) the Net Sales for such [***], divided by (b) the number of Territory Invoiced Units for such [***], provided that with respect to any [***] for which there are no Territory Invoiced Units, the Net Selling Price for such [***]
shall be equal to the Net Selling Price for the most recent preceding [***] in which there were Territory Invoiced Units. 

Section 1.86 “Net Sales Records” has the meaning set forth in Section 7.9(a)(vi). 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 8 

 Section 1.87 “Option Exercise Period” has the meaning
set forth in Section 8.1(b). 
 Section 1.88 “Option Payment” has the meaning set
forth in Section 8.1(b). 
 Section 1.89 “Order” means any award, decision,
injunction, judgment, decree, order, ruling, or verdict entered, issued, made, or rendered by any Governmental Authority or by any arbitrator. 

Section 1.90 “P1 Detail” means a Detail in which the promotional message involving the Product is
the principal topic of discussion during the contact, regardless of the Incentive Compensation of the Sales Representative who performs the Detail. 

Section 1.91 “P2 Detail” means a Detail in which the promotional message involving the Product is
emphasized more than any other product during the contact, except for the product in the P1 Detail, regardless of the Incentive Compensation of the Sales Representative who performs the Detail. 

Section 1.92 “Paragraph IV Notice” has the meaning set forth in Section 10.3(a). 

Section 1.93 “PDMA” means the Prescription Drug Marketing Act, as amended, and the rules and
regulations promulgated thereunder. 
 Section 1.94 “Person” means any individual,
corporation (including any non-profit corporation), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union, or other entity or Governmental Authority. 

Section 1.95 “Phase IV Clinical Studies” means all post-Regulatory Approval clinical studies
conducted with the Product, including studies to evaluate effectiveness or impact on patient’s quality of life, to monitor safety, or to fulfill post-Regulatory Approval requirements of a Governmental Authority. 

Section 1.96 “PhRMA Code” means the PhRMA Code on Interactions with Healthcare Professionals
(revised as of July 2008 and as may be further revised from time to time). 
 Section 1.97
“PIR” or “Product Information Request” has the meaning set forth in Section 4.9. 

Section 1.98 “Post-Effective Date” means, with respect to costs and expenses, only those costs and
expenses incurred by a Party (a) after the Effective Date, or (b) prior to the Effective Date and listed on Schedule 1.98. 
  

 9 

 Section 1.99 “Primary Detail Equivalent” means a
primary Detail equivalent for the Product equal to [***], [***], or [***]. For the avoidance of doubt, Details that are not P1 Details, P2 Details, or Co-P2 Details [***]. 

Section 1.100 “Product” means Sumavel DosePro needle-free delivery system (sumatriptan injection
6mg/0.5mL), or such other formulations or dosage strengths of such product deemed to be a Product in accordance with Section 2.6. 

Section 1.101 “Product Complaint” means any written, electronic, or verbal communication that
alleges deficiencies related to the identity, quality, durability, reliability, effectiveness, or performance of the Product after the Product is released for distribution. 

Section 1.102 “Product Website” has the meaning set forth in Section 4.11. 

Section 1.103 “Professional” means a physician or other health care practitioner who is permitted by
law to prescribe the Product. 
 Section 1.104 “Promote,” “Promotional”
and “Promotion” mean those activities normally undertaken by a pharmaceutical company to encourage sales or appropriate use of a product, including details, product sampling, detail aids, coupons, discount cards, journal
advertising, direct mail programs, direct-to-consumer advertising, convention exhibits and other forms of marketing, advertising, public relations or promotion. 

Section 1.105 “Promotion Commencement Date” means the date that is the [***] of (i) the date
that [***], and (ii) the [***] (x) [***], and (y) [***]. 
 Section 1.106 “Promotion
Records” has the meaning set forth in Section 7.9(a)(ii). 
 Section 1.107
“Promotional Effort Reinstatement Date” has the meaning set forth in Section 4.1(e). 

Section 1.108 “Promotional Materials” has the meaning set forth in Section 4.6(a). 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 10 

 Section 1.109 “Proprietary Information” means any
proprietary or confidential information communicated by or on behalf of one Party (or any of its Affiliates) to the other Party (or any of its Affiliates) in connection or relating to this Agreement (including discussions and negotiations relating
hereto), whether communicated prior to, on, or following the Effective Date, including the Technology and financial, marketing, business, technical and scientific information or data, information related to a Party’s compensation of its Sales
Representatives, information contained within any Commercial Plan or Base Brand A&P Budget, and the information exchanged pursuant to this Agreement, whether communicated in writing, orally or electronically. For the avoidance of doubt, the
commercial data and information generated by each Party in connection with its activities under this Agreement are the Proprietary Information of that Party, the terms of this Agreement are the Proprietary Information of both Parties, and training
materials provided by Astellas to Zogenix are the Proprietary Information of Astellas (in each case, subject to the exceptions below). Proprietary Information shall not include information that the receiving Party can show through written
documentation: 
 (a) at the time of disclosure, is publicly known; 

(b) after the time of disclosure, becomes part of the public domain, except by breach of an agreement between the
disclosing Party or any Affiliate thereof and the receiving Party or any Affiliate thereof; 
 (c) is or was in
the possession of the receiving Party or any Affiliate thereof at the time of disclosure by the disclosing Party and was not acquired directly or indirectly from the disclosing Party or any Affiliate thereof or from any Third Party under an
agreement of confidentiality to the disclosing Party or any Affiliate thereof; and 
 (d) is or was developed by
the receiving Party or its Affiliates without use of or reference to the other Party’s Proprietary Information. 

Section 1.110 “Quarterly Expense Share” has the meaning set forth in Section 7.6. 

Section 1.111 “Regulatory Approval” means any and all consents or other authorizations or approvals
required from a Governmental Authority to market and sell the Product in the Territory. 
 Section 1.112
“Royalty Payments” has the meaning set forth in Section 8.4(b). 
 Section 1.113
“Safety Stock” means (a) with respect to each [***], a quantity of the Product equal to the [***] of the Product [***] prior to such [***]; and (b) with respect to each [***], the quantity of the Product for [***]; which
Product, in each case, ((a) and (b)), to qualify as Safety Stock during such month (x) shall [***], (y) must meet [***], and (z) has [***]. 

Section 1.114 “Sales Force” means the Astellas Sales Force or the Zogenix Sales Force, as the case
may be.
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 11 

 Section 1.115 “Sales Representatives” means sales
representatives employed by Astellas or Zogenix, or employed or contracted by a Third Party contracted by Astellas or Zogenix to provide sales representatives, to Detail the Product, who have been trained and equipped to Detail the Product in
accordance with this Agreement.
 Section 1.116 “Sample Forecast” has the meaning set forth
in Section 6.2(d). 
 Section 1.117 “Sample Order” means a written purchase order in a
form reasonably acceptable to Zogenix that sets forth, with respect to the period covered thereby, (a) the quantities of Samples to be delivered by Zogenix to Astellas and (b) the required delivery dates therefor. 

Section 1.118 “Samples” has the meaning set forth in Section 6.5(a). 

Section 1.119 “Selected Deductions” means all Deductions other than those described in
Section 1.41(d).  
 Section 1.120 “Serious Adverse Drug Experience” means any
“serious adverse drug experience” as defined or contemplated by 21 C.F.R. 312.32 or 314.80, as may be amended from time to time, associated with use of the Product. 

Section 1.121 “Serious Adverse Drug Experience Report” means any Adverse Drug Experience Report that
involves a Serious Adverse Drug Experience. 
 Section 1.122 “Service Fee” has the meaning
set forth in Section 7.7(a). 
 Section 1.123 “Shared A&P Expenses” means A&P
Expenses, other than Allocated A&P Expenses. 
 Section 1.124 “Specialty Level Data”
means national data provided by Wolters Kluwer (or such other Third Party data providers as the Parties may agree from time to time) that measures Units dispensed with respect to specialties in the applicable segment in the Territory during a
specified time period. 
 Section 1.125 “Subsequent Plan Period” has the meaning set forth
in Section 4.7(a). 
 Section 1.126 “Tail Payment” has the meaning set forth in
Section 7.8. 
 Section 1.127 “Technology” means all pharmacological, toxicological,
preclinical, clinical, technical or other similar information, data and analysis and know-how relating to the Product or the manufacture thereof and all proprietary rights relating thereto owned or otherwise Controlled by Zogenix or its Affiliates;
provided that, for clarity, commercial data and information generated by or for Astellas hereunder shall not constitute Technology. 

Section 1.128 “Term” means the Initial Term and any extension period following exercise of the Term
Extension Option. 
  

 12 

 Section 1.129 “Term Extension Option” has the meaning
set forth in Section 8.1(b). 
 Section 1.130 “Territory” means the United States,
excluding Puerto Rico and the other territories and possessions of the United States. 
 Section 1.131
“Territory Invoiced Units” means, with respect to a particular [***], the number of Units invoiced by or on behalf of Zogenix to Third Parties in the Territory. 

Section 1.132 “Third Party” means any Person other than Astellas or Zogenix or their respective
Affiliates. 
 Section 1.133 “Timely Supply” means (a) with respect to [***], the
delivery by Zogenix of such Samples by [***], and (b) with respect to [***] the delivery by Zogenix of such Product [***]. 

Section 1.134 “Trade Demand” means, with respect to any period, the aggregate number of Units
ordered for delivery by Zogenix during such period by Third Party wholesalers, other distributors, and retailers in the Territory. 

Section 1.135 “Trademark” means any trademark, trade dress, service mark, trade name, brand name,
corporate name, logo, business symbol, or any other source identifying word, slogan, symbol or design, or any combination thereof, whether registered or unregistered, or any registration and application therefor or any renewal of such registration.

 Section 1.136 “Trademark Consent” has the meaning set forth in Section 4.10(b).

 Section 1.137 “Training Records” has the meaning set forth in Section 7.9(a)(iii).

 Section 1.138 “Unit” means a single dose of Product. 

Section 1.139 “United States Bankruptcy Code” means the U.S. Bankruptcy Code, 11 U.S.C. §§
101, et seq. 
 Section 1.140 “Vacancy” means, with respect to a Sales Force, a vacancy in
the position of a Sales Representative included or contemplated to be included in the Sales Force or other sustained unavailability of such a Sales Representative to Detail the Product during the relevant period. 

Section 1.141 “Volume Forecast” has the meaning set forth in Section 6.2(b). 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 13 

 Section 1.142 “Volume Records” has the meaning set
forth in Section 7.9(a)(v). 
 Section 1.143 “WAC” means wholesale acquisition cost as
published by Zogenix in national price compendia. 
 Section 1.144 “Zogenix” has the
meaning set forth in the preamble to this Agreement. 
 Section 1.145 “Zogenix Change of
Control” shall occur when: 
 (a) any person or “group” (as such terms are defined below) is
or becomes the “beneficial owner” (as defined below), directly or indirectly, of shares of capital stock or other interests of Zogenix then outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in
the election of the directors, managers, or similar supervisory positions (“Voting Stock”) of Zogenix representing [***] or more of the total voting power of all outstanding classes of Voting Stock of Zogenix; 

(b) Zogenix enters into a merger, consolidation, or similar transaction with another Person (whether or not Zogenix is the
surviving entity) and as a result of such merger, consolidation, or similar transaction the Persons that beneficially owned, directly or indirectly, the shares of Voting Stock of Zogenix immediately prior to such transaction do not beneficially own,
directly or indirectly, shares of Voting Stock of the surviving Person representing at least a majority of the total voting power of all outstanding classes of Voting Stock of the surviving Person, other than a merger, consolidation, or similar
transaction with another Person in which more than [***] of the individuals with a vice president or more senior title with Zogenix prior to such merger, consolidation, or similar transaction remain with the surviving Person; 

(c) Zogenix sells or transfers to any Third Party, in one or more related transactions, properties or assets representing
all or substantially all of Zogenix’s assets; or 
 (d) the holders of capital stock of Zogenix approve a
plan or proposal for the liquidation or dissolution of Zogenix. 
 For the purpose of this definition of Zogenix Change of
Control, (A) “person” and “group” have the meanings given such terms under Section 13(d) and 14(d) of the United States Securities Exchange Act of 1934 and the term “group” includes any group acting for the
purpose of acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the United States Securities Exchange Act of 1934, (B) a “beneficial owner” shall be determined in accordance with Rule 13d-3 under
the United States Securities Exchange Act of 1934, and (C) the term “beneficially owned” and “beneficially own” shall have meanings correlative to that of “beneficial owner.” 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 14 

 Section 1.146 “Zogenix Compliance Materials” has the
meaning set forth in Section 5.3(b). 
 Section 1.147 “Zogenix [***]” means, with
respect to a particular period, the obligations set forth in Section 4.2(a). 
 Section 1.148
“Zogenix Promotional Effort” has the meaning set forth in Section 4.2(a). 

Section 1.149 “Zogenix Sales Force” means the field force of Sales Representatives employed or
contracted by Zogenix. 
 Section 1.150 “Zogenix Segment” means (a) Professionals in
the Territory with a primary classification of Neurologist as set forth on Schedule 1.150 and (b) such other Professionals in the Territory as are not included in the Astellas Segment. Such classification shall be made pursuant to a mutually
agreed upon source. 
 Section 1.151 “Zogenix Supply Failure” shall occur if, in any [***],
Zogenix [***], the lesser of (a) [***], or (b) [***] as specified in [***]. 

Section 1.152 “Zogenix Trademarks” means the Trademarks consisting of
(a) SumavelTM, for which Zogenix has sought registration for in the United States Patent and Trademark Office, (b) DoseProTM, for which Zogenix has sought registration for in the United States Patent and Trademark Office,
(c) Zogenix®, and (d) such other Trademarks owned or Controlled by Zogenix approved for use with the
Product by the JPT, and, in each case, all related domain names and other trademark related rights. 
 ARTICLE II

 GRANT 

Section 2.1 Grant of Promotion Rights 

During the Term, subject to and in accordance with the terms and conditions of this Agreement, Zogenix hereby grants to Astellas and
Astellas hereby accepts a co-exclusive (with Zogenix) right to Promote the Product under the Zogenix Trademarks in the Territory. For purposes of clarification, subject to and in accordance with the terms and conditions of this Agreement, Zogenix
shall, at all times during the Term, have the right itself or through the use of Third Party Sales Representatives to Promote the Product in the Territory. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 15 

 Section 2.2 Performance Through Affiliates and Subcontracting 

No Party may assign, subcontract, or otherwise transfer or delegate any of its rights (including rights and licenses granted pursuant to
Section 4.6 or 4.10) or obligations under this Agreement without the express written permission of the other Party, which consent may be withheld by the other Party in its sole discretion, except that: (a) either Party may transfer,
assign, or delegate such rights or obligations pursuant to Section 15.10; and (b) without the other Party’s consent, (i) either Party may perform any or all of its obligations and exercise any or all of its rights and licenses
under this Agreement through any of its Affiliates; provided, however, that such Party shall remain responsible for the performance of its obligations under this Agreement; (ii) either Party may subcontract with one or more Third Parties
to provide Sales Representatives to Detail the Product; and (iii) Zogenix may subcontract or sublicense to a Third Party its right and obligation to manufacture the Product hereunder. 

Section 2.3 Limitation on Sumatriptan Promotion 

Neither Party shall Promote, distribute, offer for sale, or sell any product containing injectable sumatriptan or injectable triptan as
an active ingredient in the Territory during the Term, other than the Product (such Promotion, distribution, offering for sale or selling, “Competing Activities”), provided, however, that if either Party is the subject of any
acquisition, merger, consolidation, or similar transaction with or by a Third Party (including any acquisition of all or substantially all of such Party’s business or assets relating to the Product by a Third Party or the acquisition by such
Party of the business or any assets of a Third Party) and that Third Party (or its assets that are being acquired) is engaged in Competing Activities or has a license, ownership interest or other rights in one or more products, the Promotion,
distribution, offering for sale, or selling of which would constitute Competing Activities (each, a “Competing Product”), then the continuation or other conduct of those Competing Activities or Competing Activities with respect to
any such Competing Product by such Party (or its successor, acquiror, or assignee) shall be deemed not to be a breach of this Section 2.3. 

Section 2.4 [***] 

[***]. 

Section 2.5 Retention of Rights 

Zogenix retains and shall retain all proprietary and property interests in the Product until the point of sale or, in the case of
Samples, until delivered to Astellas as contemplated by Section 6.5. Astellas shall not have nor represent that it has any control or proprietary interest or property interests in the Product, except for the rights and licenses granted
hereunder. Except as expressly set forth herein, nothing contained herein shall be deemed to grant Astellas, by implication, a license or other right or interest in any patent, Trademark or other similar property of Zogenix or its
Affiliates. Except as expressly set forth herein, nothing contained herein shall be deemed to grant Zogenix, by implication, a license or other right or interest in any patent, Trademark or other similar property of Astellas or its Affiliates.

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 16 

 Section 2.6 New Formulations or Dosage Forms 

If Zogenix develops during the Term an injection product with sumatriptan as an active ingredient administered through the DosePro
needle-free delivery system with a formulation or dosage strength of sumatriptan that is different from the Product, then Zogenix shall provide written notice to Astellas of such development [***] and Astellas shall have the right upon written
notice to Zogenix within [***] elect to have such product be deemed a Product under this Agreement. If Astellas timely makes such election, the Parties shall diligently and in good faith negotiate suitable amendments to this Agreement to incorporate
such product in this Agreement (including financial terms) and to provide Astellas the right to co-promote such product. For the avoidance of doubt, nothing contained in this Section 2.6 is in derogation of Zogenix’s obligations under
Section 2.3. 
 ARTICLE III 

COORDINATION OF ACTIVITIES 

Section 3.1 Establishment of Committees 

Within thirty (30) days of the Effective Date, the Parties agree to establish, in each case for the purposes specified herein,
(i) a Joint Steering Committee (the “JSC”); (ii) a Joint Product Team (“JPT”); (iii) a Joint Medical Team (“JMT”); and (iv) a Joint Promotional Review Committee
(“JPRC”, and collectively with the JSC, the JPT, and the JMT, the “Committees”)). The Parties acknowledge and agree that none of the Committees has the power to amend, modify or waive any of the terms or
conditions of this Agreement. 
 Section 3.2 Joint Steering Committee 

(a) The JSC shall be established by the Parties and shall be made up of an equal number of representatives from each Party. Initially,
the JSC shall have [***] members, [***] of whom shall be appointed by Zogenix in its sole discretion, and [***] of whom shall be appointed by Astellas in its sole discretion. Subject to appropriate confidentiality undertakings, each Party shall have
the right, upon written notice to the other Party, to have present at JSC meetings additional, non-voting participants (which participants may be members of Committees). Such additional participants shall not be deemed to be, and shall not have
any of the rights or responsibilities of, members of the JSC. 
 (b) The JSC shall have the following responsibilities:
(i) providing oversight and guidance for the strategic development and commercial direction of the Product in the Territory; (ii) reviewing and approving the Commercial Plan (other than the Initial Commercial Plan), the Base Brand A&P
Budget (other than the Initial Base Brand A&P Budget), and the Call Plan on an annual basis, and reviewing and approving updates and amendments thereto; (iii) overseeing the work of the other Committees, and receiving and reviewing reports
and other information submitted by the other Committees; (iv) serving as a forum for the Parties to agree upon alternative scenarios with respect to the minimum Promotional efforts required by one or both Parties in calendar year 2011 or any
later year as contemplated in Sections 4.1(c)(ii), 4.1(d)(ii), and 4.2(c)(ii); (v) approving Promotional activities or expenditures proposed to be undertaken or paid by a Party, which activities or expenditures are different than or in excess
of those required to be conducted by such Party pursuant to the then-current Commercial Plan or Base Brand A&P Budget; (vi) resolving all disputes referred to it by the other Committees; (vii) approving Volume Forecasts;
(viii) determining the quantity of Safety Stock required as contemplated in Section 1.113; (ix) changing the minimum number [***] required for Samples (which change shall be determined by the unanimous decision of the JSC (and for
clarity, any dispute with respect to such change may not be escalated pursuant to Section 3.7)); and (x) making such other decisions as may be delegated to the JSC pursuant to this Agreement or by written agreement of the Parties from time
to time. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 17 

 (c) Notwithstanding the foregoing, (i) the JSC has no authority to make decisions with
respect to matters that relate to the development of, or Regulatory Approval for, the Product without Zogenix’s prior written consent, (ii) the JSC has no authority to require a Party to engage in Promotion activities beyond those
obligations set forth in Article IV, and (iii) the JSC has no authority to amend or waive any term or condition of this Agreement. 

Section 3.3 Joint Product Team 

The JPT shall be established by the Parties and shall be made up of an equal number of representatives of each Party. Initially, the JPT
shall have [***] members, [***] of whom shall be appointed by Zogenix in its sole discretion, and [***] of whom shall be appointed by Astellas in its sole discretion. The JPT shall have the following responsibilities: (i) facilitating
collaboration between the Parties on all Product sales and marketing strategies and programs in the Territory, including matters relating to managed care and trade; (ii) preparing updates to the Commercial Plan and the related Base Brand
A&P Budget, including allocating Allocated A&P Expenses, and monitoring, reviewing, discussing and amending such plan and budget as necessary throughout the year; (iii) preparing and updating the Call Plan and monitoring the
Parties’ performance thereunder; (iv) preparing and updating Volume Forecasts and Sample forecasts, consistent with Article VI; (v) reviewing Incentive Compensation for the Astellas Sales Force and the Zogenix Sales Force
(provided that Parties shall only be obligated to share those aspects of Incentive Compensation that are required to be shared to demonstrate Incentive Compensation weighting obligations under Sections 4.1 and 4.2, respectively);
(vi) reviewing and approving (subject to Section 3.7) all matters impacting Net Sales, and matters relating to managed care/health systems, trade and pricing, including matters relating to the WAC and Deductions; (vii) creating,
developing, or otherwise obtaining all Promotional Materials; (viii) approving Promotional activities proposed to be undertaken by a Party, which activities are in excess of those required to be conducted by such Party pursuant to the
then-current Commercial Plan or Base Brand A&P Budget; and (ix) making such other decisions as may be delegated to the JPT pursuant to this Agreement or by written agreement of the Parties from time to time. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 18 

 Section 3.4 Joint Medical Team 

The JMT shall be established by the Parties and shall be made up of an equal number of representatives of each Party. Initially, the JMT
shall have [***] members, [***] of whom shall be appointed by Zogenix in its sole discretion, and [***] of whom shall be appointed by Astellas in its sole discretion; provided that no representative from either Party may have a functional
area of responsibility that is sales or marketing. The JMT shall have the following responsibilities: (i) pre-approving and allocating the projected and actual costs and expenses of Third Party contractors and vendors (including contract
research organizations) engaged in connection with the performance of Phase IV Clinical Studies that the Parties agree in writing to conduct jointly and facilitating activities related to the development, execution and funding of such Phase IV
Clinical Studies and other clinical related efforts for the Product in the Territory, and (ii) reviewing and approving in advance any expenses payable or that may become payable to Third Party contractors and vendors engaged in connection with
the performance of Zogenix’s medical affairs obligations under Section 4.9 that are proposed to be treated as Co-Funded Medical Affairs Expenses. 

Section 3.5 Joint Promotional Review Committee 

The JPRC shall be established by the Parties and shall be made up of an equal number of representatives of each Party. Initially, the
JPRC shall have [***] members, [***] of whom shall be appointed by Zogenix in its sole discretion, and [***] of whom shall be appointed by Astellas in its sole discretion; provided that among each Party’s appointees shall be [***] whose
functional area of responsibility is legal affairs, [***] whose functional area of responsibility is regulatory affairs, [***] whose functional area of responsibility is medical affairs, and [***] whose functional area of responsibility is
marketing. The JPRC shall be responsible for (i) reviewing and approving all Promotional Materials, and (ii) reviewing and approving all standard written materials (including scripts) to by provided or used by or on behalf of Zogenix in
responding to PIRs (as set forth in Section 4.9) pursuant to a process to be mutually agreed between the Parties (however, the representatives performing the review and approval under this clause (ii) shall be limited to the
representatives whose functional areas of responsibility are legal affairs, regulatory affairs, and medical affairs). For the avoidance of doubt, Zogenix shall have primary responsibility for managing the overall JPRC process, and as the holder of
the NDA shall have responsibility for all DDMAC submissions and managing the DDMAC relationship. 
 Section 3.6 Other
Terms Applicable to Committees 
 (a) Subject to Section 3.7, decisions of each Committee shall be made by
agreement between the representatives of Astellas, on the one hand, and the representatives of Zogenix, on the other hand. For the avoidance of doubt, each Party shall have an equal voice in decision-making, regardless of the number of
representatives of that Party present or voting. No decision of a Committee shall be valid unless each Party is represented by at least [***] member at the meeting at which the decision is made. The Parties shall cause their respective
representatives on each Committee to use their good faith efforts to resolve all matters appropriately presented to them in an expeditious manner. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 19 

 (b) Each Party has, prior to the Effective Date, provided to the other Party its initial
appointments to each Committee. A Party may change any of its representatives at any time by giving written notice to the other Party. The total number of members on a Committee may be changed by agreement of the Parties from time to time,
provided that each Party has the right, in its sole discretion, to appoint an equal number of members to the Committee. The members appointed to the Committee by each Party shall be employees of such Party and shall have the requisite
experience and seniority to make decisions on behalf of such Party with respect to issues falling within the jurisdiction of the Committee; provided that either Party may appoint non-employee legal representatives or consultants to serve as
members of the JPT, JMT, or JPRC with the prior written consent of the other Party, such consent not to be unreasonably withheld. 

(c) The chair of each Committee will be an employee of Zogenix or, with Zogenix’s consent, an employee of Astellas. The chair
of a Committee shall have the authority and responsibility to call meetings of the Committee, to propose agendas for (and any other member of the Committee may add items to such agendas) and preside over such meetings, and to appoint a secretary to
record minutes for such meetings. The chair shall have no tie-breaking vote, or any other authority or power beyond those of the other members of the Committee, except to the extent granted by agreement of the Parties. 

(d) Meetings of any Committee may be called by the chair of the Committee from time to time and, upon no less than ten
(10) days’ notice, shall otherwise be called when requested by a Party; provided, however, that (i) the JSC shall meet at least one time in calendar year 2009, and at least three (3) times each calendar year thereafter,
and otherwise as required to resolve disputes; (ii) the JPT shall meet at least monthly during the Launch Period and at least every other month thereafter; (iii) meetings of the JMT shall be held as mutually determined by the Parties; and
(iv) meetings of the JPRC shall be held weekly. Meetings may be held in person or by video or telephone conference. Unless otherwise agreed, the location of in-person meetings shall alternate between the corporate offices of the
Parties. The format of the meetings and all other procedural matters shall be decided by the Committee. Minutes of a Committee meeting shall be circulated to the Parties by the secretary promptly following the meeting for review and comment and
for ratification by both Parties at the next meeting of the Committee, which ratification must be unanimous. Each Party shall bear its own travel and related costs incurred in connection with participation in the Committees. 

(e) Communications among members of a Committee in connection with the conduct of the day-to-day business of the Committee shall not be
subject to the notice provisions set forth in Section 13.1, but shall be governed by the communications protocol agreed upon unanimously by the members of the Committee; provided, however, that any notice relating to disputes with
respect to matters arising under the jurisdiction of the Committee (or otherwise) shall be provided pursuant to Section 13.1. 
  

 20 

 Section 3.7 Disputes 

The Parties shall cause their respective representatives on a Committee to use their reasonable efforts to resolve all matters presented
to them as expeditiously as possible. In the event that the JPT, the JMT, or the JPRC is unable to make a decision due to a lack of required unanimity [***], either Party may submit the dispute to the JSC, specifying the nature of the dispute with
sufficient detail to permit adequate consideration. In the event that the JSC is unable to resolve such dispute due to a lack of required unanimity within [***] following consideration of the dispute by the JSC, then either Party may submit the
matter to the Commercial Officers (or, in the case of a dispute arising under the JMT, to the Development Officers) for a joint decision. The Commercial Officers (or Development Officers) shall diligently and in good faith attempt to resolve
the referred dispute expeditiously and, in any event, within [***] days of receiving such written notification, or within such other time as mutually agreed upon in writing between such officers (and if the officers resolve the dispute, such
resolution shall be deemed to be a decision of the JSC). In the event that the Commercial Officers (or Development Officers) are unable to reach a resolution of the dispute within such time period, then: 

(a) if the dispute concerns the adoption of a Commercial Plan (or any update or amendment thereto), then the dispute shall be resolved
pursuant to Section 4.7(a); 
 (b) if the dispute concerns a matter under the jurisdiction of the JPRC (except for matters
relating to the incurring of expenses by one or both Parties or the use of any Astellas Trademark), then Zogenix shall have final decision-making authority after considering in good faith Astellas’s comments and positions with respect to the
issue(s); 
 (c) if the dispute concerns the adoption of a Volume Forecast, then the dispute shall be subject to
Section 6.2(f) and subject to arbitration pursuant to Section 15.1; and 
 (d) all other unresolved disputes shall be
resolved by arbitration pursuant to Section 15.1. 
 For clarity, any dispute with respect to whether a Party has breached its obligations
under this Agreement is not subject to the escalation procedures set forth in this Section 3.7, but either Party may refer such a dispute for resolution by arbitration pursuant to Section 15.1 (and such arbitration shall be the exclusive
means of resolving such dispute). 
 Section 3.8 Alliance Manager. 

Each Party shall appoint one employee who possesses a general understanding of compliance, regulatory, manufacturing, and commercial
issues to act as a primary point of contact between the Parties and to help create and maintain a collaborative work environment within and among the Committees (each such employee, an “Alliance Manager”). Each Alliance Manager may
attend meetings of any Committee as a non-voting participant (unless the Alliance Manager has been appointed as a member of the Committee) and may support the representatives of the Party that appointed the Alliance Manager in the discharge of their
responsibilities. Each Party may change its designated Alliance Manager from time to time upon written notice to the other Party. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 21 

 ARTICLE IV 

PRODUCT PROMOTION 

Section 4.1 Product Detailing by Astellas 

(a) Subject to applicable Legal Requirements as well as the provisions of this Agreement, Astellas shall, from and after the Promotion
Commencement Date during the Term, use commercially reasonable efforts to Detail the Product in the Astellas Segment within the Territory in accordance with the Commercial Plan (the “Astellas Promotional Effort”), provided,
however, that (i) Astellas’s commercially reasonable efforts shall be deemed to be satisfied if Astellas [***] (such obligations, the “Astellas [***]”), and (ii) in the event that, [***]. Astellas shall also have
the right, but not the obligation, to Detail the Product [***]. Astellas shall cause the Astellas Sales Force and Astellas employees and agents acting on Astellas’s behalf to comply with this Agreement and all applicable Legal Requirements in
connection with the Detailing of the Product. It is understood, and Astellas agrees, that it will be accountable for the acts and omissions of the Astellas Sales Force and its employees and agents to the extent such acts or omissions fail to
comply with Astellas’s obligations under this Agreement. 
 (b) From the Promotion Commencement Date until [***] (the
“Launch Period”), Astellas shall Detail the Product in the Astellas Segment pursuant to either of the following scenarios, as Astellas may elect in its sole discretion: 

(i) [***] 

(ii) [***] 
 provided
that Astellas shall not be in breach of this requirement as a result of the Astellas Sales Force having Vacancies up to but not exceeding [***] of the total number of required Sales Representatives during such period. 

(c) During [***], Astellas shall Detail the Product in the Astellas Segment pursuant to one of the following scenarios: 

(i) [***]; or 

(ii) Dedicating such other Astellas Promotional Effort as mutually agreed by the Parties through the JSC. 

(d) During [***], Astellas shall Detail the Product in the Astellas Segment pursuant to one of the following scenarios: 

(i) [***]; or 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 22 

 (ii) Dedicating such other Astellas Promotional Effort as mutually agreed by the Parties
through the JSC. 
 For clarity, the obligation in Section 4.1(d)(i) is not limited by the reference [***]. 

(e) Notwithstanding anything contained in this Section 4.1, Astellas shall have the right to suspend its performance of its
obligations pursuant to this Section 4.1 immediately upon written notice to Zogenix: (i) in the event that Zogenix fails or is unable to Timely Supply [***], provided that the [***] required to be supplied by Zogenix pursuant to
[***] shall be deemed to not include [***] that is [***]; (ii) in the event that Zogenix fails or is unable to Timely Supply Product to satisfy Trade Demand; provided that Zogenix shall not be required to supply an aggregate quantity of
the Product in excess of [***] of the quantity of the Product forecasted for any Agreement Month in the Volume Forecast most recently approved by the JSC prior to such Agreement Month, (iii) in the event that Zogenix fails or is unable to
maintain the continued effectiveness of the Regulatory Approval (the continued effectiveness of which shall be deemed not to have been maintained if the FDA or any other Governmental Authority suspends the manufacturing, use, marketing, sale, or
Promotion of the Product), (iv) in the event of a large-scale recall, large-scale market withdrawal, or similar corrective action with respect to the Product, or (v) in the event that Zogenix or any of its Affiliates or, to Zogenix’s
knowledge, any Person under its or their direction or control, is debarred by the FDA under the Generic Drug Act. Once released from such obligations, Astellas’s obligations under this Section 4.1 shall be reinstated only if and [***] on
which (x) Zogenix is in compliance with the requirements of clauses (i) through (v), and (y) Zogenix has reasonably satisfied Astellas that Zogenix can continue to satisfy such requirements on a going-forward basis (such date, the
“Promotional Effort Reinstatement Date”), at which point Astellas shall use reasonable efforts, taking account of the time reasonably required to rededicate the required level of Astellas Promotional Effort, to resume compliance
with the applicable requirements of this Section 4.1, and in any event shall resume compliance with the applicable requirements of this Section 4.1 no later than the [***] of the first full Incentive Compensation period following the
Promotional Effort Reinstatement Date. For the purposes of this Section 4.1, an “Incentive Compensation period” means a period under the Astellas Incentive Compensation plan with respect to which Incentive Compensation is measured and
awarded, which period is typically a period of [***]. For the avoidance of doubt, the release of Astellas from its obligations pursuant to this paragraph shall be in addition to all other rights and remedies available to Astellas hereunder, at law
or in equity or otherwise, with respect to the event(s) triggering such release. 
 Section 4.2 Product Detailing by
Zogenix 
 (a) Subject to applicable Legal Requirements as well as the provisions of this Agreement, Zogenix shall,
from and after the Promotion Commencement Date use commercially reasonable efforts to Detail the Product in the Zogenix Segment within the Territory in accordance with the Commercial Plan (the “Zogenix Promotional Effort”);
provided, however, that (i) Zogenix’s commercially reasonable efforts shall be deemed to be satisfied if [***] (such obligations, the “Zogenix [***]”) and (ii) in the event that, [***]. Zogenix shall also have
the right, but not the obligation, to Detail the Product (x) in the Astellas Segment, (1) to Professionals that Astellas does not intend to call upon during the applicable period, and (2) until the end of the second Agreement Quarter
in the 2010 Agreement Year, to [***]. Zogenix shall cause the Zogenix Sales Force and Zogenix employees and agents acting on Zogenix’s behalf to comply with this Agreement and all applicable Legal Requirements in connection with the Promotion
of the Product. It is understood, and Zogenix agrees, that it will be accountable for the acts and omissions of the Zogenix Sales Force and its employees and agents to the extent such acts or omissions fail to comply with Zogenix’s
obligations under this Agreement. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 23 

 (b) [***], Zogenix shall Detail the Product in the Zogenix Segment and to Jointly Called On
Physicians using [***] each with no less than [***]; provided that Zogenix shall not be in breach of this requirement as a result of the Zogenix Sales Force having Vacancies up to but not exceeding [***] of the total number of required Sales
Representatives during such period. 
 (c) [***] Zogenix shall Detail the Product pursuant to one of the following scenarios:

 (i) Providing not less than [***] in each such [***] (with any portion of a calendar year pro-rated); or 

(ii) Dedicating such other Zogenix Promotional Effort as mutually agreed by the Parties through the JSC. 

Section 4.3 Mutual Promotion 

(a) Each of Astellas and Zogenix shall commence Detailing the Product in accordance with this Agreement no later than the later of
(i) January 25, 2010, and (ii) [***] following achievement by Zogenix of the milestone set forth in Section 7.1(b)(iv). The Parties agree to cooperate with each other in good faith in furtherance of the first sentence in
this Section 4.3(a). 
 (b) Neither Party shall be prohibited from undertaking Promotional activities in addition to those
contemplated to be undertaken by such Party pursuant to the then-current Commercial Plan (or that would require such Party to bear expenses in excess of the amounts required to be borne by such Party pursuant to the then-current Base Brand A&P
Budget), provided that such excess activities are consistent with the then-current Commercial Plan and approved in advance by the JSC. Notwithstanding the foregoing, in no event shall a Party become obligated to participate in activities in
addition to those contemplated in the then-current Commercial Plan or incur amounts in excess of those required to be borne by such Party pursuant to the then-current Base Brand A&P Budget unless so required pursuant to a duly updated Commercial
Plan or Base Brand A&P Budget. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 24 

 Section 4.4 Representations to Customers 

Each Party shall, in connection with its Promotion of the Product, refrain from making (a) any false or misleading representations
to Professionals, customers or others regarding the other Party or the Product or (b) representations, warranties, or guarantees with respect to the specifications, features, or capabilities of the Product that are not consistent with the
Promotional Materials, the applicable then-current FDA approved labeling and package insert (except to the extent permitted by applicable Legal Requirements), and applicable Legal Requirements. Each Party shall undertake timely corrective action
with respect to any deviations from this Section 4.4, subject to discussion and review by the other Party’s designated regulatory affairs and quality assurance personnel. 

Section 4.5 Staffing and Training 

(a) Each Party shall be solely responsible for all costs and expenses incurred to train and compensate its Sales
Representatives. Consistent with applicable Legal Requirements and subject to Sections 4.1(b), 4.1(c), 4.1(d), and 4.2(b), as applicable, (i) Astellas shall pay Incentive Compensation to its Sales Representatives with respect to the
Product in accordance with Astellas’s Incentive Compensation plan applicable to Astellas’s own products, subject to any deviations implemented by Astellas to comply with Astellas’s [***], and (ii) Zogenix shall pay Incentive
Compensation to its Sales Representatives with respect to the Product in accordance with Zogenix’s Incentive Compensation plan applicable to products of Zogenix other than the Product, subject to any deviations implemented by Zogenix to comply
with Zogenix [***]. 
 (b) From time to time, each Party shall, in consultation with the other Party (a) establish
training objectives and training plans for members of such Party’s Sales Force and (b) develop and produce all training programs and materials to be used by such Party for initial and refresher training of the members of its Sales Force;
it being understood and agreed by the Parties that in the event of any dispute between the Parties with respect to such objectives or plans or the content of any such programs or materials, each Party shall have discretion to make final
determinations with respect to such objectives, plans, or content, subject to Section 4.6. 
 (c) Such training materials
and programs with respect to the Sales Forces shall address the following matters: disease state, Product knowledge, competitive product knowledge, such Party’s applicable business policies, Sample distribution policies, obligations under this
Agreement, coordination with counterparts on the other Party’s Sales Force, administration, and other appropriate information. 

(d) Without limitation to Section 5.3(c), each Party shall provide training to each member of its Sales Force prior to his or her
commencement of Promotion of the Product hereunder to ensure that he or she is properly trained with respect to all matters described in Section 4.5(c) and able to satisfy his or her Promotion responsibilities under this Agreement (the
“Initial Sales Force Training Program”). In addition to the Initial Sales Force Training Program, each Party shall provide to the members of its Sales Forces such reinforcement and refresher training with respect to the Product in
accordance with the applicable Commercial Plan then in effect. If the Product receives approval for an indication other than that set forth in the NDA as approved as of the Effective Date or there are other material changes in the Product labels and
inserts following the Promotion Commencement Date, each Party shall provide training materials to each member of its Sales Force with respect to such matters. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 25 

 (e) Each Party shall assign to its Sales Forces only those individuals who demonstrate a
thorough knowledge of the Product. 
 (f) [***], neither Party shall actively recruit or solicit for employment any
then-current member of the Sales Force of the other Party or any other staff member of the other Party who is engaged or had been engaged in the Promotion or Detailing of the Product. For the avoidance of doubt, nothing in this Agreement shall limit
a Party from engaging in general recruitment through advertisements or recruiting through “head-hunters” so long as the staff members of the other Party are not specifically targeted in such recruitment effort. 

Section 4.6 Promotional Materials; Educational Materials 

(a) The Parties shall collaborate, by and through their respective representatives on the JPT, to create, develop, produce, or otherwise
obtain promotional, advertising, marketing, educational, and training materials which are necessary or reasonably useful to support fully the Parties’ Promotional efforts with respect to the Product (“Promotional Materials”). All
such materials, whether printed or electronic (including content on the Product Website), shall be deemed Promotional Materials. Promotional Materials may include, by way of example: detailing aids, leave behind educational items, journal
advertising, educational programs, formulary binders, appropriate reprints and reprint carriers, product monographs, patient support kits, convention exhibit materials, direct mail, training materials, and scripts for telemarketing and
teleconferences. All Promotional Materials shall be reviewed and approved by the JPRC. All Promotional Materials (i) shall prominently display such Zogenix Trademark(s) as shall be specified by Zogenix in accordance with Section 4.10,
and (ii) shall, at Astellas’s request and agreement by Zogenix (not to be unreasonably withheld), prominently display the Astellas Trademarks (but no more prominently than the Zogenix Trademark described in Section 1.152(c)) pursuant
to and in accordance with a Trademark Consent. 
 (b) Prior to the use thereof, the JPT shall provide to the JPRC
(i) fully referenced copies of Promotional Materials and, (ii) if necessary for review, a prototype of any Promotional Materials, in each case ((i) and (ii)), for review and approval. Upon approval by the JPRC, the Promotional Materials
may be produced in quantity (or, in the case of content for the Product Website, may be displayed on the Product Website). In furtherance of the foregoing provisions of this Section 4.6(b), the Parties will endeavor to cooperate to facilitate
the timely and efficient review of Promotional Materials and, subject to Section 3.7, resolution of any disputes or disagreements related to Promotional Materials, with a view to containing both Parties’ internal personnel resources and
external costs associated with the creation, review, and approval of the Promotional Materials. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 26 

 (c) The Parties shall at all times during the Term collaborate and use commercially
reasonably efforts to ensure sufficient quantities of Promotional Materials as set forth in the then-current Commercial Plan for use in Promoting the Product and performing their respective obligations hereunder. Each Party shall be permitted to use
in connection with the Promotion of the Product only (i) the Promotional Materials approved under this Agreement (including pursuant to the dispute resolution procedures set forth in Section 3.7) and (ii) the Product labels and
inserts. Each Party shall use such Promotional Materials only in the form so approved and consistent with the training provided pursuant to Section 4.5 and neither Party shall change such Promotional Materials in any way following such approval
and training (including by underlining or otherwise highlighting any text or graphics or adding any notes thereto). 
 (d) All
Promotional Materials shall comply with all applicable Legal Requirements. Notwithstanding anything in this Agreement to the contrary, neither Party shall be required to take any action if such Party reasonably determines that such action would
violate applicable Legal Requirements, including any such action involving the use or dissemination of any Promotional Materials or training materials. 

(e) Subject to this Section 4.6(e), Zogenix shall own all copyrights to all Promotional Materials that are created during the Term
of this Agreement (other than those items which are subject to Third Party copyrights) in connection with and to the extent relating to the Promotion of the Product. In the event that any such Promotional Materials are commissioned by Astellas,
Astellas shall use commercially reasonable efforts consistent with accepted business practices to obtain assignments of copyrights in and to such Promotional Materials from the authors and creators of such materials as may be necessary to vest
ownership of such copyrights in Zogenix. Zogenix shall, and does hereby, grant to Astellas a royalty-free, non-exclusive right and license to use, reproduce and distribute Promotional Materials or any other Product-related materials made
available to Astellas by Zogenix hereunder, in each case solely in conjunction with the Promotion of the Product and the performance of Astellas’s obligations under this Agreement, which license shall not be sublicensable, assignable, or
transferable by Astellas, except in accordance with the terms of Section 2.2. 
 Section 4.7 Commercial Plan
(Including Base Brand A&P Budget) 
 (a) The Initial Commercial Plan, covering the period commencing on [***] (the
“Initial Period,” and each subsequent twelve (12) month period, a “Subsequent Plan Period”) has been prepared and exchanged by the Parties as of the Effective Date and is made binding hereunder. On or prior to [***] of the
preceding Agreement Year with respect to each Agreement Year during the Term beginning with the [***], the JPT shall develop an annual update to the then-current Commercial Plan (including a Base Brand A&P Budget), and subject to
Section 4.7(d), the then-current Call Plan, in each case covering the upcoming Subsequent Plan Period. Each proposed annual and other update or amendment to the Commercial Plan (including the Base Brand A&P Budget) and the Call Plan shall
be prepared by the JPT and submitted to the JSC for review. The JSC shall use all reasonable efforts to review, provide comments to and approve each annual update to the Commercial Plan and the Call Plan not later than [***] of each preceding
Agreement Year, and as expeditiously as possible in the case of other updates and amendments. In the event the JSC is unable, and, failing agreement by the JSC, the Commercial Heads are unable, to agree on any such update or amendment, other than an
annual update to the then-current Commercial Plan (including the associated Base Brand A&P Budget), such update or amendment shall not be adopted. In the event the JSC is unable to agree, and failing agreement of the JSC, the Commercial Heads
are unable to agree, on any annual update to the then-current Commercial Plan (including the associated Base Brand A&P Budget), the last-approved Commercial Plan or Base Brand A&P Budget, as the case may be, shall remain in effect, and the
Parties shall conduct activities and be responsible for expenses in the subsequent Agreement Year in a manner and at a level consistent with the activities and expenses to which such Party was committed under the then-current Commercial Plan;
provided, however, that notwithstanding the foregoing, in the event that the Parties fail to agree on a final Base Brand A&P Budget for the [***] in accordance with Section 3.7, the Parties shall be required to continue negotiating in good
faith, by and through their representatives on the JPT and JSC, to approve a final Base Brand A&P Budget for the [***] that is consistent in all respects with the [***], until such budget is approved, and, for clarity, in no event shall the
Initial Base Brand A&P Budget establish the Parties’ respective obligations with respect to expenses for the [***]. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 27 

 (b) The Commercial Plan shall set forth the activities that the Parties shall conduct in
connection with Promotion of the Product (and preparations therefor) during the period to which the Commercial Plan relates. The Commercial Plan shall include, at a minimum: 

(i) [***]; 

(ii) [***]; 

(iii) [***]; 

(iv) [***]; 

(v) [***]; 

(vi) [***]; 

(vii) [***]; and 

(viii) [***]. 

(c) Notwithstanding anything to the contrary contained in this Agreement, (i) neither Party may modify its obligations under any
Commercial Plan without complying with the update or amendment procedures set forth in this Agreement, and (ii) in the event that, with respect to a particular period, the Commercial Plan contemplates Astellas Promotional Efforts or Zogenix
Promotional Efforts that in any manner or to any extent [***]. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 28 

 (d) On or prior to December 15, 2009, the JPT shall develop and the JSC shall adopt
the initial Call Plan. Thereafter, with respect to each Agreement Year during the Term beginning with the [***] the JPT shall develop and the JSC shall adopt an annual update to the Call Plan in accordance with Section 4.7(a). For clarity, in
other respects, each Party has the right independently to develop its call plan with respect to the Professionals in its segment, in each case consistent with the Call Plan. 

Section 4.8 Promotion Reports 

(a) Within [***] following the end of each [***] Astellas shall provide the JSC with a status report, which report will summarize
Astellas’s Detailing activities pursuant to this Agreement for such prior [***] and [***], including: [***]; and (vi) such other information as may be agreed upon in writing by the Parties. 

(b) Within [***] following the end of each [***], Zogenix shall provide the JSC with a status report, which report will summarize
Zogenix’s Detailing activities pursuant to this Agreement for such prior [***] and [***] including: (i) [***] (vi) such other information as may be agreed upon in writing by the Parties. 

Section 4.9 Medical Inquiries 

(a) Zogenix shall be solely responsible for all medical affairs activities relating to the Product, including medical information
support and medical communications and publishing activities, which activities shall be performed by or on behalf of Zogenix at its sole expense, except to the extent that the expenses constitute Co-Funded Medical Affairs Expenses governed by
Section 7.3. The Parties acknowledge that each Party may receive requests for medical information concerning the Product from members of the medical and paramedical professions and consumers. Zogenix shall have the exclusive right to respond to
questions and requests for information about the Product received from such Persons that (a) warrant a response beyond the understanding of the Sales Representative or (b) are beyond the scope of the Product labels and inserts (each such
request, a “PIR”). If PIRs are received by Astellas, the request will be referred to Zogenix’s medical information department or appointed Third Party vendor to which Zogenix has instructed Astellas in writing to refer PIRs. Zogenix
shall also be responsible for responding to PIRs that are not received by Astellas. Zogenix shall notify Astellas of all PIRs no less than once prior to December 31, 2009, and thereafter on a regular basis and in any event no less often than
once per Agreement Quarter. Zogenix’s responses to PIRs and its performance of its obligations under this Section 4.9 shall be in compliance with all applicable Legal Requirements and the NDA. In addition, standard written materials
(including scripts) to be provided or used by Zogenix in responding to PIRs and performing its obligations under this Section 4.9 shall be reviewed in advance and approved by the JPRC, and all written materials (including scripts) addressing
the use of the Product outside of the approved labeling shall be consistent with such standard written materials. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 29 

 (b) If either Party intends to use scientific liaisons in connection with its Promotion of
the Product or its activities under this Agreement, such Party shall discuss its use thereof with the other Party, shall provide the other Party with a copy of its policies and procedures with respect to scientific liaisons, and shall ensure that
the scientific liaisons are personnel who are not involved in the Party’s sales organization. 
 Section 4.10
Trademarks 
 (a) The “Zogenix” Trademark must appear on all Promotional Materials that make reference
to the Product, to the extent such Promotional Materials would typically contain a company trademark. The “DosePro” Trademarks must appear on all Promotional Materials that make reference to the “DosePro” delivery device
incorporated into the Product and the “Sumavel” and “DosePro” Trademarks (or such other FDA-approved Trademarks) must appear on all Promotional Materials that make reference to the Product (or such Trademark). In no event shall
Zogenix use or permit or cause to be used in connection with the Product or the Promotion thereof any Trademark other than a Zogenix Trademark, and in the case of any Astellas Trademark, is the subject of a Trademark Consent. Zogenix hereby grants
to Astellas a non-exclusive, royalty-free right and license to use the Zogenix Trademarks in the Territory solely in connection with the Promotion of the Product and Astellas’s performance of its obligations under the Agreement, which license
shall not be sublicensable, assignable, or transferable except to any Third Party providing Sales Representatives for or acting as the Astellas Sales Force or in accordance with the terms of Section 2.2. Such license shall expire immediately
upon the expiration or termination of this Agreement. Astellas recognizes Zogenix’s title to the Zogenix Trademarks, and shall not at any time, during or after the Term, intentionally do or knowingly suffer to be done any act or thing
which would impair the rights of Zogenix in or to the Zogenix Trademarks. Astellas acknowledges and agrees that it shall not acquire and shall not claim any title to the Zogenix Trademarks adverse to Zogenix by virtue of the rights granted under
this Agreement or through Astellas’s use of the Zogenix Trademarks hereunder, it being the intention of the Parties that all goodwill and improved reputation generated by Astellas and use of the Zogenix Trademarks shall inure to the benefit of
Zogenix. 
 (b) Astellas hereby grants to Zogenix a non-assignable, non-sublicensable (except to any Third Party providing
Sales Representatives for or acting as the Zogenix Sales Force), non-exclusive, royalty-free right and license to use those Astellas Trademarks in the Territory that are approved in advance in writing by an authorized officer of Astellas, solely for
any specific use related to the Promotion of the Product in the Territory that is approved in such writing (any such approval, a “Trademark Consent”). Such license shall expire immediately upon the expiration or termination of
this Agreement. Zogenix recognizes Astellas’s title to the Astellas Trademarks, and shall not at any time, during or after the Term, intentionally do or knowingly suffer to be done any act or thing which would impair the rights of Astellas
in or to the Astellas Trademarks. Zogenix shall not have any right or license to use (and shall not use) any Astellas Trademarks in connection with the Promotion of the Product or otherwise unless and until a Trademark Consent is obtained for
the specific use, and may not use the Astellas Trademarks in connection with Promotional Materials to which Astellas’s representatives on the JPRC object and that Astellas elects not to use pursuant to Section 5.3(d). Zogenix
acknowledges and agrees that it shall not acquire and shall not claim any title to the Astellas Trademarks adverse to Astellas by virtue of the rights granted under this Agreement or through Zogenix’s use of the Astellas Trademarks hereunder,
it being the intention of the Parties that all goodwill and improved reputation generated by Zogenix and use of the Astellas Trademarks shall inure to the benefit of Astellas. 

 

 30 

 (c) Each of Astellas with respect to its use of the Zogenix Trademarks and Zogenix with
respect to its use of the Astellas Trademarks will maintain quality standards for all of its uses of the Trademarks of the other Party in connection with the Promotion of the Product that are substantially equivalent to those standards that are
(i) used by the owner of such Trademarks in connection with pharmaceutical products, and (ii) communicated by the owner to the other Party in writing, and (iii) if first communicated to the other Party after the Effective Date,
reasonable. Subject to the foregoing and to the other provisions of this Agreement, each Party acknowledges and agrees that the owner or licensee of the Trademark has the right, at any time, to modify or supplement such quality standards and
that the licensee (or sublicensee, if applicable) must implement such new standards or changes following receipt of written notice of such additions or changes; provided that the licensor agrees to bear all reasonable costs associated with
such modifications and supplements and that such modifications and supplements are reasonable. Compliance with this Section 4.10(c) shall be determined pursuant to the Promotional Material review and approval procedures set forth in
Sections 4.6(b). 
 Section 4.11 Product Website 

Unless otherwise agreed in writing by the Parties, Zogenix shall maintain a Product website designed with respect to the Promotion of the
Product in the US (the “Product Website”) and shall implement any changes to the Product Website in accordance with the procedure set forth in Section 4.6 with respect to Promotional Materials. Expenses associated with
maintaining and updating the Product Website, to the extent set forth in the then-current Base A&P Brand Budget, shall constitute [***]. Zogenix shall ensure that the Product Website complies with all applicable Legal Requirements. 

ARTICLE V 

CLINICAL, COMPLIANCE, AND REGULATORY AFFAIRS 

Section 5.1 Regulatory Approvals 

Zogenix shall use diligent efforts to obtain, and thereafter to maintain and continue, all Regulatory Approvals for the Product. Astellas
agrees that all Regulatory Approvals, applications therefor and any other submissions to a Governmental Authority with respect to the Product shall be in the name of, and shall be owned by, Zogenix or its designee. During the Term, Zogenix shall
provide Astellas with access, free of charge, to all clinical and non-clinical data related to the Product generated by or on behalf of and owned or otherwise Controlled by Zogenix, whether before or after the Effective Date. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 31 

 Section 5.2 Compliance with Regulatory Requirements 

Unless otherwise required by applicable Legal Requirements or expressly provided by this Agreement, Zogenix will retain exclusive
authority over and responsibility for complying with all regulatory requirements and maintaining all contacts with Governmental Authorities with respect to the Product, including the maintenance and updating of the NDA, the development and
submission of applications for new formulations, dosage strengths or indications of the Product (and, for the avoidance of doubt, products with such new formulations and dosage strengths shall become subject to Astellas’s right to elect to have
those products be deemed Products under this Agreement pursuant to Section 2.6), the reporting of any Adverse Drug Experiences to the FDA, the compliance of Promotional Materials with FDA rules and regulations, and the filing of Promotional
Materials with the FDA. 
 Section 5.3 Compliance 

(a) During the Term, Astellas, its Affiliates, and its and their employees, agents, representatives, and contractors having any
interactions with Health Care Providers with respect to the Product shall comply with applicable Legal Requirements, [***]. 

(b) During the Term, Zogenix, its Affiliates, and its and their employees, agents, representatives, and contractors having any
interactions with Health Care Providers with respect to the Product shall comply with applicable Legal Requirements, [***]. Zogenix has, prior to the Effective Date, provided to Astellas the Zogenix Compliance Materials in draft form, and shall
provide to Astellas the Zogenix Compliance Materials in final form, no later than October 1, 2009, and shall from time to time thereafter promptly provide updates to such Zogenix Compliance Materials. 

(c) In performing its duties hereunder, each Party shall, and shall cause the Astellas Sales Force or Zogenix Sales Force, as
applicable, its Affiliates, and its and their employees, agents, representatives, and contractors to comply with applicable Legal Requirements. Each Party shall ensure that none of it, its Sales Force, its Affiliates, and its and their employees,
agents, representatives, and contractors shall offer, pay, solicit or receive any remuneration to or from any Professional in order to induce referrals of or purchase of the Product in violation of applicable Legal Requirements, including
anti-kickback Legal Requirements. Astellas shall train the Astellas Sales Force and Zogenix shall train the Zogenix Sales Force, each in compliance with applicable Legal Requirements, prior to engaging in Promotion of the Product. 

(d) Notwithstanding any other term or condition of this Agreement, neither Party shall be required to participate in, fund, or support
any sales or marketing activities that in such Party’s judgment would conflict with or be inconsistent with such Party’s Compliance Materials or that are to be undertaken over the objections of such Party or the Party’s Committee
representatives pursuant to the dispute resolution procedures set forth in Section 3.7. For the avoidance of doubt, notwithstanding anything herein to the contrary, Astellas shall not be obligated to use Promotional Materials that in
Astellas’s judgment conflict with or are inconsistent with the Astellas Compliance Materials or to which Astellas’s representatives on the JPRC objected in writing, and shall not be obligated to pay expenses with respect to such
Promotional Materials that are incurred after the date on which Astellas or one of its representatives on the JPRC objects to such Promotional Materials in writing. Each Party shall ensure that its Compliance Materials comply with all applicable
Legal Requirements. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 32 

 Section 5.4 Communications with Regulatory Authorities 

(a) Except to the extent set forth in Section 5.4(b), all communications with Government Authorities concerning the Product shall
be the sole responsibility of Zogenix. Zogenix shall within [***] provide Astellas with copies of all such communications (including summaries of all relevant verbal communications) related to Promotional Materials and Serious Adverse Drug
Experiences (except that routine communications as to such matters (e.g., FDA 2253 correspondence) may be forwarded to Astellas within [***]) and shall reasonably respond to all inquiries by Astellas relating thereto. Zogenix will reasonably consult
with Astellas concerning Adverse Drug Experience reporting to the FDA and communications related to Promotional matters with the FDA or other Governmental Authorities that could reasonably be considered to be material to the Product, including
regulatory responses to follow up inquiries regarding Adverse Drug Experiences. Zogenix will provide to Astellas a copy of all draft responses related to such matters [***] and will endeavor to provide such responses at least [***] in advance of
their submission (to the extent allowable under Legal Requirements), and will consider in good faith any comments provided to Zogenix by Astellas. 

(b) Astellas shall not, without the consent of Zogenix, correspond or communicate with the FDA or with any other Governmental Authority,
whether within the Territory or otherwise, concerning the Product, or otherwise take any action concerning any Regulatory Approval under which the Product is sold or any application for Regulatory Approval of the Product; provided that during the
Term, Astellas shall have the right to do so: (i) if Astellas believes in good faith that it is necessary to do so to comply with the terms of this Agreement or any Legal Requirement (including without limitation state or local Legal
Requirements related to marketing activities undertaken by Astellas or the Astellas Sales Force), or (ii) at the request of a Governmental Authority (provided that, where practicable, Astellas shall have requested that such Governmental
Authority communicate with Zogenix instead), and in each such case, ((i) or (ii)), to the extent permitted by Legal Requirements and not prohibited by the Governmental Authority, Astellas shall give Zogenix notice as soon as reasonably practicable
of such communication and, to the extent practicable, shall permit Zogenix to accompany Astellas, take part in any such communications and receive copies of all such communications. Astellas shall within [***] after receipt of any communication
from the FDA or from any other Governmental Authority relating to the Product, to the extent so permitted by Legal Requirements and not so prohibited by the FDA or the applicable Governmental Authority, forward a copy of the same to Zogenix and
reasonably respond to all inquiries by Zogenix relating thereto. If Astellas is required by Legal Requirements to communicate with the FDA or with any other Governmental Authority relating to the Product or is requested to do so by the FDA or
the Governmental Authority, then Astellas shall so advise Zogenix, to the extent practicable and permitted by Legal Requirements and not prohibited by the FDA or the Governmental Authority, within [***] and shall provide Zogenix in advance with a
copy of any proposed written communication, or a written summary of any proposed oral communication with the FDA or any other Governmental Authority. Astellas shall comply with any and all reasonable direction of Zogenix concerning any meeting or
written or oral communication with the FDA or any other Governmental Authority relating to the Product unless otherwise required by Legal Requirements or otherwise requested by the FDA or the other Governmental Authority. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 33 

 Section 5.5 Product Complaints 

Astellas shall refer any oral or written Product Complaints which it receives concerning the Product to Zogenix within [***] of its
receipt thereof; provided, that all Product Complaints concerning suspected or actual Product tampering, contamination or mix-up shall be delivered within [***] its receipt thereof. Astellas shall not take any other action in respect of
any such Product Complaint without the consent of Zogenix unless otherwise required by applicable Legal Requirements. At Zogenix’s request, Astellas will reasonably cooperate with Zogenix to resolve any Product Complaints and Zogenix shall
reimburse Astellas for its reasonable, out-of-pocket expenses for such cooperation. All Product Complaints shall be directed to the attention of Zogenix’s Vice President, Regulatory Affairs, at Zogenix’s address set forth in
Section 13.1 (or to Zogenix’s designated Third Party vendor providing such services to Zogenix, at Zogenix’s request). Zogenix shall provide Astellas with a summary of all Product Complaints received directly or indirectly by
Zogenix no less than once per Agreement Month; provided, however, that Zogenix shall provide Astellas with all Product Complaints concerning suspected or actual Product tampering, contamination, or mix-up within [***] hours of its receipt
thereof. 
 Section 5.6 Adverse Drug Experience Reports 

(a) Each Party shall notify the other: (i) of all Serious Adverse Drug Experience Reports within [***] of the time such
Serious Adverse Drug Experience Report becomes known to such Party (including its employees); and (ii) of all Adverse Drug Experience Reports within [***] of the time such Adverse Drug Experience Report becomes known to such Party (including
its employees). 
 (b) Except as may otherwise be required by Legal Requirements, (i) Astellas shall not disclose any
information concerning Adverse Drug Experience Reports or Serious Adverse Drug Experience Reports to any Person or Governmental Authority without the prior consent of Zogenix; and (ii) Zogenix shall have the sole discretion to determine whether
any Product Complaint, Adverse Drug Experience Report or Serious Adverse Drug Experience Report must be reported to the FDA or any other Governmental Authority. 

(c) All follow-up investigations concerning Adverse Drug Experience Reports and Serious Adverse Drug Experience Reports shall be
conducted by Zogenix or its appointed Third Party vendor to which Zogenix has delegated such authority; provided that Astellas shall have the right to participate in such investigations upon its request. At Zogenix’s request, Astellas
shall provide all reasonable cooperation with any such follow-up investigation. Zogenix shall reimburse Astellas for its reasonable, out-of-pocket expenses for such cooperation. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 34 

 (d) The Parties will enter into a separate and more detailed pharmacovigilance agreement,
consistent with the terms of this Agreement, reasonably in advance of the Promotion Commencement Date. Zogenix shall maintain, at its sole expense, the global safety database relating to the Product, and shall be responsible for complying with all
reporting and other applicable Legal Requirements related thereto. 
 Section 5.7 Recalls or Other Corrective
Action 
 Zogenix shall have sole responsibility for and shall make all decisions with respect to any recall (including
recall of packaging and promotion materials), market withdrawals, or any other corrective action related to the Product. Zogenix shall promptly consult with Astellas with respect to any such actions proposed to be taken by Zogenix (and in all
events reasonably in advance of the taking of such actions), including all actions that are reasonably likely to result in a material adverse effect on the marketability of the Product in the Territory. At Zogenix’s request, Astellas shall
provide reasonable assistance to Zogenix in conducting such recall, market withdrawal, or other corrective action (including retrieving Samples distributed by the Astellas Sales Force to Professionals). [***]. 

Section 5.8 Assistance 

Each Party agrees to provide to the other Party all reasonable assistance, and to take all actions reasonably requested by the other
Party, in each case that are reasonably necessary to enable the other Party to comply with any Legal Requirement applicable to the Product in the Territory. Except as otherwise expressly provided herein, [***], except to the extent [***].

 ARTICLE VI 

MANUFACTURING AND SUPPLY; SALES; PRICING 

Section 6.1 Obligations of Zogenix 

(a) In accordance with the provisions of this Agreement and all applicable Legal Requirements, Zogenix shall, at its cost and expense,
use commercially reasonable efforts to perform or cause to be performed all Product manufacture, labeling, packaging, warehousing, distribution and return, order entry, payment processing, customer services and all other activities to supply and
distribute the Product in the Territory. 
 (b) Zogenix shall use commercially reasonable efforts to ensure Timely Supply of
(i) the Product ordered by Third Party wholesalers, other distributors or retailers in the Territory commencing with the month in which the Promotion Commencement Date occurs; provided that Zogenix shall not be required to supply in any rolling
[***] period an aggregate quantity of the Product in excess of [***] of the aggregate quantity of the Product forecasted for such [***] period in the Volume Forecast most recently approved by the JSC prior to such Agreement Month, and
(ii) Samples ordered by Astellas in accordance with Section 6.5. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 35 

 (c) In addition, Zogenix shall use commercially reasonable efforts to maintain during each
Agreement Month commencing [***] after Launch, the amount of Safety Stock for such [***]. 
 Section 6.2 Volume
Forecasts; Sample Forecasts 
 (a) At least [***] prior to the beginning of each Agreement Quarter ending after the
Promotion Commencement Date, the JPT shall prepare, in accordance with Article III, and submit to the JSC a written forecast, by month, of the expected Trade Demand during the [***] period beginning with such Agreement Quarter, which forecast shall
be prepared by the JPT in good faith. 
 (b) No later than [***] following [***], the Parties shall agree upon a written
forecast, by month, of the expected Trade Demand during the twenty-four (24) month period following the Effective Date (the “Initial Volume Forecast”). Thereafter, at least forty five (45) days prior to the beginning of each
Agreement Quarter beginning with January 1, 2010, the JSC shall approve, in accordance with Article , a written forecast, by month, of the expected Trade Demand during the twenty-four (24) month period beginning with such Agreement Quarter
(the “Volume Forecast” for such Agreement Quarter). If the JSC does not approve a Volume Forecast for an Agreement Quarter, such Volume Forecast shall be determined in accordance with Section . 

(c) No later than [***], the Parties shall agree upon (i) the aggregate number of Sample units available to be utilized in the
Territory (including Sample units to be held by each Party as safety stock of Sample units), by month, during the Launch Period and (ii) the allocation, by month, of such number of Sample units between Zogenix and Astellas (the “Initial
Sample Forecast”). 
 (d) At least [***] prior to the beginning of each Agreement Quarter ending after the Launch Period,
the JPT shall determine, in accordance with Article III: (i) the aggregate number of Sample units available to be utilized in the Territory (including Sample units to be held by each Party as safety stock of Sample units), by month, during the
twelve- (12-) month period beginning with such Agreement Quarter; and (ii) the allocation, by month, of such number of Sample units between Zogenix and Astellas (the “Sample Forecast”). Each Sample Forecast shall be determined by
the JPT in good faith and shall reflect the levels of Astellas Promotional Effort and Zogenix Promotional Effort set forth in the Commercial Plan in effect for the period covered by such Sample Forecast and reasonable quantities of Sample units to
be held by each Party as safety stock of Sample units. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 36 

 (e) In the event that Trade Demand in any Agreement Month exceeds the quantity forecasted
for such Agreement Month in the Volume Forecast most recently approved by the JSC prior to such Agreement Month, then the Parties shall work in good faith to address such shortfall, including by allowing Safety Stock to temporarily fall below the
level required by Section 6.1(c), reallocating Sample production to trade, and other such measures as the Parties may agree. 

(f) If the JSC fails to timely approve a Volume Forecast for any Agreement Quarter pursuant to Section 6.2(b), then the Volume
Forecast most recently approved by the JSC shall continue to serve as the Volume Forecast for the Agreement Quarter in dispute until an updated Volume Forecast is adopted by the JSC or determined by an arbitrator pursuant to Section 15.1 (which
for clarity, in the case of a Volume Forecast determined through arbitration, shall not be retroactive). Any Volume Forecast adopted by the arbitrator pursuant to Section 15.1 shall serve as the Volume Forecast (as if adopted by the JSC) from
and after the first day of the first Agreement Month following final determination by the arbitrator. 
 Section 6.3 [***]

 (a) Zogenix shall provide to Astellas [***] and [***] in each case, ((i) and (ii)), within [***] following the beginning of
each Agreement Month ending after the Promotion Commencement Date (or, if later, within [***] after such information becomes available to Zogenix). 

(b) Not later than the [***] of each Agreement Month, Zogenix shall provide to Astellas reports (in a format reasonably agreed by the
Parties) specifying: 
 [***]. 

(c) Zogenix shall promptly (and in no event later than five (5) days) inform Astellas of any back-order situations (collectively,
“Back Order Events”), and the Parties shall work in good faith to establish a remediation plan for any such Back Order Events. 

(d) If reasonably requested by either Party, Astellas and Zogenix shall discuss in good faith the potential business impact of the data
provided in the foregoing reports and notifications, and potential contingency plans to improve situations that may impact Zogenix’s ability to satisfy Trade Demand. 

Section 6.4 Sales; Pricing 

(a) Zogenix or its Affiliates shall book all sales of the Product in the Territory and shall be responsible for entering into any
contracts and other arrangements with any Person regarding the sale of the Product. Subject to Sections 3.3 and 3.7, Zogenix shall be responsible for establishing and approving the form, content, and terms and conditions of contracts and other
arrangements, including any discount, allowance, rebate, chargeback, or other term granted therein. Zogenix shall use commercially reasonable efforts to obtain favorable terms under such contracts, including with respect to Selected Deductions.
Zogenix shall contract with wholesalers, other distributors, and retailers in the Territory without regard to Zogenix’s relative interests in the Zogenix Segment compared to the Astellas Segment, and shall not discriminate in favor of the
Zogenix Segment at the expense of the Astellas Segment. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 37 

 (b) During the period commencing on the Effective Date and ending on the date forty-five
(45) days following the Effective Date (or such other date thereafter as the Parties may agree), the Parties shall discuss in good faith the possibility of Astellas (by and through its contractors or Affiliates) providing certain services with
respect to Product in the Territory, including trade, distribution, and managed care contracting support on terms to be agreed by the Parties. 

Section 6.5 Samples 

(a) Zogenix shall provide or cause to be provided to Astellas, as ordered by Astellas hereunder, samples of the Product that are not for
sale and are distributed with no fee associated (“Samples”) to be distributed by Astellas solely in connection with the performance of Details to Professionals in accordance with this Agreement. 

(b) Astellas shall place Sample Orders with Zogenix for Samples at least [***] in advance of the required date of delivery set forth in
such Sample Orders. Unless Zogenix consents, Astellas shall not order for delivery in any month a quantity of Samples in excess of the quantity of Samples allocated to Astellas for such month in the Initial Sample Forecast or the Sample Forecast
most recently determined by the JPT prior to the submission of the applicable Sample Order, as applicable. [***] after a Sample Order is received by Zogenix, Zogenix shall be deemed to have accepted such Sample Order provided that such Sample Order
complies with the ordering requirements of this Section 6.5(b). 
 (c) Zogenix shall deliver all Samples ordered by
Astellas in accordance with Section 6.5(b) to Astellas [***] by the required delivery date specified in each Sample Order, and [***]. Astellas shall be responsible for distributing the Samples to its Sales Representatives in a timely
manner. Zogenix shall invoice Astellas, at the time of shipment, for each shipment of Samples, at the [***] payment due to Zogenix within [***] the invoice date.

(d) Samples supplied by Zogenix to Astellas shall be used by Astellas solely in performing Details to Professionals in accordance with
this Agreement. Upon its receipt of Samples, Astellas shall be solely responsible for accountability and compliance with the PDMA for the Astellas Sales Force, and other applicable Legal Requirements relating to the distribution of such Samples
by the Astellas Sales Force, and shall be responsible for adherence by its Sales Representatives to such Legal Requirements. Astellas shall also be responsible for securing the return and appropriate disposal of and reconciling existing Sample
inventories from discontinued Astellas Sales Representatives. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 38 

 Section 6.6 Manufacturing Matters; Inability to Supply. 

(a) Zogenix shall promptly inform Astellas in the event that Zogenix becomes aware of any matters which might reasonably be expected to
(i) result in a failure to supply Product or Samples in accordance with Section 6.1(b) hereof, or (ii) otherwise have an adverse impact on the ability to supply trade Product or Samples in a timely manner; including, in each case,
((i) and (ii)), any such matters relating to the availability or production of Components. 
 (b) Notwithstanding the
generality of the foregoing, Zogenix agrees to notify Astellas within [***] after Zogenix has become aware of any event or circumstance related to the manufacture of the Product that might reasonably be expected to impact the safety or efficacy of
Product that has been released by Zogenix or that might reasonably be expected to cause such released Product to be adulterated or misbranded within the meaning of the Act. 

(c) Without limitation of any other remedy available to Astellas, in the event that in any Agreement Month Zogenix and its Affiliates
have insufficient inventory of Product to satisfy Trade Demand in the Territory and trade demand outside of the Territory during such month: (i) Zogenix shall notify Astellas of the shortage as soon as possible; (ii) Zogenix shall allocate
for sale in the Territory, an amount of Product no less than [***], divided by [***]; and (iii) Zogenix shall distribute Product in the Territory by allocating such Product in accordance with [***]. 

(d) Without limitation of any other remedy available to Astellas, in the event that in any Agreement Month Zogenix has insufficient
inventory of Samples to fulfill its delivery requirements for such month pursuant to Sample Orders submitted by Astellas in accordance with Section 6.5(b): (i) Zogenix shall notify Astellas of the shortage as soon as possible; and
(ii) Zogenix shall allocate for distribution as Samples to Astellas a quantity of Sample units no less than [***], divided by [***]. 

ARTICLE VII 

COMPENSATION; RECORDKEEPING; AUDITS 

Section 7.1 Astellas Up-Front and Milestone Payments 

(a) In partial consideration for the rights granted to Astellas hereunder, prior to the Effective Date Astellas has paid to Zogenix, and
Zogenix acknowledges receipt of, [***]. 
 (b) In partial consideration for the rights granted to Astellas hereunder, Astellas
shall pay to Zogenix the following milestone payments: 
 (i) [***], payable five (5) Business Days following the
Effective Date; 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 39 

 (ii) [***], payable within [***] of (x) [***]; 

(iii) [***], payable within [***] 9.3(a); and 

(iv) [***], payable within [***]. 

(v) Notwithstanding anything contained in this Section 7.1(b): 

(A) if Astellas terminates this Agreement pursuant to Section 8.2(a)(i), the milestone described in Section 7.1(b)(i) shall be
refundable in full and the milestone described in Section 7.1(b)(ii) shall not be payable; 
 (B) if Astellas terminates
this Agreement pursuant to Section 8.2(b)(ii), the milestone described in Section 7.1(b)(i) shall not be refundable (except pursuant to Section 8.4(d)), the milestone described in Section 7.1(b)(ii) shall be refundable in full,
and the milestone described in Section 7.1(b)(iii) shall not be payable; and 
 (C) if Astellas terminates this Agreement
pursuant to Section 8.2(b)(iii), the milestones described in Sections 7.1(b)(i) and 7.1(b)(ii) shall not be refundable (except pursuant to Section 8.4(d)), the milestone described in Section 7.1(b)(iii) shall be refundable in full,
and the milestone described in Section 7.1(b)(iv) shall not be payable. 
 In order to permit Astellas to review and consider matters
relating to the achievement of the milestones set forth in this Section 7.1(b), Zogenix shall provide to Astellas such information and final documents that Astellas reasonably requires as such information and documents are generated by or
become available to Zogenix. 
 Section 7.2 A&P Expenses 

Each Party shall be responsible for and shall pay, in accordance with the terms hereof, (i) [***] of all Shared A&P Expenses,
and (ii) such Party’s [***] of Allocated A&P Expenses, in each case incurred by either Party during the Term in accordance with the then-current Commercial Plan (including the then-current Base Brand A&P Budget) (such Shared
A&P Expenses and [***] of Allocated A&P Expenses, “Co-Funded A&P Expenses”); provided that Zogenix shall be responsible for and shall pay [***]. For clarity, any A&P Expenses incurred by a Party (or any of its
Affiliates) that are not included in the then-current Base Brand A&P Budget or that are in excess of the amounts set forth in the then-current Base Brand A&P Budget shall not constitute Co-Funded A&P Expenses. 

Section 7.3 Certain Medical Affairs Expenses 

Each Party shall be responsible for and shall pay, in accordance with the terms hereof, [***] (i.e., relating to medical affairs
activities) and (ii) approved in advance by the JMT (“Co-Funded Medical Affairs Expenses”). For clarity, any costs and expenses incurred by Zogenix (or any of its Affiliates) in connection with the performance of its
obligations under Section 4.9 that are not approved by the JMT or are in excess of the amounts approved by the JMT shall not constitute Co-Funded A&P Expenses, and Astellas shall not have any obligation to pay any share of such costs and
expenses. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 40 

 Section 7.4 Expenses Associated with Certain Phase IV Studies 

Each Party shall be responsible for and shall pay, in accordance with the terms hereof, such Party’s [***] (as agreed in advance by
the Parties in writing, it being understood that the costs and expenses of the study contemplated by the Parties as of the Effective Date, if the Parties agree to collaborate with respect to such Phase IV Clinical Studies, shall be [***], but that
the allocated share of all other Post-Effective Date costs and expenses [***]) of Post-Effective Date costs and expenses (i) paid by a Party (or its Affiliates) to Third Party contractors and vendors (including clinical research organizations)
engaged in connection with the performance of a Phase IV Clinical Study with respect to which the Parties have agreed (in advance in writing) to collaborate under this Agreement, and (ii) approved in advance by the JMT (“Co-Funded Phase
IV Expenses”). For clarity, any costs and expenses incurred by a Party (or any of its Affiliates) in connection with (i) the performance of any Phase IV Clinical Study other than one with respect to which the Parties have agreed to
collaborate, or (ii) the performance of a Phase IV Clinical Study with respect to which the Parties have agreed to collaborate but that are in excess of the amounts approved by the JMT, in each case, ((i) and (ii)), shall not constitute
Co-Funded A&P Expenses, and the other Party shall not have any obligation to pay any share of such costs and expenses incurred by the other Party. 

Section 7.5 Other Expenses 

Each Party shall bear and be solely responsible for all costs and expenses paid by it in connection with the Promotion of the Product and
the performance of its obligations hereunder, which costs and expenses are not Co-Funded A&P Expenses, Co-Funded Medical Affairs Expenses, or Co-Funded Phase IV Expenses. Without limitation to the foregoing, each Party will bear any Excluded
Expenses (except Excluded Expenses that are Co-Funded Medical Affairs Expenses or Co-Funded Phase IV Expenses) it incurs. 

Section 7.6 Quarterly Payment of Expenses 

Each Party shall submit to the other Party written reports containing detailed descriptions of all Co-Funded A&P Expenses, Co-Funded
Medical Affairs Expenses, and Co-Funded Phase IV Expenses, in each case paid by the Party during the applicable period in accordance with the Commercial Plan (in the case of A&P Expenses) or Committee approvals (in the case of Co-Funded Medical
Affairs Expenses and Co-Funded Phase IV Expenses). Each Party shall provide written reports setting forth a good faith estimate of such expenses with respect to each Agreement Month within [***] after the end of each Agreement Month,
and shall provide written reports of the actual expenses with respect to each Agreement Quarter within [***] after the end of each Agreement Quarter. As soon as reasonably practicable after the exchange of such quarterly reports, Zogenix shall
calculate and provide a statement to Astellas reflecting (a) the total amount of Co-funded A&P Expenses, Co-Funded Medical Affairs Expenses and Co-Funded Phase IV Expenses paid by both Parties collectively in accordance with this Agreement
during such Calendar Quarter, and (b) the amount of Co-funded A&P Expenses, Co-Funded Medical Affairs Expenses and Co-Funded Phase IV Expenses payable by each Party pursuant to Section 7.2, 7.3, or 7.4, respectively, with respect to
such Agreement Quarter (the “Quarterly Expense Share”). Not later than thirty (30) days after the end of each Agreement Quarter, each Party shall make reconciling payments to the other as necessary to ensure that each Party
bears its Quarterly Expense Share with respect to the applicable period; provided that Zogenix may offset any Quarterly Expense Share reconciliation payments due to Zogenix by Astellas hereunder against the Service Fee owed to Astellas for
the applicable period. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 41 

 Section 7.7 Service Fees and Adjustment Payments 

(a) In partial consideration for Astellas’s performance of its obligations under this Agreement, Zogenix shall pay to Astellas
(i) a service fee (the “Service Fee”) equal to [***] Astellas Net Sales for each Agreement Month during the Term, and (ii) any annual reconciliation payment required under Section 7.7(d). 

(b) Within [***] after the end of each Agreement Month, Zogenix shall provide to Astellas a written report setting forth a good faith
estimate of the gross invoiced sales of Product to Third Parties in the Territory during such Agreement Month. Within [***] following the end of each Agreement Month, Zogenix shall provide Astellas with a statement in a mutually agreeable format
setting forth: (i) [***]. If any material discrepancies are identified, Zogenix and Astellas shall work collaboratively to make the necessary corrections with respect to the measurement of Units dispensed and any necessary changes to Astellas
Net Sales calculations hereunder. For the purposes of the preceding sentence, a “material discrepancy” shall be any discrepancy [***]. Such collaboration as contemplated in this Section 7.7(b) shall take into account all reasonably
relevant and available information as relates to both the number of Units dispensed and Units measured by wholesaler reported outflow and returns, including in the case of wholesaler outflow and returns, information with respect to current retailer
inventory levels, wholesaler outflow to institutions, and any other outflow not related to the retail or mail order segments. 

(c) The Service Fee will be paid to Astellas following each Agreement Quarter with respect to each Agreement Month within such Agreement
Quarter within [***] after the end of the Agreement Quarter, subject to offset as set forth in Sections 7.6 and 7.7. 
 (d) No
earlier than the end of the second full calendar quarter following the end of each Agreement Year (or as otherwise agreed by the Parties), Zogenix shall perform a true-up for all Net Sales with respect to each Agreement Quarter in such Agreement
Year. Such true-up shall reconcile the Deductions that were incurred with respect to such Net Sales with the Deductions that were accrued or estimated with respect thereto. Each Party shall make reconciling payments to the other as necessary to
effect such true-up with respect to the Service Fees paid for the Agreement Year. Zogenix shall provide to Astellas such reconciliation no later than [***] the end of the second full calendar quarter following the end of the Agreement Year. If
Zogenix is required to make a payment to Astellas to effect such reconciliation, then Zogenix shall provide such payment to Astellas along with such reconciliation. If Astellas is required to make a payment to Zogenix to effect such reconciliation,
Zogenix shall offset such payment against future amounts owed by Zogenix to Astellas pursuant to Section 7.7(c) (or, following the expiration or termination of this Agreement, Astellas shall make such payment directly to Zogenix within [***]
following receipt of the reconciliation). Zogenix shall provide to Astellas, along with the reconciliation, all documentation reasonably requested by Astellas in a form to be agreed by the Parties to document the reconciliation. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 42 

 Section 7.8 Tail Payments 

Following the Term, except as set forth in Section 8.4, Zogenix shall pay Astellas the following payments based on Astellas Net
Sales during the last full twelve (12) months of Astellas [***] (such period, the “Final Astellas Promotional Period;” each such payment, a “Tail Payment”): 

(a) On the [***] of the last day of the Final Astellas Promotional Period, an amount equal to [***] of the Astellas Net Sales during the
Final Astellas Promotional Period; and 
 (b) On the [***] of the last day of the Final Astellas Promotional Period, an amount
equal to [***] of the Astellas Net Sales during the Final Astellas Promotional Period. 
 Section 7.9 Maintenance of
Records; Audits 
 (a) Each Party shall maintain the following books and records: 

(i) Books and records documenting the Party’s compliance with applicable Legal Requirements and the applicable requirements of
Articles IV, V, and VI (“Compliance Records”). The Compliance Records shall include the Party’s policies and procedures concerning compliance with applicable Legal Requirements and the requirements of Articles IV, V, and VI
then in effect, and records of any investigations and remedial and disciplinary actions taken to address material violations of applicable Legal Requirements or the requirements of Articles IV, V, or VI. 

(ii) Books and records documenting the Party’s performance of its Promotional efforts hereunder, including books and records
documenting (A) the number of individual Sales Representatives Promoting the Product in each Agreement Month, (B) all Vacancies in the Sales Force Promoting the Product, (C) all Details performed by each Sales Representative with
respect to the periods in which these metrics are applicable, including the Professionals called upon and whether the Details were P1 Details, P2 Details, or Co-P2 Details, and (D) Incentive Compensation weightings for each Sales Representative
with respect to the periods in which these metrics are applicable (provided that Parties shall not be obligated to share those aspects of Incentive Compensation plans that are not required to be shared to demonstrate Incentive Compensation
weighting) (“Promotion Records”). 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 43 

 (iii) Books and records documenting the Party’s performance of its training
obligations hereunder (“Training Records”). 
 (iv) Books and records documenting Co-funded A&P Expenses,
Co-Funded Medical Affairs Expenses, and Co-Funded Phase IV Expenses (“Expense Records”). 
 (v) In the case of
Zogenix, books and records documenting all Sample Orders, Sample Forecasts, Volume Forecasts, and Trade Demand, and Zogenix’s levels of Safety Stocks, Sample Orders fulfilled, Samples and Product distributed by Zogenix in the Territory, Samples
and Product distributed outside the Territory, and manufacturing, supply, and shipping records, and in the case of Astellas, books and records documenting all Samples distributed by Astellas in the Territory (with respect to a Party, its
“Volume Records”). 
 (vi) In the case of Zogenix, books and records documenting gross invoiced sales of
Product in the Territory, Deductions, Astellas Segment Dispensed Units, and Territory Invoiced Units during each Agreement Month in the Agreement Year, and any related adjustments and reconciliations for each Agreement Year (“Net Sales
Records”). 
 (b) Such books and records shall be maintained for the greater of three (3) years after the end of
the calendar year to which such books and records pertain, and such additional period as is required by applicable Legal Requirements. Such books and records shall be complete and accurate, and maintained, when applicable, with such Party’s
accounting practices, consistently applied. Such books and records shall be maintained in sufficient detail and only for the purpose of enabling a Third Party to (i) in the case of Compliance Records, verify the Party’s compliance with
Legal Requirements and the applicable requirements of Articles IV, V, and VI, (ii) in the case of Promotion Records, verify the Party’s performance of its Promotion obligations hereunder, (iii) in the case of Training Records, verify
the Party’s performance of its training obligations hereunder, (iv) in the case of Expense Records, verify the accuracy of the expenses shared between the Parties hereunder, (v) in the case of Volume Records, verify Zogenix’s
compliance with its supply obligations hereunder with respect to the delivery of Samples and Product, and verify Sample Forecasts and Volume Forecasts made, (vi) in the case of Volume Records, verify Astellas’s compliance with its
obligations hereunder with respect to delivery of Samples, and (vii) in the case of Net Sales Records, verify the calculation of Net Sales, Service Fees, Tail Payments, and Royalty Payments. 

(c) Upon thirty (30) days prior written notice, such books and records shall be made available for audit during business hours by
an independent certified public accounting firm designated by the other Party and reasonably acceptable to the Party being audited for the purposes set forth in Section 7.9(b). Each Party shall cooperate with the audit. A Party may
exercise this audit right no more frequently than once in each period of twelve (12) consecutive months; provided that (i) if the audit reveals that the audited Party is or was not in material compliance with Legal Requirements or
the requirements of Articles IV, V, or VI or its obligations hereunder, or (ii) if the audit reveals that the audited Party incorrectly reported or calculated expenditures, payments, Net Sales figures, Astellas Net Sales figures, Territory
Invoiced Unit or Astellas Segment Dispensed Unit figures, or the adjustments or reconciliations contemplated in Section 7.7(d), and the amount of such discrepancy is at least [***] of the aggregate amount that should have been reported or
calculated for the period examined, then (A) the audited Party shall promptly implement corrective actions reasonably acceptable to the auditing Party to thereafter ensure compliance or accurate reporting, as applicable, and (B) the
auditing Party shall have the right to conduct such additional audits during the following twelve (12) months as may be reasonably required by such auditing Party to determine whether the audited Party has appropriately remedied such
non-compliance or inaccurate reporting, as applicable. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 44 

 (d) If the audit concludes that additional payments were owed or that excess payments were
made during such period, the owing Party shall pay the additional payments or the receiving Party shall reimburse such excess payments within forty-five (45) days. 

(e) The fees and expenses of the auditor shall be borne by the auditing Party; provided, however, that if the audit reveals that
the audited Party is or was not in material compliance with Legal Requirements or the requirements of Articles IV, V, or VI or its obligations hereunder, or has reported or calculated incorrectly expenditures, payments, Net Sales figures, Astellas
Net Sales figures, Territory Invoiced Unit or Astellas Segment Dispensed Unit figures, or the adjustments or reconciliations contemplated in Section 7.7(d), and the amount of such discrepancy is at least [***] of the aggregate amount that
should have been reported or calculated for the period examined, then the audited Party shall pay the entire amount of the audit fees and expenses. 

(f) If the audited Party disputes the audit, such Party promptly shall notify the other Party in writing and the Parties shall use good
faith efforts to resolve such dispute. If the Parties are unable to resolve such dispute within thirty (30) days after such written notice, an independent accounting firm mutually agreed to by the Parties (the costs of which shall be paid
one-half by each Party) shall resolve such dispute and such accounting firm’s resolution shall be final and binding on the Parties. Each Party shall cooperate with such accounting firm’s investigation. 

Section 7.10 Payments 

Any payments required to be made under this Agreement shall be made in United States dollars via wire transfer of immediately available
funds to such bank account as a Party shall designate in writing prior to the date of such payment. All payments shall bear interest from the date due until paid at a rate equal to the prime rate effective for the date that payment was due [***], as
quoted by the Wall Street Journal, New York Edition, on the date such payment was due, or, if less, the maximum rate permitted by applicable law. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 45 

 Section 7.11 Zogenix Segment/Astellas Segment 

If at any time during the Term either Party reasonably determines that the Specialty Level Data fails to, or is likely to fail to,
reasonably accurately reflect the portion of Net Sales attributable to prescriptions written by Professionals in the Zogenix Segment or the Astellas Segment (whether as a result of Professionals opting out of Wolters Kluwer (or such other mutually
agreed upon source) or otherwise), the Parties shall negotiate in good faith with respect to implementing a revised manner of measuring the portion of Net Sales attributable to prescriptions written by Professionals in the Zogenix Segment and the
Astellas Segment. The Parties shall consider in their discussions any other customary manner of determining similar information in similar circumstances. 

ARTICLE VIII 

TERM AND TERMINATION 

Section 8.1 Term 

(a) The term of this Agreement shall commence on the Effective Date and shall continue, unless terminated sooner in accordance with this
Article VIII, until (i) June 30, 2013, or (ii) if the Promotion Commencement Date has not occurred on or before January 31, 2010, forty-two (42) months following the Promotion Commencement Date (the “Initial
Term”). The Initial Term may be extended as set forth in Section 8.1(b) (the Initial Term, as may be extended, the “Term”). 

(b) Astellas shall have a one-time option (the “Term Extension Option”) to extend the Initial Term by an additional
twelve (12) months. Astellas may exercise the Term Extension Option by written notice to Zogenix at any time during the period beginning on [***] and ending on [***] (the “Option Exercise Period”). Such written notice shall be
accompanied by a one-time, non-refundable, non-creditable payment to Zogenix in the amount of [***] (the “Option Payment”). Upon receipt by Zogenix of the Option Payment during the Option Exercise Period, the Initial Term shall
automatically be extended through (i) June 30, 2014, or (ii) if the Promotion Commencement Date of the Product has not occurred on or before January 31, 2010, fifty-four (54) months following the Promotion Commencement Date.

 Section 8.2 Early Termination 

(a) Astellas Termination Rights. Astellas shall have the following termination rights: 

(i) Astellas may terminate this Agreement upon written notice to Zogenix if the milestone described in Section 7.1(b)(ii) is not
achieved by October 15, 2009. 
 (ii) Astellas may terminate this Agreement upon written notice to Zogenix if the
milestone described in Section 7.1(b)(iii) is not achieved by January 1, 2010. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 46 

 (iii) Astellas may terminate this Agreement upon written notice to Zogenix if the milestone
described in Section 7.1(b)(iv) is not achieved by April 1, 2010. 
 (iv) Astellas may terminate this Agreement for
any reason or no reason by providing one hundred eighty (180) days’ prior written notice to Zogenix; provided that such notice may not be provided at any time before September 30, 2010. 

(v) Astellas may terminate this Agreement by providing ninety (90) days’ prior written notice to Zogenix in the event of a
Zogenix Change of Control; provided, however, that such notice of termination must be delivered to Zogenix no later than thirty (30) days following receipt by Astellas of notice by Zogenix of the occurrence of a Zogenix Change of
Control; provided, further, that Zogenix may provide written notice to Astellas in advance of the occurrence of a Zogenix Change of Control (and along with such notice Zogenix shall provide the identity of the counterparty(ies) in the Zogenix
Change of Control transaction and such other information reasonably necessary to assure Astellas of the ability of the surviving entity in the transaction to satisfy Zogenix’s obligations under this Agreement), and following such notice (and
the provision of the other required information), Astellas shall have thirty (30) days to provide notice to Zogenix of its intention to terminate this Agreement pursuant to this Section 8.2(a)(v), such notice to be provided to Zogenix in
writing. For clarity, if Zogenix provides the notice referred to herein in advance of the occurrence of a Zogenix Change of Control (along with the other information required pursuant to this Section 8.2(a)(v)) and Astellas does not comply with
its notice requirements with respect to its intention to terminate, Astellas thereafter shall have no right to terminate this Agreement in connection with such Zogenix Change of Control pursuant to this Section 8.2(a)(v). 

(vi) Astellas may terminate this Agreement immediately upon written notice to Zogenix in any of the following circumstances:
(A) any Governmental Authority takes any action or raises any objection that prevents Astellas from performing its obligations under this Agreement or makes such activity unlawful; (B) a Zogenix Supply Failure occurs; (C) a Third
Party (x) asserts in writing that the using, making, having made, selling, offering for sale, or importing of the Product infringes an issued patent in the Territory controlled by such Third Party, and Zogenix’s patent counsel has not,
within thirty (30) days of Zogenix’s receipt of such written assertion, rendered a written opinion that the assertions are without merit, or (y) files an action making such assertions; or (D) Zogenix materially breaches its
Zogenix [***] obligation, and such breach remains uncured ninety (90) days following written notice from Astellas reasonably specifying the nature of such material breach. 

(b) Zogenix Termination Rights. Zogenix may terminate this Agreement with ninety (90) days’ prior written notice to
Astellas if Astellas materially breaches its Astellas [***] obligation (and such material breach must be described with reasonable specificity in such notice); provided that with respect to the first such material breach with respect to which
Zogenix has provided notice to Astellas pursuant to this Section 8.2(b) in any twelve- (12-) month period, such termination shall not become effective if Astellas cures the material breach within such ninety- (90-) day period. For the avoidance
of doubt, with respect to the second or any subsequent material breach within any twelve- (12-) month period with respect to which Zogenix has provided notice to Astellas pursuant to this Section 8.2(b), the termination shall become effective
at the end of such ninety- (90-) day period, notwithstanding any cure by Astellas. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 47 

 (c) Mutual Termination Rights. 

(i) Either Party shall have the right to terminate this Agreement immediately upon written notice to the other Party in the event of a
large-scale recall or withdrawal of the Product from the Territory resulting from a significant safety risk inherent in the Product and not due to tampering, a remediable manufacturing problem, or other defect that can be cured with respect to the
Product manufactured after such risk is discovered. 
 (ii) Either Party shall have the right to terminate this Agreement upon
ninety (90) days’ prior written notice to the other Party if (x) the [***] Threshold (as defined with respect to the applicable periods below) and (y) solely in the case of the period set forth in Section 8.2(c)(ii)(C)
below, the [***] Threshold (as defined with respect to the applicable periods below) are not achieved in any of the periods set forth below. Such notice shall be given within thirty (30) days after the first date on which the Net Sales data and
Demand Unit data (solely in the case of the period set forth in Section 8.2(c)(ii)(C)) for the relevant period are provided to Astellas by Zogenix pursuant to Section 7.7(b). If the Promotion Commencement Date is delayed beyond
January 31, 2010, the Parties will renegotiate in good faith the [***] Thresholds and the [***] Threshold to reflect the expected impact of such delay. 

(A) For the period commencing on January 1, 2010, and ending on September 30, 2010, the “[***] Threshold” will be
[***] of aggregate Net Sales in the Territory for the period and there will be no “[***] Threshold.” 
 (B) For the
period commencing on January 1, 2010, and ending on December 31, 2010, the “[***] Threshold” will be [***] of aggregate Net Sales in the Territory for the period and there will be no “[***] Threshold.” 

(C) For the period commencing on January 1, 2011, and ending on December 31, 2011, the “[***] Threshold” will be
[***] of aggregate Net Sales in the Territory for the period and the “[***] Threshold” will be [***]. 
 Notwithstanding the
foregoing, if Zogenix fails to Timely Supply Product in amounts sufficient to meet the agreed-upon 2010 Volume Forecasts or the 2011 Volume Forecasts, as applicable, Zogenix shall not have the right to terminate this Agreement pursuant to this
Section 8.2(c)(ii). 
 (iii) Except with respect to events giving rise to early termination elsewhere in this
Section 8.2, either Party may terminate this Agreement with sixty (60) days’ prior written notice to the other Party in the event of a material failure of the other party to comply with its material obligations contained in this
Agreement (and such material failure must be described with reasonable specificity in such notice); provided that such termination shall not become effective if the breaching Party cures the material failure within such sixty- (60-) day
period. Notwithstanding the previous sentence, in the case of a material failure of Zogenix to comply with its Safety Stock obligations under Section 6.1, Astellas shall provide ninety (90) days’ prior written notice, and such
termination shall not become effective with respect to the first such material failure with respect to such Safety Stock obligations in any twelve- (12-) month period if Zogenix cures the material failure within such ninety- (90-) day
period. For the avoidance of doubt, with respect to the second or any subsequent material failure with respect to such Safety Stock obligations within any twelve (12) month period with respect to which Astellas has provided notice to
Zogenix pursuant to this Section 8.2(c)(iii), the termination shall become effective at the end of such ninety- (90-) day period, notwithstanding any cure by Zogenix. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 48 

 (iv) To the extent permitted by law, either Party may terminate this Agreement upon written
notice to the other Party in the event of (A) the entry of an order for relief under the United States Bankruptcy Code (or any corresponding remedy under successor laws) against the other Party, (B) the filing of a petition by or against
the other Party under any bankruptcy, insolvency, or similar law (which petition is not dismissed within sixty (60) days after filing), except Chapter 11 of the United States Bankruptcy Code or any successor statute that permits a corporation
to continue its operation while protecting it from creditors, (C) the appointment of a receiver for the other Party’s business or property, or (D) the other Party’s making of a general assignment for the benefit of its creditors.

 Section 8.3 Force Majeure 

In the event of a material failure of a Party to perform any of its material obligations under this Agreement (including Zogenix’s
supply obligations) by reason of a Force Majeure Event for a period of [***], (i) the other Party may terminate this Agreement upon written notice to the non-performing Party, or (ii) the other Party may have this Agreement continue in
full force and effect without modification. No Party will be liable to the other for its inability to perform under this Agreement due to any such Force Majeure Event. 

Section 8.4 Effect of Termination 

(a) In the event of termination by Astellas of this Agreement pursuant to Section 8.2(a)(iv), which termination becomes effective
in calendar year 2011, Astellas shall pay to Zogenix a termination fee of [***] and Zogenix shall have no obligation to pay to Astellas the Tail Payments. In the event of termination by Astellas of this Agreement pursuant to Section 8.2(a)(iv)
effective in calendar year 2012, Astellas shall pay to Zogenix a termination fee of [***] and Zogenix shall be obligated to pay Astellas only the Tail Payment set forth in Section 7.8(a). For the avoidance of doubt, Zogenix shall have no
obligation to pay to Astellas the Tail Payment set forth in Section 7.8(b). 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 49 

 (b) In the event of termination by Astellas of this Agreement pursuant to
Section 8.2(a)(vi), Zogenix shall pay to Astellas a royalty of [***] of all Net Sales in the Territory until such time as (i) if the notice of termination is provided at any time prior to or on the first anniversary of the Effective Date,
Astellas has received an aggregate of [***] of royalty payments, or (ii) if the notice of termination is provided at any time after the first anniversary of the Effective Date and prior to or on the second anniversary of the Effective Date,
Astellas has received an aggregate of [***] of royalty payments (such payments, the “Royalty Payments”). Royalty Payments due under this Section 8.4(b) shall be in lieu of the right to receive the Tail Payments as set forth in
Section 7.8. If the notice of termination is provided after the second anniversary of the Effective Date, no royalty payments shall be due to Astellas pursuant to this Section 8.4(b) and, instead, Astellas shall be entitled to receive the
Tail Payment set forth in Section 7.8(a), but not the Tail Payment set forth in Section 7.8(b). 
 (c) In the event
of termination by Zogenix of this Agreement pursuant to Section 8.2(b), Zogenix shall have no obligation to pay to Astellas the Tail Payments. 

(d) In the event of termination by Astellas of this Agreement pursuant to Section 8.2(c)(i) at any time prior to or on the first
anniversary of the Effective Date, Zogenix shall refund to Astellas the milestone payments paid pursuant to Section 7.1(b) up to an amount not to exceed [***]. For clarity, if the notice of termination is provided pursuant to
Section 8.2(c)(i) after the first anniversary of the Effective Date, no milestone payments shall be refunded pursuant to this Section 8.4(d) and, instead, Astellas shall be entitled to receive the Tail Payment set forth in
Section 7.8(a), but not the Tail Payment set forth in Section 7.8(b). 
 (e) In all other circumstances of expiration
or termination, no termination fee shall be owed to either Party and Astellas shall be entitled to receive the Tail Payments. 

(f) In the event of termination by Astellas of this Agreement pursuant to Section 8.2(a)(iv) or by Zogenix pursuant to
Section 8.2(b) or Section 8.2(c)(iii), Astellas shall reimburse Zogenix for its reasonable out-of-pocket costs and expenses incurred as a result of destruction of Promotional Materials containing the Astellas Trademark and the replacement
of such Promotion Materials. 
 (g) Expiration or termination of this Agreement shall not relieve either Party of any
obligations accruing prior to such expiration or termination. The following provisions of this Agreement by their terms continue after the expiration or termination of this Agreement: Sections 4.5(f), 4.6(e) (solely with respect to the first
two sentences thereof), 4.8, 5.5 through 5.7 (with respect to Products distributed during the Term), 6.3(a) (solely with respect to Agreement Months), 6.5(d), 7.1(b)(v), 7.2 through 7.6 (solely with respect to costs and expenses incurred during the
Term), 7.7 (solely based on Net Sales during the Term and related reconciliations), 7.8 through 7.11, 10.2 (solely, in the case of the second sentence, for the period set forth therein), 10.3(b) (solely with respect to Enforcement Actions pertaining
to activities during the Term), and this Section 8.4, and Articles XI (as set forth therein), XII (solely to the extent set forth in Section 12.4), XIII, XIV, and XV. In addition, any other provisions required to interpret and enforce
the Parties’ rights and obligations under this Agreement shall also survive, but only to the extent required for the full observation and performance of this Agreement. 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 50 

 (h) Expiration or termination of this Agreement shall be without prejudice to (i) any
remedies which any Party may then or thereafter have hereunder or at law or in equity; (ii) a Party’s right to receive any payment accrued under the Agreement prior to the termination date but which became payable thereafter; and
(iii) either Party’s right to obtain performance of any obligations provided for in this Agreement that survive termination by their terms or by a fair interpretation of this Agreement. Except as expressly set forth herein, the rights
to terminate as set forth herein and the consequences of such termination shall be in addition to all other rights and remedies available under this Agreement, at law or in equity, or otherwise. 

(i) Upon the expiration or termination of this Agreement pursuant to this Article VIII, each Party shall promptly destroy or delete all
embodiments, whether printed or electronic, of the Proprietary Information of the other Party in its control or possession (or in the control or possession of its Affiliates, employees, officers, directors, agents, and contractors) (including, in
the case of Astellas as the destroying Party, the Promotional Materials, and in the case of Zogenix as the destroying Party, all training materials provided by Astellas), and shall certify to the other Party as to such destruction and
deletion. Notwithstanding the foregoing, the destroying Party may keep one copy of such Proprietary Information or materials, as applicable, for archival purposes, and such copies of the foregoing as are required to be kept by Legal
Requirements or the Party’s internal compliance policies, consistently applied. 
 ARTICLE IX 

REPRESENTATIONS AND WARRANTIES 

Section 9.1 Representations and Warranties of Zogenix 

Zogenix hereby represents and warrants to Astellas as of the date hereof, and covenants to Astellas, as follows: 

(a) Organization. Zogenix (i) is a corporation duly organized, validly existing and in good standing under the laws of the
state of Delaware, and (ii) has all necessary corporate power and corporate authority to own its properties and to conduct its business, as currently conducted. 

(b) Authorization. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby are
within the corporate power of Zogenix, have been duly authorized by all necessary corporate proceedings of Zogenix, and this Agreement has been duly executed and delivered by Zogenix. 

(c) No Conflict. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby do
not: (i) conflict with or result in a breach of any provision of Zogenix’s organizational documents; (ii) result in a material breach of any material agreement to which Zogenix is Party; (iii) result in a violation of any
Order to which Zogenix is subject; (iv) require Zogenix to obtain any material approval or consent from any Governmental Authority or Third Party other than those consents and approvals which have been obtained prior to the date hereof; or
(v) violate any Legal Requirement applicable to Zogenix in any material respect. 
  

 51 

 (d) Enforceability. This Agreement constitutes the valid and binding obligation of
Zogenix, enforceable against Zogenix in accordance with its terms, subject to bankruptcy, reorganization, insolvency and other similar laws affecting the enforcement of creditors’ rights in general and to general principles of equity
(regardless of whether considered in a proceeding in equity or an action at law). 
 (e) Zogenix Intellectual Property.
To the knowledge of Zogenix, the manufacture and importation of the Product and the Promotion and sale of the Product in the Territory in accordance with this Agreement will not infringe any patents, Trademarks or other intellectual property rights
of any Third Party; provided that Zogenix makes no representation as to the Astellas Trademarks. Zogenix has not received any written claim or demand from any Third Party alleging that any infringement, violation, or misappropriation of
such Third Party’s intellectual property rights has occurred as a result of or in connection with the manufacture, use, offer for sale, sale or importation of the Product in the Territory. Zogenix is not aware of any actual, alleged, or
threatened infringement, violation, or misappropriation by a Third Party of any Zogenix intellectual property rights covering the Product or its manufacture, use, or sale. Zogenix has not received any written claim or demand from any Third Party
alleging invalidity or unenforceability of any patents or patent applications owned or otherwise Controlled by Zogenix covering the Product or its manufacture, use, or sale. 

(f) Litigation. There is no litigation, arbitration proceeding, governmental investigation, action, or claims of any kind,
pending or, to the knowledge of Zogenix, threatened, by or against Zogenix or any of its Affiliates relating to the Product or its manufacture, use, or sale that would reasonably be expected to materially affect Zogenix’s or Astellas’s
ability to perform its obligations hereunder. 
 (g) Documentation and Diligence. 

(i) Zogenix has made available to Astellas (A) the NDA; (B) any clinical and non-clinical data and reports, medical
information, and regulatory documentation not otherwise included in the NDA with respect to safety and efficacy of the Product, in each case known to Zogenix as of the Effective Date; and (C) any material non-public market research, agreements,
and other documentation related to the Product in Zogenix’s possession, in the case of clause (C), that have been requested by Astellas in writing prior to July 24, 2009 (subject to limitations imposed by Third Party confidentiality
agreements), and in each case, ((A), (B) and (C)), all such copies, documents, and information were true, complete, and correct as of the date of delivery by Zogenix to Astellas. 

(ii) Zogenix has provided Astellas with (A) any information with respect to the manufacture of the Product or any of its Components
that has been requested by Astellas in writing prior to July 24, 2009; (B) any other information with respect to the manufacture of the Product or any of its Components that would reasonably be expected to materially and adversely affect
the manufacture of the Product or any of its Components or the supply of Product in accordance with the terms of this Agreement; and (C) any information relating to the manufacture of the Product or any of its Components that would reasonably
be expected to result in a delay in the Launch of the Product until or after April 1, 2010, and in each case, ((A), (B) and (C)), all such information was true, complete, and correct as of the date of delivery by Zogenix to Astellas.

  

 52 

 (iii) Except to the extent made available or provided to Astellas by Zogenix prior to
July 24, 2009, as of the Effective Date, there is no information known to Zogenix that would reasonably be expected to materially and adversely affect the commercialization of the Product in the Territory as contemplated in this Agreement,
including by delaying the Launch of the Product after April 1, 2010. 
 (h) Generic Drug Act. Pursuant to the
Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335a, as may be amended or supplemented (the “Generic Drug Act”), 

(i) none of Zogenix, its Affiliates, or, to the knowledge of Zogenix, any Person under its direction or control is currently debarred by
the FDA under the Generic Drug Act; 
 (ii) none of Zogenix, its Affiliates, or, to the knowledge of Zogenix, any Person under
its direction or control is currently using or will use in any capacity in connection with the Product any Person that is debarred by FDA under the Generic Drug Act; and 

(iii) there have been no convictions of Zogenix, its Affiliates, or, to the knowledge of Zogenix, any Person under its direction or
control for any of the types of crimes set forth in the Generic Drug Act within the five years prior to the Effective Date. 

(i) Legal Requirements. None of Zogenix, its Affiliates, or, to the knowledge of Zogenix, any Person under its direction or
control is currently or has been excluded from a federal or state health care program under Sections 1128 or 1156 of the Social Security Act, 42 U.S.C. §§ 1320a-7, 1320c-5 as may be amended or supplemented. None of Zogenix, its
Affiliates, or, to the knowledge of Zogenix, any Person under its direction or control is otherwise currently excluded or has otherwise been excluded from contracting with the federal government. None of Zogenix, its Affiliates, or, to the
knowledge of Zogenix, any Person under its direction or control is otherwise currently or has otherwise been excluded, suspended, or debarred from any federal or state program. Zogenix shall immediately notify Astellas if, at any time during
the Term, (x) Zogenix or its Affiliates is convicted of an offense that would subject Zogenix or Astellas to exclusion, suspension, or debarment from any federal or state program, or (y) Zogenix becomes aware that any Person under the
direction or control of Zogenix or its Affiliates is convicted of an offense that would subject Zogenix or Astellas to exclusion, suspension, or debarment from any federal or state program. 

Section 9.2 Representations and Warranties of Astellas 

Astellas hereby represents and warrants to Zogenix as of the date hereof, and covenants to Zogenix, as follows: 

(a) Organization. Astellas (i) is a corporation duly organized, validly existing and in good standing under the laws of
the state of Delaware, and (ii) has all necessary corporate power and corporate authority to own its properties and to conduct its business, as currently conducted. 
  

 53 

 (b) Authorization. The execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby are within the corporate power of Astellas, have been duly authorized by all necessary corporate proceedings of Astellas, and this Agreement has been duly executed and delivered by Astellas. 

(c) No Conflict. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby do
not: (i) conflict with or result in a breach of any provision of Astellas’s organizational documents; (ii) result in a material breach of any material agreement to which Astellas is Party; (iii) result in a violation of any
Order to which Astellas is subject; (iv) require Astellas to obtain any material approval or consent from any Governmental Authority or Third Party other than those consents and approvals which have been obtained prior to the date hereof; or
(v) violate any Legal Requirement applicable to Astellas in any material respect. 
 (d) Enforceability. This
Agreement constitutes the valid and binding obligation of Astellas, enforceable against Astellas in accordance with its terms, subject to bankruptcy reorganization, insolvency, and other similar laws affecting the enforcement of creditors’
rights in general and to general principles of equity (regardless of whether considered in a proceeding in equity or an action at law). 

(e) Astellas Trademarks. To the knowledge of Astellas, the use of the Astellas Trademarks in accordance with this Agreement will
not infringe any trademarks or other intellectual property rights of any Third Party. 
 (f) Litigation. There is no
litigation, arbitration proceeding, governmental investigation, action, or claims of any kind, pending or, to the knowledge of Astellas, threatened, by or against Astellas or any of its Affiliates that would reasonably be expected to materially
affect Astellas’s ability to perform its obligations hereunder. 
 (g) Generic Drug Act. Pursuant to the Generic
Drug Act, 
 (i) none of Astellas, its Affiliates, or, to the knowledge of Astellas, any Person under its direction or control
is currently debarred by the FDA under the Generic Drug Act; 
 (ii) none of Astellas, its Affiliates, or, to the knowledge of
Astellas, any Person under its direction or control is currently using or will use in any capacity in connection with the Product any Person that is debarred by FDA under the Generic Drug Act; and 

(iii) there have been no convictions of Astellas, its Affiliates, or, to the knowledge of Astellas, any Person under its direction or
control for any of the types of crimes set forth in the Generic Drug Act within the five years prior to the Effective Date. 
  

 54 

 (h) Legal Requirements. None of Astellas, its Affiliates, or, to the knowledge of
Astellas, any Person under its direction or control is currently excluded or has been from a federal or state health care program under Sections 1128 or 1156 of the Social Security Act, 42 U.S.C. §§ 1320a-7, 1320c-5 as may be amended or
supplemented. None of Astellas, its Affiliates, or, to the knowledge of Astellas, any Person under its direction or control is otherwise currently excluded or has otherwise been excluded from contracting with the federal government. None of
Astellas, its Affiliates, or, to the knowledge of Astellas, any Person under its direction or control is otherwise currently or has otherwise been excluded, suspended, or debarred from any federal or state program. Astellas shall immediately
notify Zogenix if, at any time during the Term, (x) Astellas or its Affiliates is convicted of an offense that would subject Astellas or Zogenix to exclusion, suspension, or debarment from any federal or state program, or (y) Astellas
becomes aware that any Person under the direction or control of Astellas or its Affiliates is convicted of an offense that would subject Astellas or Zogenix to exclusion, suspension, or debarment from any federal or state program. 

Section 9.3 Product Warranty 

Zogenix warrants to Astellas that: 

(a) at the time of delivery of all Product (excluding Samples delivered to Astellas hereunder) by or on behalf of Zogenix to a Third
Party (including any delivery to a 3PL or any delivery by a 3PL on behalf of Zogenix to a wholesaler, other distributor, or retailer), (i) such Product will be in conformity with the applicable specifications therefor and the NDA;
(ii) such Product will have been manufactured in compliance with cGMP, all other applicable Legal Requirements, and this Agreement; (iii) such Product will have been manufactured in facilities that are in compliance with all applicable
Legal Requirements at the time of such manufacture (including applicable inspection requirements of FDA and other Governmental Authorities); (iv) such Product will not be adulterated or misbranded under the Act; (v) such Product may be
introduced into interstate commerce pursuant to the Act; and (vi) the expiration date of such Product shall be no earlier than twelve (12) months after the date of delivery thereof. 

(b) at the time of delivery of all Samples to Astellas hereunder, (i) such Samples will be in conformity with the applicable
specifications therefor and the NDA; (ii) such Samples will have been manufactured in compliance with cGMP, all other applicable Legal Requirements, and this Agreement; (iii) such Samples will have been manufactured in facilities that are
in compliance with all applicable Legal Requirements at the time of such manufacture (including applicable inspection requirements of FDA and other Governmental Authorities); (iv) such Samples will not be adulterated or misbranded under the
Act; (v) such Samples may be introduced into interstate commerce pursuant to the Act; and (vi) the expiration date of such Samples shall be no earlier than [***] after the date of delivery thereof (or such other number of months as may be
determined by the unanimous decision of the JSC (and for clarity, any dispute with respect to such number of months may not be escalated pursuant to Section 3.7)). 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 55 

 Section 9.4 Zogenix Disclaimer 

EXCEPT AS EXPRESSLY PROVIDED HEREIN, ZOGENIX DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH REGARD TO THE PRODUCT, INCLUDING
ANY WARRANTY OF MERCHANTABILITY, ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, AND ANY WARRANTY OF NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 

Section 9.5 Astellas Disclaimer 

EXCEPT AS EXPRESSLY PROVIDED HEREIN, ASTELLAS DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF
MERCHANTABILITY, ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, AND ANY WARRANTY OF NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 

ARTICLE X 

INTELLECTUAL PROPERTY MATTERS 

Section 10.1 Intellectual Property Prosecution and Maintenance 

Zogenix shall, at its own expense, use commercially reasonable efforts to prosecute and maintain all Zogenix intellectual property in the
Territory (including patents, the Zogenix Trademarks and any copyrights associated with the Promotional Materials) related to the Product or its manufacture, use, or sale. Zogenix shall keep Astellas promptly informed regarding the ongoing
prosecution and maintenance of Zogenix patents to the extent they relate to the Product or its manufacture, use, or sale, including all office actions and notices of allowance. In addition, Zogenix shall keep Astellas reasonably informed regarding
material developments relating to the prosecution, maintenance, or enforcement of Zogenix’s intellectual property rights related to the Product or its manufacture, use, or sale outside the Territory that could reasonably be expected to have a
material impact on Zogenix’s intellectual property rights related to the Product or its manufacture, use, or sale in the Territory. 

Section 10.2 Ownership 

Zogenix shall own all intellectual property rights in and to the regulatory and clinical data (but not commercial data generated in the
course of performance hereunder) or other inventions and improvements related to the Product, including any such inventions and improvements related to the “DosePro” delivery device incorporated into the Product, in each case conceived or
reduced to practice by either Party pursuant to this Agreement. In addition, during the Term and for a period of two (2) years thereafter, Astellas shall not file, without Zogenix’s prior written consent, any patent application relating to
the Product or its manufacture, use, or sale. Each Party shall own all intellectual property rights with respect to commercial data generated by or on behalf of it in the course of performance hereunder. 

Section 10.3 Infringement 

(a) If either Party shall learn of a claim or assertion that the manufacture, use, or sale of the Product in the Territory infringes or
otherwise violates the intellectual property rights of any Third Party or that any Third Party violates the intellectual property rights owned or Controlled by (i) Zogenix in the Product or the Zogenix Trademarks in the Territory or
(ii) Astellas in the Astellas Trademarks, then the Party becoming so informed shall promptly, but in all events within fifteen (15) days thereof, notify the other Party to this Agreement of the claim or assertion. In the event Zogenix
receives a notice under Paragraph IV of the U.S. Federal Drug Price Competition and Patent Term Restoration Act of 1984, as amended, also known as the Hatch-Waxman Act, with respect to the Product, Zogenix shall provide Astellas with written notice
of such Paragraph IV notice within two (2) business days (each, a “Paragraph IV Notice”). 
  

 56 

 (b) In the event of any infringement of Zogenix patent rights related to the Product or its
manufacture, use, or sale, or the Zogenix Trademarks in the Territory, which infringement involves a product that could or does compete with the Product or could adversely affect the Parties’ interests in the Product under this Agreement,
Zogenix shall, in its sole discretion, after considering the advice and comments of Astellas, determine to take the appropriate legal action (an “Enforcement Action”), if any. In the event such an Enforcement Action is initiated,
Zogenix shall use commercially reasonable efforts to prosecute such matter. At Zogenix’s reasonable request, Astellas shall cooperate fully with Zogenix with respect to any such Enforcement Action, and Zogenix shall reimburse Astellas for
its reasonable out-of-pocket expenses incurred in providing such cooperation. Astellas may be represented by counsel of its own selection at its own expense in any such Enforcement Action, but Zogenix shall have the right to control the suit or
proceeding. Any recovery received as a result of any Enforcement Action [***] and any amounts remaining thereafter allocable as compensation for lost sales or profits of the Product shall be shared between the Parties [***] to Astellas and [***] to
Zogenix. 
 (c) In the event of an Enforcement Action by Astellas with respect to any Astellas Trademark, at Astellas’s
reasonable request, Zogenix shall cooperate fully with Astellas with respect to any such Enforcement Action, and Astellas shall reimburse Zogenix for its reasonable out-of-pocket expenses incurred in providing such cooperation. 

ARTICLE XI 

INDEMNIFICATION; LIMITS ON LIABILITY 

Section 11.1 Indemnification 

(a) Each Party (each, an “Indemnifying Party”) shall defend, at its own expense, indemnify, and hold harmless the other
Party (the “Indemnified Party”) and its Affiliates, and its and their respective directors, officers, employees, agents, Sales Representatives, and other representatives (collectively, the “Indemnified Persons” of
the Indemnified Party), from and against any and all damages, liabilities, losses, costs, and expenses, including reasonable attorneys’ fees (“Losses”) arising out of any Third Party claim, suit or proceeding
(“Claim”) brought against the Indemnified Party or its Indemnified Persons to the extent such Claim arises out of or relates to (i) any breach or violation by the Indemnifying Party of, or failure to perform by the Indemnifying
Party of, any representation, warranty, covenant, or other obligation in this Agreement, unless waived in writing by the Indemnified Party; (ii) the negligence or willful misconduct of the Indemnifying Party or any of its Indemnified Persons or
its Third Party contractors (including Third Party manufacturers or suppliers); (iii) any violation of applicable Legal Requirements by the Indemnifying Party or any of its Indemnified Persons or its Third Party contractors (including Third
Party manufacturers or suppliers); or (iv) any actions of the Indemnifying Party’s Sales Force or scientific liaisons, including any false or misleading representations to Professionals, customers, or others regarding the Indemnified Party
or the Product; excluding, in each case, ((i), (ii), (iii) and (iv)), any Loss for which the Indemnified Party has an obligation to indemnify the Indemnifying Party or its Indemnified Persons pursuant to this Section 11.1, as to which Loss
each Party shall indemnify the other to the extent of their respective liability for such Loss. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 57 

 (b) In addition, Zogenix shall defend, at its own expense, indemnify, and hold harmless
Astellas and its Indemnified Persons, from and against Losses arising out of Claims brought against Astellas or its Indemnified Persons to the extent such Claim arises out of or relates to (i) any claim made by any Person that the manufacture,
use, or sale of the Product infringes or misappropriates the patent, Trademark, or other intellectual property rights of such Person, except with respect to any claim relating to the Astellas Trademarks; (ii) any claim for products liability
with respect to the Product, except to the extent liability is caused by a breach by Astellas of Section 4.1 (as to which Loss each Party shall indemnify the other to the extent of their respective liability for such Loss); (iii) without
limitation of clause (ii), any claim based on death, personal injury, or property damage arising out of the manufacture of the Product by or on behalf of Zogenix (including such manufacture of supply by Third Party manufacturers or suppliers),
except to the extent liability is caused by a breach by Astellas of Section 4.1 (as to which Loss each Party shall indemnify the other to the extent of their respective liability for such Loss); (iv) any decision taken hereunder with
respect to which Zogenix or its officers or representatives had final decision-making authority, including those disputes over the determination of WAC or the amount of Selected Deductions, which disputes are to be resolved pursuant to
Section 3.7, and certain disputes arising out of matters within the jurisdiction of the JPRC, which disputes are to be resolved pursuant to Section 3.7(b); or (v) Zogenix’s use of the Astellas Compliance Materials or
Astellas’s training materials. 
 (c) The Indemnified Party shall promptly notify the Indemnifying Party in writing of any
Claim and shall give the Indemnifying Party full information and assistance in connection therewith. The Indemnifying Party’s obligation to defend, indemnify, and hold harmless any Indemnified Person shall be reduced to the extent the
Indemnified Party’s delay in providing notification pursuant to the previous sentence results in prejudice to the Indemnifying Party. The Indemnifying Party shall have the sole right to control the defense and the sole right to settle or
compromise the Claim, except that the prior written consent of the Indemnified Party shall be required in connection with any settlement or compromise that could (i) place any obligation on or require any action on the part of the Indemnified
Party or its Indemnified Persons, or (ii) admit or imply any liability or wrongdoing on the part of the Indemnified Party or its Indemnified Persons. Notwithstanding the foregoing, the Indemnified Party may participate in such defense
through counsel of its choice, but the cost of such counsel shall be borne solely by the Indemnified Party. 
  

 58 

 Section 11.2 Consequential Damages 

NEITHER ASTELLAS NOR ZOGENIX, NOR THEIR RESPECTIVE AFFILIATES, NOR THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, OR AGENTS (OR THE
DIRECTORS, OFFICERS, EMPLOYEES OR AGENTS OF THEIR AFFILIATES) SHALL HAVE ANY LIABILITY TO THE OTHER PARTY (OR TO THE OTHER PARTY’S AFFILIATES OR ITS OR THEIR DIRECTORS, OFFICERS, EMPLOYEES, OR AGENTS) FOR ANY PUNITIVE DAMAGES, SPECIAL,
INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES, RELATING TO OR ARISING FROM THIS AGREEMENT, EVEN IF SUCH DAMAGES MAY HAVE BEEN FORESEEABLE; PROVIDED THAT SUCH LIMITATION SHALL NOT APPLY (A) IN THE CASE OF EITHER PARTY’S
INDEMNIFICATION OBLIGATIONS UNDER SECTION 11.1, OR (B) IN THE CASE OF FRAUD, GROSS NEGLIGENCE, OR WILLFUL MISCONDUCT. 

ARTICLE XII 

CONFIDENTIALITY AND PUBLICITY 

Section 12.1 Proprietary Information 

A Party receiving Proprietary Information from the other, directly or indirectly, will treat such Proprietary Information as
confidential, will use such Proprietary Information only for the purposes of this Agreement, and will not disclose, and will take all reasonable precautions to prevent the disclosure of, such Proprietary Information to (a) any of its Affiliates
or its or their officers, directors, managers, equity holders, employees, agents, representatives, or consultants, except those who reasonably need to know such Proprietary Information in order for such Party to exercise its rights or fulfill its
obligations under this Agreement and who are bound by a like obligation of confidentiality or (b) to Third Parties. 

Section 12.2 Disclosures Required by Law 

If a Party that is the recipient of Proprietary Information of the other Party is required under applicable Legal Requirements to
disclose such Proprietary Information (a) to any Governmental Authority to obtain any Regulatory Approval for the Product, (b) in connection with bona fide legal process (including in connection with any bona fide dispute hereunder) or
(c) under the rules of the securities exchange upon which its securities are traded, then the recipient Party may do so only if (i) it limits disclosure of the Proprietary Information only to that information required to be disclosed,
(ii) it limits disclosure to that purpose, and (iii) except in the case of clause (b) in circumstances involving a bona fide dispute hereunder, it gives the disclosing Party, if practicable under the circumstances, prompt written
notice of any instance of such a requirement in reasonable time for the disclosing Party to attempt to object to or to limit such disclosure. With respect to disclosures required under applicable Legal Requirements, the recipient Party shall
cooperate with the disclosing Party as reasonably requested thereby, consistent with such Legal Requirements. 

Section 12.3 Publicity 

The Parties have agreed upon the form and content of a joint press release to be issued by the Parties promptly following the execution
of this Agreement. Once such press release or any other written statement is approved for disclosure by both Parties, either Party may make subsequent public disclosure of the contents of such statement (if such contents remain accurate and not
misleading) without the further approval of the other Party. Any other publicity, news release, public comment or other public announcement, whether to the press, to stockholders, or otherwise, relating to this Agreement, including activities
conducted hereunder, shall first be reviewed and approved by both Parties, except no such approval shall be required for such publicity, news release, public comment or other public announcement which, in accordance with the advice of legal counsel
to the Party making such disclosure, is required by law or for appropriate market disclosure. Notwithstanding the foregoing, each Party shall be entitled to refer publicly to the relationship of the Parties reflected in this Agreement (i.e.,
Zogenix as the developer of the Product and Astellas as the co-promoter of the Product in the Territory) in a manner that is consistent with the joint press release issued by the Parties. For clarity, any Party making any announcement which is
required by law will, unless prohibited by law, give the other Party an opportunity to review the form and content of such announcement and comment before it is made. The Parties shall work together to coordinate filings with governmental agencies,
including the United States Securities and Exchange Commission, as to the contents and existence of this Agreement as the Parties shall reasonably deem necessary or appropriate, and each Party shall provide the other Party an opportunity to comment
on any proposed filings, including redactions proposed thereto. 
  

 59 

 Section 12.4 Survival 

The provisions of this Article XII shall survive termination of this Agreement and shall remain in effect until a date [***] after the
expiration or termination of this Agreement. 
 ARTICLE XIII 

NOTICES 

Section 13.1 Notices 

Subject to Section 3.6(e) (governing certain communications relating to the day-to-day business of a Committee), all notices
required or permitted hereunder shall be given in writing and sent by facsimile transmission (with a copy sent by first-class mail), mailed postage prepaid by certified or registered mail (return receipt requested), sent by a nationally recognized
express courier service, or hand-delivered at the addresses below: 
 If to Zogenix: 

Zogenix, Inc. 

12671 High Bluff Drive 

Suite 200 
 San
Diego, CA 92130 
 Attention: General Counsel 

Fax No: (858) 259-1166 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 60 

 With a copy to (which shall not constitute notice hereunder): 

Latham & Watkins LLP 

12636 High Bluff Drive 

Suite 400 
 San
Diego, CA 92130 
 Attention: Faye H. Russell 

Fax No: (858) 523-5450 

If to Astellas: 

Astellas Pharma US, Inc. 

Three Parkway North 

Deerfield, IL 60015 

Attention: Senior Vice President, Marketing and Sales 

Fax No: (847) 317-7297 

With a copy to (which shall not constitute notice hereunder): 

Astellas US LLC 

Three Parkway North 

Deerfield, IL 60015 

Attention: Senior Vice President, General Counsel and Secretary 

Fax No: (847) 317-7288 

All notices shall be deemed made upon receipt by the addressee as evidenced by the applicable written receipt. 

ARTICLE XIV 

INSURANCE 

Section 14.1 Insurance 

(a) During the Term and for a period of ten (10) years after any expiration or termination of this Agreement, each Party shall
obtain and maintain at its own expense from an insurance company rated A(XIII) or better by A.M. Best or an equivalent rating from Standard & Poor’s (i) a commercial general liability insurance policy or policies with minimum
limits of [***] and [***] on an annual basis, and (ii) a product liability insurance policy or policies with minimum limits of [***] and [***] on an annual basis. Such policies shall include protection against claims, demands, and causes of
action arising out of any defects or failure to perform, alleged or otherwise, of the Product or any material used in connection therewith or any use thereof. Notwithstanding the foregoing, either Party may satisfy its obligations under this
Section 14.1, in whole or in part, through a program of self-insurance; provided that (x) any such program of self-insurance shall be established through a captive insurance company duly established and properly maintained under the
laws of the jurisdiction of formation, and (y) at the request of the other Party, such Party shall provide reasonably satisfactory evidence of its compliance with clause (x). 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 61 

 (b) Each Party shall furnish within thirty (30) Business Days after the Effective
Date, and upon each policy renewal thereafter or at the request of the other Party, a certificate of insurance evidencing that such insurance is in effect. Each Party will provide the other Party thirty (30) days’ prior written notice of
cancellation, non-renewal, or material change in the insurance required by this Agreement. Neither Party’s liability to the other is in any way limited to the extent of its insurance coverage. 

ARTICLE XV 

MISCELLANEOUS 

Section 15.1 Arbitration 

Any dispute which has not been resolved as set forth in Section 3.7 or any other dispute arising between the Parties hereunder shall
be settled by binding arbitration in accordance with the Judicial Arbitration and Mediation Services (“JAMS”) Comprehensive Arbitration Rules and Procedures, as such rules may be modified by this Section 15.1 or by agreement of
the Parties. The Parties shall mutually select a single independent, conflict-free arbitrator, who shall have sufficient background and experience to resolve the matter in dispute. If the Parties are unable to reach agreement on the selection of the
arbitrator within [***] after submission to arbitration, then either or both Parties shall immediately request JAMS to select an arbitrator with the requisite background, experience and expertise. Notwithstanding the applicable JAMS rules,
(i) the arbitrator shall resolve the dispute as expeditiously as reasonably possible, and in any event no later than [***] following referral of the dispute to the arbitrator (or, in the case of disputes relating to Volume Forecasts referred
pursuant to Section 6.2(f), no later than [***] following such referral); and (ii) the arbitrator shall resolve the dispute in a manner that is fair and reasonable to the Parties in light of the totality of the circumstances and the terms
of this Agreement. The place of arbitration shall be New York, New York, and all proceedings and communications shall be in English. Either Party may apply to the arbitrator for interim injunctive relief or may seek from any court having
jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending resolution of the matter pursuant to this Section 15.1. The Parties shall have the right to be represented by counsel. Any
judgment or award rendered by the arbitrator shall be final and binding on the Parties, and shall be governed by the terms and conditions hereof, including the limitation on damages set forth in Section 11.2. The Parties agree that such a
judgment or award may be enforced in any court of competent jurisdiction. The statute of limitations of the State of New York applicable to the commencement of a lawsuit shall apply to the commencement of arbitration under this Section 15.1.
Each Party shall bear its own costs and expenses and attorneys’ fees, and, unless otherwise agreed by the Parties or determined by the arbitrator, the Party that does not prevail in the arbitration proceeding shall pay the arbitrator’s
fees and any administrative fees of arbitration; provided that it is the intent of the Parties with respect to any dispute relating to Volume Forecasts referred to the arbitrator pursuant to Section 6.2(f) that the arbitrator shall award
to the prevailing party its costs, expenses, and attorneys’ fees (in addition to the arbitrator’s fees and the administrative fees of arbitration). All proceedings and decisions of the arbitrator(s) shall be deemed Proprietary Information
of each of the Parties, and shall be subject to Article XII. For the avoidance of doubt, disputes arising on issues within the jurisdiction of a Committee shall be resolved in accordance with the procedures set forth in Section 3.7. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 62 

 Section 15.2 Headings 

The titles, headings or captions and paragraphs in this Agreement are for convenience only and do not define, limit, extend, explain, or
describe the scope or extent of this Agreement or any of its terms or conditions and therefore shall not be considered in the interpretation, construction, or application of this Agreement. 

Section 15.3 Severability 

In the event that any of the provisions or a portion of any provision of this Agreement is held to be invalid, illegal, or unenforceable
by a court of competent jurisdiction or a Governmental Authority, such provision or portion thereof will be construed and enforced as if it had been narrowly drawn so as not to be invalid, illegal, or unenforceable, and the validity, legality, and
enforceability of the enforceable portion of any such provision and the remaining provisions will not be adversely affected thereby. 

Section 15.4 Entire Agreement 

This Agreement, together with the schedules and exhibits hereto, the Initial Commercial Plan, the Initial Base Brand A&P Budget, and
the test plan referred to in Section 7.1(b)(ii), all of which are incorporated by reference, contains all of the terms agreed to by the Parties regarding the subject matter hereof and supersedes any prior agreements, understandings, or
arrangements between them, whether oral or in writing. For the avoidance of doubt, (a) that certain Letter Agreement between the Parties dated June 25, 2009, as amended (the “Letter Agreement”), remains in full force and
effect through the Exclusivity Period (as defined in the Letter Agreement), but solely with respect to Section 3 (“Exclusivity Related to Hydrocodone CR”) and other Sections of the Letter Agreement to the extent relating to a
potential Hydrocodone Transaction (as defined in the Letter Agreement), and the negotiations and discussions related thereto; and (b) the Confidentiality Agreement remains in full force and effect with respect to negotiations and discussions
related to a potential Hydrocodone Transaction, but is superseded with respect to the subject matter hereof. 

Section 15.5 Amendments 

This Agreement may not be amended, modified, altered, or supplemented except by means of a written agreement or other instrument executed
by both of the Parties hereto. No course of conduct or dealing between the Parties will act as a modification or waiver of any provisions of this Agreement. 

 

 63 

 Section 15.6 Counterparts 

This Agreement may be executed in any number of counterparts, each of which will be deemed an original as against the Party whose
signature appears thereon, but all of which taken together will constitute but one and the same instrument. 
 Section 15.7
Waiver 
 The failure of either Party to enforce or to exercise, at any time or for any period of time, any term
of or any right arising pursuant to this Agreement does not constitute, and will not be construed as, a waiver of such term or right, and will in no way affect that Party’s right later to enforce or exercise such term or right. 

Section 15.8 Force Majeure 

(a) In the event of any failure or delay in the performance by a Party of any obligation under this Agreement due to events beyond the
reasonable control of such Party (such as, for example, fire, explosion, strike, inability to obtain transportation, fuel, or power, accident, act of God, declared or undeclared wars, or acts of terrorism) (a “Force Majeure Event”),
then such Party shall have such additional time to perform as shall be reasonably necessary under the circumstances. For clarity, a Force Majeure Event shall not include a failure to commit sufficient resources, financial or otherwise, to the
performance of obligations under this Agreement or general market or economic conditions not accompanied by circumstances described in the first sentence of this Section 15.8(a). In the event of such failure or delay, the affected Party will
use its diligent efforts, consistent with sound business judgment and to the extent permitted by Legal Requirements, to correct and mitigate such failure or delay as expeditiously as possible. In the event that a Party is unable to perform by a
reason described in this Section 15.8, its obligation to perform under the affected provision of this Agreement shall be suspended during such time of nonperformance. 

(b) Neither Party shall be liable hereunder to the other Party nor shall be in breach for failure to perform its obligations caused by a
Force Majeure Event except as otherwise set forth in this Agreement. In the case of any such Force Majeure Event, the affected Party shall promptly, but in no event later than [***] after its occurrence, notify the other Party stating the
nature of the condition, its anticipated duration, and any action being taken to avoid or minimize its effect. Furthermore, the affected Party shall keep the other Party informed of the efforts to resume performance. After [***] of such
inability to perform, the Parties shall meet and discuss in good faith how to proceed. In the event that the affected Party is prevented from performing its obligations pursuant to this Section 15.8 for a period of [***] (which period of
time shall include the [***] following which the Parties are to meet pursuant to the previous sentence), the other Party shall have the right to terminate this Agreement pursuant to the provisions of Sections 8.3. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 64 

 Section 15.9 Successors and Assigns 

Subject to Section 15.10, this Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their
respective successors and assigns permitted under this Agreement. 
 Section 15.10 Assignment 

(a) This Agreement and the rights granted herein shall not be assignable (or otherwise transferred) by either Party hereto without the
prior written consent of the other Party. Any attempted assignment without consent shall be void. Notwithstanding the foregoing, a Party may transfer, assign or delegate its rights and obligations under this Agreement without consent to
(i) an Affiliate reasonably capable of performing such Party’s obligations under this Agreement, or (ii) a successor to all or substantially all of its business or assets of the assigning Party to which this Agreement relates, whether
by sale, merger, consolidation, acquisition, transfer, operation of law or otherwise. [***]. For the avoidance of doubt, prior to or following any such assignment in connection with a Zogenix Change of Control, Astellas shall have the right to
terminate this Agreement pursuant to and in accordance with Section 8.2(a)(v). 
 (b) In connection with (i) any
assignment pursuant to this Section 15.10 of this Agreement or any of the rights granted herein, or (ii) with any subcontract permitted hereunder, the assignor or Party subcontracting shall ensure that the assignee or subcontractor
represents and warrants the matters set forth (x) in Sections 9.1(h) and 9.1(i) (in substantially the same form as set forth in Sections 9.1(h) and 9.1(i)) where Zogenix (or one of its successors or assigns) is the assignor or subcontracting
Party, or (y) in Sections 9.2(g) and 9.2(h) (in substantially the same form as set forth in Sections 9.2(g) and 9.2(h)), where Astellas (or one of its successors or assigns) is the assignor or subcontracting Party. Neither Party shall
engage any Third Party appearing on the FDA’s debarment list or the list of excluded individuals/entities of the Office of Inspector General of the Department of Health and Human Services to perform, or assist such Party in the performance of,
its obligations under this Agreement, and each Party shall review each such list prior to so engaging any Third Party. 

Section 15.11 Construction 

The Parties acknowledge and agree that: (a) each Party and its representatives have reviewed and negotiated the terms and provisions
of this Agreement and have contributed to its revision; and (b) the terms and provisions of this Agreement will be construed fairly as to each Party hereto and not in favor of or against either Party regardless of which Party was generally
responsible for the preparation or drafting of this Agreement. Unless the context of this Agreement otherwise requires: (i) words of any gender include each other gender; (ii) words using the singular or plural number also include the
plural or singular number, respectively; (iii) the terms “hereof,” “herein,” “hereby,” and derivative or similar words refer to this entire Agreement; (iv) the terms “Article,” “Section,”
“Exhibit,” “Schedule,” or “clause” refer to the specified Article, Section, Exhibit, Schedule, or clause of this Agreement; (v) “or” means “and/or;” and (vi) the term “including”
or “includes” means “including without limitation” or “includes without limitation.” Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified.

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 65 

 Section 15.12 Governing Law 

This Agreement will be construed under and in accordance with, and governed in all respects by, the laws of the State of New York,
without regard to its conflicts of law principles. 
 Section 15.13 Equitable Relief 

Each Party acknowledges that a breach by it of its obligations under Sections 2.3, 2.4, and 2.6, and Article XII may not reasonably or
adequately be compensated in damages in an action at law, and that such a breach may cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party is entitled to seek, in addition to any other
remedies it may have under this Agreement or otherwise, preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of such Sections and Articles of this Agreement by the other Party; provided, however,
that no specification in this Agreement of a specific legal or equitable remedy will be construed as a waiver or prohibition against the pursuing of other legal or equitable remedies in the event of such a breach. Each Party agrees that the
existence of any claim, demand, or cause of action of it against the other Party, whether predicated upon this Agreement, or otherwise, will not constitute a defense to the enforcement by the other Party, or its successors or assigns, of the
covenants contained in this Agreement. 
 Section 15.14 Relationship Between Parties 

The Parties hereto are acting and performing as independent contractors, and nothing in this Agreement creates the relationship of
partnership, joint venture, sales agency, or principal and agent. Neither Party is the agent of the other, and neither Party may hold itself out as such to any other Person. All financial obligations associated with each Party’s
business will be the sole responsibility of such Party. 
 [Signature page follows] 

 

 66 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed in duplicate on the day and year
first above written. 
  

			
	ZOGENIX, INC.
	
	 /s/ Roger Hawley

	By:	 	Roger Hawley
	Its:	 	CEO
	
	ASTELLAS PHARMA US, INC.
	
	 /s/ Seigo Kashii

	By:	 	Seigo Kashii
	Its:	 	President and CEO

  

 67 

 Schedule 1.19 

Primary Specialty Classifications of Professionals in the Astellas Segment 

[***] 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 68 

 Schedule 

Post-Effective Date Expenses 
  

			
	 Expenses
	 	 Allocation

	[***]	 	Each Party to pay [***] of the costs and expenses of the study [***].
	[***]	 	Each Party to pay [***] of the costs and expenses of the work[***].

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 69 

 Schedule 

Primary Specialty Classifications of Neurologist Professionals in the Zogenix Segment 

 

			
	N	  	[***]
	CN	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 70

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}]]